Central fatigue during exercise: potential manuipulations and limiting factors by Ruth M. Hobson (7237820)
 
 
 
This item was submitted to Loughborough’s Institutional Repository 
(https://dspace.lboro.ac.uk/) by the author and is made available under the 
following Creative Commons Licence conditions. 
 
 
 
 
 
For the full text of this licence, please go to: 
http://creativecommons.org/licenses/by-nc-nd/2.5/ 
 
 CENTRAL FATIGUE DURING EXERCISE: POTENTIAL 
MANIPULATIONS AND LIMITING FACTORS. 
 
 
 
 
 
By 
 
RUTH M HOBSON 
 
 
 
 
 
 
A Doctoral Thesis 
 
 
Submitted in partial fulfilment of the requirements for the award of Doctor of 
Philosophy of Loughborough University 
 
 
July 2010 
 
 
© Ruth M Hobson (2010) 
 
 
 
 
 i 
ABSTRACT  
The development of fatigue has been an area of interest to athletes and 
scientists alike for many years. Often, particularly during prolonged exercise in 
the heat, there is no obvious peripheral reason for fatigue and the central 
nervous system is cited as the source. The mechanisms and potential 
manipulations of this fatigue remain largely unclear. 
 
Chapters Three and Four attempted to reduce the transport of the serotonin 
precursor tryptophan into the brain in order to reduce or delay serotonin 
synthesis and therefore increase exercise capacity. In Chapter Three 
branched-chain amino acid drinks were fed before and during prolonged 
cycling to exhaustion in the heat on two occasions and control drinks were fed 
on two other occasions. There was no effect of the branched-chain amino 
acids on exercise capacity and the intra-individual variability in seven of the 
eight participants was small. One participant did appear to cycle for longer on 
the branched-chain amino acid trials compared to the control trials. In Chapter 
Four a 104 g bolus of amino acids, designed to deplete plasma tryptophan 
concentration, was fed seven hours before a prolonged cycle to exhaustion in 
the heat. There was no difference in exercise capacity between the 
tryptophan depletion trial and the control trial in which tryptophan was also 
ingested. These findings suggest that the delivery of tryptophan to the central 
nervous system is not the only factor influencing the onset of fatigue. 
 
The investigation undertaken in Chapter Five looked at the serotonin 
transporter density on the blood platelets of current and retired international 
level athletes competing in either endurance or sprint running events and a 
sedentary control group. Using the platelet as an accessible and reliable 
model for the serotonergic neuron, the maximum number of binding sites was 
assessed using the radio-labelled serotonin reuptake inhibitor [3H]Paroxetine. 
Those currently training for endurance events had a greater number of 
binding sites than any of the other groups. This supports previous findings 
and suggests that endurance training can increase the number of serotonin 
transporters on blood platelet membranes. 
 
 ii 
During resting heat exposure in Chapter Six, the application of a 1 % menthol 
solution to the skin of the forearms, back and forehead elicited a warming 
sensation in some individuals and a cooling sensation in other individuals, but 
never any change in skin or core temperature nor skin blood flow. A small 
proportion of individuals did not perceive any change in skin thermal 
sensation. Chapter Seven applied these findings to a pre-loaded twenty 
minute exercise performance test in the heat. It was hypothesised that those 
who perceived a warming effect may perform worse when a menthol solution 
was applied compared to a control solution and conversely, those who 
perceived a cooling sensation may perform better with a menthol solution than 
with a control solution. There was no difference in exercise performance 
between those who felt a warming sensation and those who felt a cooling 
sensation. Those who felt a warming sensation felt significantly warmer on the 
menthol trial than the control trial but this did not affect their performance. 
However, those who reported a cooling sensation tended to feel cooler on the 
menthol trial than the control trial, and there was a tendency for an 
improvement in performance on the menthol trial compared to the control trial. 
 
Due to the experimental protocols adopted in this thesis it was possible to 
assess the reliability of an exercise capacity test compared to an exercise 
performance test. Chapter Three showed a coefficient of variation of 11.0 ± 
11.2 % and Chapter Four showed a 11.5 ± 12.4 % variability for exercise 
capacity tests. Chapter Seven showed a coefficient of variation in a pre-
loaded time-trial exercise performance test of 3.9 ± 9.6 % suggesting that an 
exercise performance test may be more reliable than an exercise capacity 
test. However, the aims of an investigation are still likely to be the main factor 
influencing the choice of protocol. 
 
It seems likely that no single mechanism will be responsible for the cessation 
of exercise. The investigations undertaken in this thesis also highlight many 
avenues for future exploration. 
 
KEY WORDS: Central fatigue; Tryptophan; Serotonin transporters; Thermal 
sensation.
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CHAPTER ONE 
 
General introduction. 
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1.1 Definition of fatigue 
For many years the development of fatigue during exercise has received 
considerable interest from athletes, coaches and scientists alike.  From as far 
back as the late 19th century it has been suggested that the central nervous 
system plays a key role in the development of exercise fatigue, to the extent 
that central fatigue is a protective mechanism over peripheral fatigue (Waller, 
1891).  Several years later, Bainbridge took this further and stated that there 
were two types of exercise fatigue: one that was entirely centrally mediated 
and the other which was both central and peripheral in origin (Bainbridge, 
1919).  
 
Since that date, fatigue during exercise has generally been defined as an 
inability to maintain the required force or power output for a given task, 
leading to a reduction in the performance of the task (Edwards, 1981).  To this 
day fatigue is still subdivided in relation to the location of the inhibition to 
perform a task, i.e. centrally mediated or peripherally mediated fatigue.  
Central fatigue can be defined as any exercise-induced reduction in maximal 
voluntary contraction force that is not accompanied by the same reduction in 
maximal evocable force (Astrand et al., 2003A).  Peripheral fatigue 
encompasses all events leading to fatigue that occur independently of the 
central nervous system.  This includes, but is not restricted to, disturbances to 
neuromuscular transmission, sarcolemma excitability and excitation-
contraction coupling (Meeusen et al., 2006) along with substrate depletion, 
metabolic acidosis (Maughan et al., 1997A) and the peripheral effects of 
hypohydration and elevated core temperature (Maughan et al., 1997B). 
 
 
1.2 Central fatigue during prolonged exercise 
1.2.1 Introduction 
Often, when no peripheral reason for fatigue during prolonged exercise is 
apparent, the fatigue is said to be centrally mediated.  Indeed, one of the first 
symptoms of fatigue is an increase in the perception of the effort required to 
perform a task (Davis and Bailey, 1997).  This is followed by a decrement in 
the performance of the task, which will inevitably occur if the task is continued.   
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Centrally mediated fatigue has come under more scrutiny in recent decades 
with many contemporary theories being proposed to explain the possible 
mechanisms of central fatigue.  However, no definitive single cause has ever 
been found.  This thesis will focus on the role of serotonin in centrally 
mediated fatigue even though it is widely accepted that this is just one of 
many avenues of exploration into the aetiology of fatigue during exercise.  
 
1.2.2 Serotonin 
Serotonin (5-hydroxytryptamine; 5-HT) has been implicated in many 
physiological and psychological sensations and processes.  It has been 
shown to be involved in feelings of tiredness, lethargy and sleep, sensory 
perception of pain, and thermoregulation (for a full review see Jacobs and 
Azimita, 1992).  Manipulation of various aspects of the serotonergic system 
therefore offer appealing theories as to how exercise performance and 
capacity can be improved through increased resistance to, or the delayed on-
set of, fatigue.  
 
1.2.2.1 The serotonergic system 
Serotonin is just one of approximately sixty neurotransmitters within the 
nervous system.  Of all the neurons in the central nervous system, the 
complex and vast network of serotonergic neurons constitutes only about one 
in every one million neurons (Jacobs and Azimita, 1992).  The cell bodies of 
the serotonergic neuronal network tend to originate in the lower brain stem, 
with dense collections in or near the raphe nuclei (Struder and Weicker, 
2001B).  The neurons have been subdivided into two functionally significant 
groups: the superior group which supplies the forebrain and the inferior group 
which generally projects into the spinal cord (Jacobs and Azimita, 1992). 
 
Serotonin neuronal firing, release and metabolism are, sometimes at least, 
independent of each other.  Crespi and colleagues (1990) showed this 
through in vivo administration of a 5-HT agonist which decreased 5-HT 
neuronal firing and extracellular 5-HT but not extracellular serotonin 
metabolite 5-HIAA concentrations in rats.  Aghajanian (1972) proposed that 
serotonin release operates on a negative feedback system, which works to 
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regulate and normalise serotonin levels.  A simplistic and idealised overview 
of a single serotonergic neuron can be seen in Figure 1.1. 
 
 
 
Figure 1.1.  A simplistic diagram of a single serotonergic neuron, annotated. 
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1.2.2.2 Serotonin synthesis 
Only about 1 – 2 % of the serotonin in the body is found in the brain (Cooper 
et al., 2003A).  Mast cells, enterochromaffin cells in the gastrointestinal tract 
and blood platelets, none of which are involved with the nervous system, are 
all able to either synthesise and/or transport serotonin (Struder and Weicker, 
2001A).  Serotonin is not able to cross the blood brain barrier, nor is it easily 
able to diffuse across cell membranes.  Therefore, the synthesis of serotonin 
must take place within the neurons from its precursor, tryptophan.  This 
process requires several enzymes, and their presence is one of the defining 
characteristics of the serotonergic system (Cooper et al., 2003A).  
 
Tryptophan, an essential amino acid with a hydrophobic aromatic R-group, 
must be consumed in the diet.  Generally, foods that are high in protein are 
also high in tryptophan.  When eaten, these foods release tryptophan and the 
amino acid enters the circulation.  Originally it was thought that the plasma 
concentration of tryptophan was the only determinant of serotonin synthesis 
(Fernstrom and Wurtman, 1971).  It is now apparent however, that the 
situation is far more complex, with several factors influencing serotonin 
synthesis, including competition from other compounds which compete with 
tryptophan for the same transporter across the blood brain barrier.  
 
By using 14C labelling of individual amino acids, Oldendorf and Szabo (1976) 
showed that there are three amino acid transporters across the blood brain 
barrier and that, other than proline, alanine and glycine, each amino acid 
could only be transported by one of the three.  The neutral transporter, which 
is temperature dependent and stereospecific but not sensitive to external 
sodium or potassium concentrations, is responsible for transporting, among 
others, leucine, isoleucine, valine and tryptophan.  Therefore, these amino 
acids are in direct competition for transport into the brain, meaning that the 
ratio of tryptophan to competing amino acids is an important determinant of 
the rate of uptake of tryptophan across the blood brain barrier and 
subsequently the rate of serotonin production.  
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An important and potentially confounding factor, which must be considered 
from this point onwards, is the relatively recent finding that during exercise in 
a warm environment, the integrity of the blood brain barrier may be 
compromised (Watson et al., 2005B).  The blood brain barrier is characterised 
by the presence of tight junctions and selective, specific molecular carrier 
systems.  It acts as a protective mechanism maintaining a stable environment 
for the central nervous system despite changes in the peripheral circulation.  
However, after a protocol involving passive heating and exercise in a warm 
environment, the peripheral concentration of s100β, a protein found 
predominantly in the central nervous system at a concentration of around 
eighteen times that found in the peripheral circulation, was significantly 
elevated compared to the same protocol which did not induce a thermal 
strain.  This finding suggests that thermal strain and exercise lead to an 
increase in the permeability of the blood brain barrier.  In a subsequent 
investigation, the same investigators found that the increase in the serum 
concentration of s100β could be attenuated by the ingestion of water, in 
volumes similar to the body mass lost due to the exercise protocol, which was 
again performed in the heat (Watson et al., 2006). 
 
To further complicate the relationship of circulating plasma tryptophan 
concentration to serotonin production, approximately 80 – 90 % of circulating 
tryptophan is loosely bound to albumin (McMenamy and Oncley, 1958).  
Originally, it was thought that bound tryptophan was not available for uptake 
into the central nervous system due to the size of the albumin molecule (Knott 
and Curzon, 1972).  However, subsequent investigations failed to find any 
relationship between the concentration of free tryptophan in the plasma and 
the concentration of tryptophan in the brain (Fernstrom et al., 1976; Madras et 
al., 1974).  Pardridge (1983) suggested that the large neutral amino acid 
transporter at the blood brain barrier may be able to disassociate tryptophan 
from albumin, thereby making tryptophan available for transport into the brain 
across the blood brain barrier.  
 
Once tryptophan does cross the blood brain barrier, it is delivered to the 
serotonergic neurons where the enzyme tryptophan hydroxylase hydroxylates 
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the 5 carbon position to create 5-hydroxytryptophan.  Although the action of 
tryptophan hydroxylase is the rate-limiting step in the synthesis of serotonin, 
in a healthy, resting individual this enzyme is only around 50 % saturated.  
This means that an increase or decrease in the rate of tryptophan transport 
across the blood brain barrier will lead to a corresponding increase or 
decrease in the rate of serotonin synthesis within the central nervous system 
(Hamon et al., 1981).  The 5-hydroxytryptophan is then rapidly decarboxylated 
into 5-hydroxytryptamine (serotonin; 5-HT) by 5-hydroxytryptophan 
decarboxylase.  The chemical pathways involved in this are shown in the top 
half of Figure 1.2. 
 
 
 
Figure 1.2. The chemical pathways involved in the synthesis and metabolism of serotonin. 
 
The reactions synthesising serotonin from tryptophan occur in both the 
perikarya and the nerve terminals.  If the serotonin is synthesised in the 
 8  
perikarya it then travels down the axon to where it is stored, at the nerve 
terminals. 
 
1.2.2.3 Serotonin storage and release 
Serotonin is maintained at the nerve terminals of the dendrites and axons in 
vesicles so that there is a readily available store.  By being stored in the 
vesicles the serotonin is protected from further metabolism.  The serotonin 
content of the vesicles is maintained by H+-ATPase (Moriyama and Futai, 
1990).  The serotonin is released into the synaptic cleft from the pre-synaptic 
vesicles in response to voltage sensitive calcium conductance (Cooper et al., 
2003A).  Newly synthesised serotonin is preferentially released (Elks et al., 
1979).  What remains unclear is whether the vesicle undergoes rapid fusion 
with the pre-synaptic specialised membrane, allowing the stored 
neurotransmitter to diffuse out into the synaptic cleft, or whether the vesicle 
lyses whilst still inside the nerve ending, and the release of the 
neurotransmitter evokes a rapid insertion of the vesicle into the plasma 
membrane, with the reverse occurring later for endocytosis (Cooper et al., 
2003C). 
 
1.2.2.4 Serotonin reuptake 
Once in the synaptic cleft, serotonin activates both pre- and post-synaptic 
receptors.  The pre-synaptic auto-receptors have a limited effect at 
modulating serotonin release (Cooper et al., 2003A).  The action of serotonin 
is terminated by its reuptake into the presynaptic nerve terminal (Cooper et 
al., 2003A).  Serotonin transporters actively reduce the synaptic 
concentrations of serotonin to levels that are not capable of maintaining the 
activation of post-synaptic receptors.  Many pharmacological agents have 
been developed which can selectively inhibit the reuptake of serotonin into the 
pre-synaptic nerve terminal, thereby maintaining the concentration of 
serotonin at the post-synaptic receptors.  These pharmacological agents, 
often referred to as selective serotonin reuptake inhibitors (SSRIs), include 
the antidepressant drugs Citalopram, Paroxetine and Fluoxetine.  
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Serotonin is transported back into the neuron by a high affinity and low 
capacity carrier which can reach saturation and which also relies on sodium 
and chloride ions being co-transported with the serotonin and potassium or 
hydrogen ions being counter-transported (Talvenheimo et al., 1983).  This 
carrier is energy, temperature and sodium dependent (Lawrence, 1991).  
Serotonin may be returned to the synaptic vesicles for reuse or may be 
metabolised. 
 
1.2.2.5 Serotonin metabolism 
Serotonin is initially metabolised into 5-hydroxyindole acetaldehyde by 
monoamine oxidase A and then converted to either 5-hydroxyindoleacetic 
acid (5-HIAA; the main metabolite) by aldehyde dehydrogenase, or 5-
hydroxytryptophol (5-HTOH; a minor metabolite) by aldehyde reductase.  
Which of these metabolic pathways is taken is determined by the ratio of 
NAD+ to NADH in the tissue (Cooper et al., 2003A).  These pathways are 
shown in the bottom half of Figure 1.2. 
 
Serotonin is implicated in many psychiatric disorders, and therefore much of 
the research into its role within the body is from a pharmacological stand 
point.  The concentration of 5-HIAA in the brain has been used in the 
assessment of psychiatric disorders as a marker of serotonergic activity (Roy, 
1999; Gjerris et al., 1987).  
 
1.2.2.6 Peripheral models of the serotonergic neuron 
For obvious reasons, the direct examination of the central serotonergic 
system is restricted in humans.  However, as mentioned previously, the blood 
platelets are able to transport serotonin and share several commonalities with 
the serotonergic neuron.  Therefore, it is possible to use the blood platelet as 
a simple and accessible peripheral model for the examination of the 
serotonergic neuron and investigate the development of fatigue within 
individuals.  
 
In humans, the serotonin transporters in both brain tissue and blood platelets 
are encoded by a single gene on the chromosome 17q11.2.  Platelets and 
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serotonergic neurons both actively transport serotonin and are also both 
storage vesicles for serotonin; their serotonin uptake kinetics are similar, as 
are their release mechanisms (Da Prada et al., 1988).  Although there are 
many similarities between the blood platelets and the serotonergic neurons 
which can be exploited to study the central nervous system, there are also 
several differences, including the platelet’s inability to synthesise serotonin.  
Despite their dissimilarities, the relative simplicity and accessibility of a 
platelet compared to a neuron may be an advantage to investigations and the 
dense, complex network of interconnecting cells in neuronal tissue is not an 
interfering influence in platelets (Pletscher, 1988). 
 
Blood platelets vary in size and age; younger platelets are larger, denser and 
more metabolically active.  However, the functional properties of the platelets 
are believed to be independent of size and density (Thompson et al., 1983).  
Acute, strenuous exercise increases blood platelet counts by the alpha-
adrenergic stimulation of the spleen.  The spleen contains approximately one 
third of the exchangeable platelet population (Chamberlain et al., 1990), and 
the age of these platelets is similar to that of the population in the circulation 
(Chamberlain et al., 1990). 
 
There is previous research in healthy athletic populations investigating platelet 
serotonin transporter density.  Strachan and Maughan (1998) showed that the 
density of the serotonin reuptake transporter is greater in the platelet 
membranes of endurance trained participants compared to sedentary 
controls.  As discussed above in Section 1.2.2.4, the reuptake of serotonin 
reduces the concentration in the synaptic cleft to levels incapable of 
maintaining activation of post-synaptic receptors.  Therefore, an increased 
number of serotonin reuptake transporters could lead to a faster reduction in 
the synaptic concentration of serotonin, which in turn would theoretically lead 
to a delay in the onset, or a blunting in the degree, of fatigue.  Wilson and 
Maughan (1992) indirectly supported this theory by showing that 
administering a serotonin reuptake inhibitor reduced prolonged exercise 
capacity.  Furthermore, Struder et al. (1999) then found that after a bout of 
acute endurance exercise (five hours cycling on a cycle ergometer at a heart 
 11  
rate corresponding to a blood lactate concentration of 2 mmol / L) the 5-HT2A 
receptor density on blood platelets was reduced.   
 
If these peripheral changes are reflected in the central nervous system it may 
imply that individuals who regularly undertake endurance exercise have more 
serotonin transporters and also less serotonin receptors which could alter 
their perception of fatigue and pain.  Unfortunately, due to the nature of these 
investigations it can only be hypothesised that the changes which occur 
peripherally will also occur within the brain.  This being said, research into 
depression has frequently used the blood platelet as a peripheral model for 
investigating the serotonergic neuron, and the potency of tricyclic 
antidepressants to inhibit serotonin uptake in platelets and the brain are highly 
correlated (Da Prada et al., 1988). 
 
Genetic differences have been identified within healthy human participants for 
the expression and function of serotonin transporters in platelets.  The short 
form allele is dominant in healthy males, but the genotype has no effect on 
platelet [3H]Paroxetine binding (Bmax), which is a predictor of the number of 
transporters on the membrane of a serotonergic neuron (Greenberg et al., 
1999).  As suggested above, the density of transporters could alter the 
perception of fatigue.  Park et al. (2004) suggest that the short form was found 
more in elite long distance runners compared to either elite short distance 
runners or control participants.  Greenberg et al. (1999) found that the long 
form allele was associated with a rapid initial platelet serotonin uptake 
(Vmax).  Once again, a transporter with an elevated rate of uptake could also 
influence the effects of the released neurotransmitter. 
 
1.2.2.7 Serotonin overview 
Numerous proposals have been put forward as to how the synthesis and 
release of serotonin can be manipulated, and the effects of such interventions 
have been hypothesised.  As discussed above, tryptophan must be 
hydroxylated, and vital components of this process are pteridine and oxygen.  
Therefore, the availability of these substrates is also vital.   
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1.2.3 Dopamine 
The possible involvement of dopamine in the central fatigue process was 
initially discovered through studies into the effects of amphetamines in 
animals (Chaouloff et al., 1987).  These studies showed that during prolonged 
activity there are increases in dopamine activity within the brain.  
Amphetamines act to enhance exercise performance through their influence 
as potent dopamine releasers (Adams et al., 2002) and reuptake inhibitors 
(Azzaro et al., 1974).  The elevation of catecholaminergic neurotransmission 
is generally linked to feelings of reward, arousal, attention and motivation.  
Amphetamines are well known to enhance exercise performance (see Laties 
and Weiss, 1981, for a review) although, in sport, this knowledge is of no use 
due the inclusion of amphetamines, and related substances, on the list of 
prohibited substances in sport as set by the World Anti-Doping Agency 
(WADA). 
 
Subsequently, since pharmacological manipulation of dopamine using 
amphetamines is not an option for athletes, nutritional manipulation has also 
received attention.  The amino acid tyrosine is the precursor to dopamine 
production.  Unlike tryptophan however, it is not an essential amino acid and it 
can be synthesised in the liver from phenylalanine.  Tyrosine is transported 
across the blood brain barrier by the same transporter as tryptophan and 
other large neutral amino acids, as discussed above.  However, the rate 
limiting enzyme in the metabolic pathway transforming tyrosine to dopamine is 
saturated at rest (Cooper et al., 2003B), meaning increased tyrosine delivery 
will not increase dopamine synthesis (Davis and Bailey, 1997).  
 
Adenosine inhibits the release of excitatory neurotransmitters, such as 
dopamine.  Caffeine is a strong adenosine antagonist and produces a marked 
reduction in the central adenosine neurotransmission when it crosses the 
blood brain barrier, which it does with ease.  Caffeine therefore enhances the 
release of dopamine and acts in a similar way to amphetamine and cocaine.  
It has been shown to significantly improve exercise capacity in rats when 
infused directly into the brain (Davis et al., 2003) and in humans when 
ingested orally (Graham and Spriet, 1995).  Conversely, the infusion of an 
 13  
adenosine agonist drug reduced exercise capacity, and when the antagonistic 
caffeine and the agonistic drug were infused concurrently there was no 
change in the exercise capacity (Davis et al., 2003).  
 
Bupropion, as well as being widely used as an aid in the cessation of 
smoking, is an anti-depressant drug that acts to inhibit dopamine reuptake.  
Watson and colleagues (2005A) found that in warm (30 °C) environmental 
conditions, the administration of Bupropion improved pre-loaded time-trial 
cycling performance.  It has no significant effects on the serotonergic system, 
either clinically or on post synaptic receptors, making it distinctly different from 
many antidepressant drugs which cause a variety of side effects including 
sedation, weight gain and sexual dysfunction (Stahl et al., 2004).  However, 
Watson and colleagues (2005A) did not find an improvement in the 
performance of the same task with Bupropion supplementation in cooler 
ambient conditions (18 °C).  
 
 
1.3 Newsholme’s theory of central fatigue 
1.3.1 Newsholme’s theory 
The most investigated and best known theory proposed as a possible 
explanation for central fatigue during exercise was put forward over twenty 
years ago.  Newsholme and colleagues (1987) suggested that increased brain 
serotonin levels during physical activity reduces exercise capacity and is 
therefore detrimental to performance.  This theory has received a great deal 
of attention and has been the reasoning behind many investigations into the 
role of the brain during fatigue.  
 
The precursor for serotonin synthesis, as explained above in section 1.2.2.2, 
is tryptophan.  The majority of tryptophan (80 – 90 % depending upon various 
factors including recent diet and exercise) circulates in the blood loosely 
bound to albumin.  Only free tryptophan can cross the blood brain barrier for 
use in the synthesis of serotonin.  Even free tryptophan, which is not bound to 
albumin, must compete with branched-chain amino acids for transport into the 
central nervous system, also explained in section 1.2.2.2.  The Newsholme 
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theory of central fatigue is based on these situations.  A simplistic diagram of 
the resting situation at the blood brain barrier is presented in Figure 1.3. 
 
 
 
Figure 1.3. A simplistic view of the situation at the blood brain barrier at rest. 
 
As discussed above, free fatty acids are carried through the circulation by 
albumin.  At the onset of exercise there is an initial fall in the plasma 
concentration of free fatty acids due to the rate of uptake into the muscle 
increasing disproportionately to the rate of mobilisation from adipose tissue. 
As exercise progresses however, there is often a gradual increase in the 
circulating concentration of free fatty acids due to adrenaline stimulated 
lipolysis, without a concurrent increase in the rate of uptake into the working 
muscle (Spriet, 2002).  As exercise progresses, and muscle and liver 
glycogen stores become depleted, the mobilisation of free fatty acids 
increases disproportionately compared to the rate at which they can be 
transported into the muscle, resulting in further elevations in circulating free 
fatty acid levels (Newsholme and Castell, 2000).  The increase in plasma free 
fatty acid concentration leads to an increase in free tryptophan concentration 
in the circulation as they are both predominantly transported bound to 
albumin.  However, albumin has a greater affinity for free fatty acids and in the 
process of attaching to the free fatty acid, the albumin undergoes a 
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conformational change which results in the release of the tryptophan from its 
binding site into the circulation.  Plasma free tryptophan and free fatty acid 
concentrations have been shown to be highly related during exercise (Davis 
et al., 1992).  This increase in free tryptophan means that more is available to 
be transported across the blood brain barrier to form serotonin.  
 
Concurrently during prolonged exercise, plasma branched-chain amino acid 
concentrations fall as they are taken up from the blood and metabolised in 
working muscles to provide energy (Blomstrand et al., 1988).  This means 
there is less competition for tryptophan to be transported across the blood 
brain barrier.  Therefore, as exercise duration increases there is an increase 
in tryptophan availability and transport into the central nervous system 
becomes less competitive.  A simplistic diagram of the situation during 
prolonged exercise is presented in Figure 1.4. 
 
 
 
Figure 1.4. A simplistic view of the situation at the blood brain barrier during prolonged 
exercise. 
 
Newsholme’s theory suggests that this leads to increased levels of serotonin 
in the brain, increased perception of the effort required to sustain an exercise 
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intensity, loss of drive and motivation and ultimately fatigue and the cessation 
of exercise.  Evidence for this chain of events exists in animal studies.  
Prolonged exercise increased plasma free tryptophan levels and also brain 
tryptophan and 5-hydroxyindoleacetic acid levels in rats (Chaouloff et al., 
1985; Chaouloff et al., 1986A; Chaouloff et al., 1986B).  Further studies in rats 
have shown that the brain concentration of serotonin and its metabolites 
increases during prolonged exercise and peaks at the point of exhaustion 
(Bailey et al., 1993). 
 
One of the reasons for the popularity of the Newsholme theory is undoubtedly 
the opportunity it offers for manipulation in order to improve exercise capacity 
and/or performance.  The theory has been extensively investigated, yet 
contrasting and inconsistent results mean that its accuracy remains unclear. 
 
1.3.2 Pharmacological evidence 
By artificially increasing brain serotonin levels in rats through the 
intraperitoneal administration of various doses of a specific serotonin agonist 
(m-chlorophenyl piperazine), treadmill exercise time to exhaustion decreased 
in a dose response manor, with the biggest dose resulting in the shortest run 
time to exhaustion (Bailey et al., 1992).  Conversely, intraperitoneal 
administration of a serotonin antagonist (LY 53857) increased time to 
exhaustion compared to a control injection (Bailey et al., 1993).  
 
The principles employed in the aforementioned investigations in animals have 
also been studied in human participants, where drugs designed to inhibit the 
removal of serotonin from the synaptic cleft (serotonin agonists) were 
administered.  Increased effort and reduced exercise capacity were reported 
in these trials, supporting Newsholme’s theory of central fatigue (Wilson and 
Maughan, 1992; Davis et al., 1993; Marvin et al., 1997).  However, other 
studies have failed to replicate these findings (Meeusen et al., 1997; Meeusen 
et al., 2001; Strachan et al., 2004), and further experiments designed to 
improve exercise performance through altering catecholamine or brain 
dopamine concentrations have also shown little success (Meeusen et al., 
1997; Piacentini et al., 2004; Watson et al., 2005A).  
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1.3.3 Nutritional evidence 
Although there is evidence supporting the Newsholme theory in animal 
models, the picture in humans is less clear.  Well controlled laboratory based 
experiments largely discredit the theory regarding the role of fatty acids and 
branched-chain amino acids regulating tryptophan production in the brain.  
 
1.3.3.1 Branched-chain amino acid supplementation 
As discussed above it is well established that the branched-chain amino acids 
compete with tryptophan for transport across the blood brain barrier.  By 
increasing the concentration of branched-chain amino acids in the plasma 
through supplementation, the ratio of free tryptophan to branched-chain amino 
acids is also decreased.  This would result in a reduced uptake of tryptophan 
into the brain and therefore possibly a reduction in the synthesis of serotonin, 
thereby delaying the onset of fatigue.  The ratio of tryptophan to branched-
chain amino acids in plasma has been shown to be correlated with the brain 
tryptophan concentration (Leathwood, 1987).  This ratio is likely to be more 
important than the absolute concentrations of free tryptophan. 
 
Figure 1.5 shows a simplistic view of the situation at the blood brain barrier 
during prolonged exercise when amino acids are supplemented.  Only three 
studies in the published literature find that the administration of branched-
chain amino acids to human participants improves exercise performance. 
 
Chronic branched-chain amino acid supplementation has been shown to 
improve exercise performance by Hefler et al. (1995).  They put participants 
on a supplementation program feeding 16 g of branched-chain amino acids 
per day for fourteen days.  They found a 12 % improvement in performance of 
a forty kilometre time-trial in temperate conditions compared to a placebo 
treatment.  Unfortunately, little more is known about the study as this 
investigation was merely presented as an abstract and never published as a 
full article.  Supporting data and detail of the methodology are not available, 
making the findings hard to interpret and highly questionable.  
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Figure 1.5. A simplistic view of the situation at the blood brain barrier during prolonged 
exercise when branched-chain amino acids are supplemented.  
 
Mittleman and colleagues (1998) performed an apparently well-controlled 
laboratory based study into the effects of supplementation of branched-chain 
amino acids on exercise (40 %  ̇O2max) capacity in the heat (34.4 ± 1.8 °C).  
They found that exercise time to exhaustion was longer (153.1 ± 13.3 vs. 
137.0 ± 12.2 min) when participants were given drinks (5 ml / kg body mass) 
containing 5.88 g / L of BCAA (54 % leucine, 19 % isoleucine and 27 % 
valine) compared to when they were given the same volume of a placebo 
drink.  They reported no difference in any peripheral markers of fatigue 
between the trials and therefore concluded that their supplementation regimen 
was suitable for delaying the onset of central fatigue.  
 
1.3.3.1.2 Evidence against an ergogenic effect of branched-chain amino acids 
Despite the three studies which find a positive effect on exercise performance 
of branched-chain amino acid supplementation, there are many studies in the 
published literature that find no benefit.  These include exercise capacity tests 
(Blomstrand et al., 1995; Blomstrand et al., 1997; Galiano et al., 1991; Struder 
et al., 1998; Van Hall et al., 1995; Watson et al., 2004), incremental tests 
(Varnier et al., 1994), intermittent tests (Davis et al., 1999) and performance 
tests (Hassmen et al., 1994).  Details of these studies are in Table 1.1.
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Table 1.1.  A review of studies involving branched-chain amino acid supplementation, listed according to main outcome. 
 
STUDY PARTICIPANTS BCAA DETAILS PROTOCOL OUTCOME 
Mittleman  
et al., 1998 
7 males and 
6 females, 
moderate training 
5.88 g / L BCAA or 
5.88 g / L polydextrose 
placebo 
Cycle time to exhaustion 
at 40 %  ̇O2peak in 34 °C  
INCREASED EXERCISE CAPACITY  
(153.1 ± 13.3 minutes BCAA,  
137.0 ± 12.2 minutes placebo)  
Blomstrand et 
al., 1991A 
107 (BCAA) and 
111 (placebo) male 
runners 
7.5 g (cross country) or 
16 g (marathon)  
or a 5 % CHO placebo 
30 km cross country 
running race or 42.2 km 
marathon running race 
IMPROVED MARATHON PERFORMANCE 
(but in slower runners only)  
 
Hefler  
et al., 1995 
(Abstract only) 
10 competitive 
male cyclists 
16 g / day BCAA for 14 
days.  
Placebo used. 
40 km cycling time-trial IMPROVED EXERCISE PERFORMANCE  
(56.7 ± 1.6 minutes placebo,  
51.4 ± 2.6 minutes BCAA) 
Hassmen  
et al., 1994 
52 males BCAA + CHO  
or CHO only 
30 km cross country 
running race 
IMPROVED COGNITIVE FUNCTION  
(in one test, prevented a drop in performance of 
two tests) 
Blomstrand et 
al., 1991B 
6 female national 
level footballers 
6 % CHO + 7.5 g / L 
BCAA or 6 % CHO  
Stroop tests before and 
after a match 
IMPROVED COGNITIVE FUNCTION  
(after match compared to before match)  
Blomstrand et 
al., 1997 
7 endurance 
trained male 
cyclists 
7 g / L  
or flavoured water 
Pre-loaded (60 minutes at 
70 %  ̇O2max) 20 minute 
cycling time-trial 
IMPROVED RPE  
(area under the curve smaller) 
NO CHANGE IN EXERCISE CAPACITY  
(Work done: 275 kJ BCAA, 250 kJ placebo) 
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STUDY PARTICIPANTS BCAA DETAILS PROTOCOL OUTCOME 
Davis  
et al., 1999 
3 active males, 5 
active females 
20 % CHO or 20 % 
CHO + 7 g BCAA  
Preloaded (75 min 
intermittent shuttle run) 
shuttle run to exhaustion 
NO CHANGE IN EXERCISE CAPACITY  
(CHO+BCAA: 9 min, CHO alone: 9.66 min)  
Blomstrand et 
al., 1995 
5 endurance 
trained males 
6 % CHO or 6 % CHO 
+ 7 g / L BCAA or 
placebo 
20 minutes pre-loaded 
(60 minutes at 75 % 
 ̇O2max) time-trial 
NO CHANGE IN EXERCISE CAPACITY  
(work: 264 ± 11 kJ CHO+BCAA, 263 ± 13 kJ 
CHO, 231 ± 11 kJ placebo) 
Galiano  
et al., 1991 
8 trained males 6 % CHO or 6 % CHO 
with 735 mg / L BCAA 
Cycling time to 
exhaustion at 70 % 
 ̇O2max 
NO CHANGE IN EXERCISE CAPACITY  
(220 ± 11 min CHO+BCAA, 235 ± 10 min CHO) 
Struder  
et al., 1996 
10 endurance 
trained males 
26 g / L BCAA + 46.5 g 
/ L other amino acids 
90 minute treadmill run 
 (2 mmol / L lactate) 
NO CHANGE IN RPE 
Struder  
et al., 1998 
10 endurance 
trained males 
21 g of BCAA.  
Placebo used 
Cycle time to exhaustion 
at 2 mmol / L lactate  
NO CHANGE IN EXERCISE CAPACITY  
(Placebo 157 ± 53 min, BCAA 152 ± 41 min) 
Van Hall  
et al., 1995 
10 endurance 
trained males 
6 or 18 g / L BCAA 6 % 
sucrose placebo 
Cycle time to exhaustion 
at 70 – 75 % Wmax 
NO CHANGE IN EXERCISE CAPACITY  
(122 ± 3 min both conditions) 
Varnier  
et al., 1994 
6 moderately 
trained males 
260 mg / kg / h or 
saline placebo 
Incremental cycle (35 W 
every 4 minutes) time to 
exhaustion 
NO CHANGE IN EXERCISE CAPACITY 
 (about 60 min exercise duration) 
Watson  
et al., 2004 
8 recreationally 
active males 
12 g / L BCAA or 
placebo 
Cycle time to exhaustion 
at 50 %  ̇O2 max in 30 °C 
NO CHANGE IN EXERCISE CAPACITY  
(placebo 104 ± 27 min, BCAA 111 ± 29 min) 
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Despite the overwhelming evidence that branched-chain amino acid 
supplementation does not improve exercise performance or capacity, there is 
some evidence to suggest that it improves cognitive performance (Blomstrand 
et al., 1991B; Hassmen et al., 1994).  Also, ratings of perceived exertion 
during exercise have been shown to both improve (Blomstrand et al., 1997) 
and to not differ (Struder et al., 1996) with the supplementation of branched-
chain amino acids during exercise.  
 
1.3.3.2 Tryptophan depletion 
Completely removing tryptophan from the diet reduces plasma tryptophan by 
only around 20 %, and consequently has few behavioural consequences (Bell 
et al., 2001).  To induce greater falls in plasma tryptophan concentration, 
feeding an amino acid load, with the particular omission of tryptophan, 
achieves about an 80 % reduction in plasma free and total tryptophan levels 
five to seven hours after consumption, a technique known as rapid or acute 
tryptophan depletion (Delgado et al., 1990).  
 
Acute tryptophan depletion works by loading the system with amino acids, 
causing protein synthesis to be stimulated, a process which requires 
tryptophan (Bell et al., 2001).  Since it was not ingested, tryptophan is utilised 
from the stores within the body.  Administering large neutral amino acids 
further reduces the amount of tryptophan transported across the blood brain 
barrier due to increased competition for the common transporter (Pardridge, 
1983).  Such a reduction may therefore inhibit the synthesis of serotonin (Bell 
et al., 2001).  Figure 1.6 shows a simplistic view of the situation at the blood 
brain barrier with acute tryptophan depletion.  
 
Acute tryptophan depletion is a popular, well documented technique which 
has been used extensively in clinical studies into: depression (Neumeister et 
al., 2004); anxiety (Bell et al., 2001); aggression (McCloskey et al., 2009); 
sleep patterns (Bhatti et al., 1998); memory (Schmitt et al., 2000); eating 
disorders (Weltzin et al., 1995) and cognitive function (Gallagher et al., 2003).  
Through the combined effects of a tryptophan free diet and acute tryptophan 
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depletion, the lowered brain serotonin concentrations could, theoretically, lead 
to an improvement in exercise capacity.  
 
 
 
Figure 1.6. A simplistic view of the situation at the blood brain barrier when an acute 
tryptophan depletion protocol has been followed. 
 
1.3.3.3 Tryptophan supplementation 
Following the Newsholme theory of central fatigue, supplementing tryptophan 
should elicit a decrement in exercise capacity and this has been shown to be 
the case in horses (Farris et al., 1998) and rats (Soares et al., 2004; Soares et 
al., 2007).  In humans however, tryptophan supplementation (1.2 g over 
approximately fifteen hours) has been shown to improve exercise capacity 
(Segura and Ventura, 1988).  However, it should be noted that the findings of 
an improvement in exercise capacity (running at 80 %  ̇O2max) by on 
average 49 % (and 260 % and 160 % in two participants), combined with 
some incredulously short run times to exhaustion (placebo trial mean 335 ± 
140 seconds, range 150 – 570 seconds) leaves these findings open to 
speculation.  Furthermore, when this protocol was repeated with forty-nine 
participants rather than just twelve, no effect on exercise capacity was seen 
(placebo group mean of 443.5 ± 100.2 seconds vs. tryptophan group mean of 
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451.4 ± 99.6 seconds; Stensrud et al., 1992).  This finding is also reflected in 
the results by Van Hall et al. (1995). 
 
1.3.3.4 Free fatty acid supplementation 
Huffman et al. (2004) investigated the Newsholme theory from another angle.  
They hypothesised that supplementation with omega-3 fatty acids would 
reduce free tryptophan concentration, reduce serotonin production and 
therefore increase exercise capacity.  Omega-3 fatty acids cause an increase 
in the rate of free fatty acid oxidation through the activation of a nuclear 
transcription factor (Clarke, 2001).  However, chronic supplementation of 
omega-3 fatty acids (4 g / day for four weeks) in five male and five female 
participants did not alter pre-loaded exercise capacity nor free tryptophan or 
free fatty acid plasma concentrations, although the average free tryptophan to 
branched-chain amino acid ratio over the exercise bouts was significantly 
lower after supplementation than before.  
 
1.3.3.5 Ammonia  
Ammonia has been suggested to have an influence on cerebral metabolism 
and on the development of central fatigue.  Ammonia concentration increases 
with the deamination of branched-chain amino acids, as occurs during 
prolonged exercise.  Therefore, when branched-chain amino acids are 
supplemented there is an even greater increase in the circulating 
concentration of ammonia.  Indeed, Watson et al. (2004) found that branched-
chain amino acid supplementation did not change plasma ammonia 
concentration at rest.  During subsequent exercise to exhaustion at 50 % 
 ̇O2peak in 30 °C, the plasma ammonia concentration on the branched-chain 
amino acid trials was significantly greater than on the placebo trials (Watson 
et al., 2004).   
 
This exercise-induced hyperammonaemia has been hypothesised to be one 
of the reasons for the failure to see an improvement in exercise capacity after 
supplementation of branched-chain amino acids (Nybo and Secher, 2004).  
Ammonia and glutamate are the precursors for the synthesis of glutamine. 
24 
 
The brain has no mechanism for the removal of excess ammonia, which can 
cross the blood brain barrier, other than glutamine synthesis. Glutamine 
synthesis may therefore lower the concentration of glutamate in the brain, and 
glutamate is a precursor for the synthesis of gamma-aminobutyric acid 
(GABA), meaning that this could also be lowered as a result of increased 
ammonia concentrations (Nybo and Secher, 2004).  GABAergic neurons are 
the major source of synaptic inhibition in the nervous system (Bear et al., 
2001).  Therefore, reduction in GABA could be involved in central fatigue.  
However, this theory has been sparsely investigated in humans and therefore 
it is impossible to conclude whether or not this plays a role in the failure to see 
an ergogenic effect of branched-chain amino acid supplementation protocols. 
 
1.3.3.6 Carbohydrate supplementation 
Carbohydrate supplementation has been suggested to influence central 
fatigue through its actions on the serotonergic system because carbohydrate 
attenuates the transportation of tryptophan across the blood brain barrier.  
Exogenous carbohydrate suppresses lipolysis, thereby reducing circulating 
free fatty acid concentration in the plasma.  With less free fatty acids 
displacing the albumin-bound tryptophan, carbohydrate limits the rise in 
circulating free tryptophan concentration seen during prolonged exercise.  
This reduces the level of tryptophan uptake into the brain compared to when 
plain water is given (Blomstrand et al., 2005).  This may subsequently lead to 
a reduction in serotonin synthesis, thereby improving exercise performance.  
 
Indeed, plasma branched-chain amino acid concentrations fell from around 
400 µmol / L at rest to around 325  µmol / L and 275 µmol / L at the point of 
exhaustion when 6 % and 12 % carbohydrate drinks respectively were 
administered.  Branched-chain amino acid concentration was maintained 
throughout the exercise on the placebo trial.  There was also a five- to seven-
fold increase in the ratio of free tryptophan to branched-chain amino acids in 
plasma during the 6 % and 12 % carbohydrate trials compared to the placebo 
trial (Davis et al., 1992).  Exercise capacity, assessed as time to exhaustion 
on a cycle ergometer at approximately 68 %  ̇O2max, was increased in the 
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carbohydrate trials (average (mean ± SEM) of 235 ± 10 and 234 ± 9 minutes 
for the 6 % and 12 % carbohydrate drinks respectively) compared to the 
placebo trials (average of 190 ± 4 minutes), suggesting that the 
supplementation of exogenous carbohydrate delayed the onset of central 
fatigue (Davis et al., 1992). 
 
Rats, however, showed no additive effect of carbohydrate with branched-
chain amino acid supplementation (171 ± 12 minutes) compared to when the 
two supplements were administered individually, in an exercise to exhaustion 
test following a glycogen depletion protocol (Calders et al., 1999).  There was 
an improvement in the time to exhaustion in the branched-chain amino acid 
trial (158 ± 26 minutes) and in the carbohydrate trial (179 ± 21 minutes) 
compared to the saline trial (118 ± 35 minutes), probably resulting from their 
contribution as a fuel source.  The lack of an additive effect was purported to 
be due to the presence of carbohydrate inhibiting amino acid catabolism. 
 
Further evidence for the effect of carbohydrate on the brain during exercise 
comes from studies which have investigated the effects of mouth rinsing 
carbohydrate.  The presence of 6.4 % carbohydrate (glucose or maltodextrin) 
in the mouth activates reward related regions of the brain, including the frontal 
operculum and the striatum (Chambers et al., 2009).  Interestingly, the 
artificial sweetener sucralose does not elicit such a strong response in these 
regions as sucrose (Frank et al., 2008).  This activation of reward related 
brain regions by the presence of carbohydrate in the mouth without ingestion 
has been shown to result in improvements in exercise performance in cycling 
(Carter et al., 2004; Chambers et al., 2009) and running (Rollo et al., 2010), 
when participants were fasted for six or more hours.  However, the same 
improvements were not seen in a running time-trial performance conducted 
after a four hour fast (Whitham and McKinney, 2007). 
 
Unfortunately, due to the well reported ergogenic effect of carbohydrate 
supplementation on peripheral causes of fatigue (Neufer et al., 1987; 
Jeukendrup et al., 1997; Coggan and Coyle, 1991), it is very difficult to 
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interpret the extent of the central element of improvements in exercise 
performance or capacity as a result of exogenous carbohydrate supply.  
 
1.3.4 Overview  
It is important to consider the limitations of all investigations in order to 
determine whether or not their findings can be applied to alternative 
situations.  Much of the early research on the role of the serotonergic system 
in fatigue used brain homogenates and therefore may not represent true in 
vivo situations.  Often, research is not done using human participants and 
inter-species differences in substrate supply and neurotransmitter 
metabolism, storage and release, are likely to exist.  
 
It has been hypothesised that neurotransmitters, other than serotonin, may 
also have roles to play in the onset of central fatigue.  It is likely that there is 
not just a single mechanism of fatigue.  Rather, an interdigitated response of 
several neurochemicals, which act in concert to bring about fatigue and the 
cessation of exercise, is a more plausible theory.  However, the serotonin 
system will still undoubtedly play a role in the central response.  Furthermore, 
the precise role and influence of each neurochemical may be dependent upon 
many other factors such as core temperature and individual fitness levels.  
 
 
1.4 Prolonged exercise in the heat 
1.4.1 Overview 
Mechanically, humans are at most 20 – 30 % efficient; the majority of energy 
is lost as heat (Powers and Howley, 2007).  Exercise and physical activity can 
substantially increase metabolic heat production, but due to effective heat loss 
mechanisms (radiation, conduction, convection and evaporation) the human 
core body temperature remains relatively stable over a large range of ambient 
temperatures (Astrand et al., 2003B).  Autonomic temperature regulation is 
under the control of the central nervous system and involves the activation of 
heat loss mechanisms such as sweating or heat retention mechanisms such 
as peripheral vasoconstriction (Parsons, 2003B). 
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1.4.1.1 Performance 
Unless endurance exercise is undertaken in cool conditions or at low 
intensities then a steady rise in core body temperature occurs.  In some 
power based events an elevated core temperature is thought to be of benefit, 
since this increases the rates of the actin / myosin interaction within the 
muscle fibre (Astrand et al., 2003B) and also increases mitochondrial ATPase 
activity (Brookes et al., 1971).  However, it is generally accepted that during 
prolonged exercise a rising core temperature, due to a reduction in the body’s 
ability to lose heat, will result in a decrement in performance due to the onset 
of hyperthermia.  
 
High ambient temperatures (31 °C) can reduce the capacity to perform 
prolonged exercise, compared to a cooler environment (11 °C), by just below 
50 % (Galloway and Maughan, 1997).  A 6.5 % reduction in mean power 
output during a thirty minute cycling time-trial was seen when ambient 
temperature increased from 23 °C to 32 °C, without a change in rectal 
temperature between trials (Tatterson et al., 2000).  Often, when ambient 
temperature is increased there is also an accompanying increase in the rating 
of perceived exertion for the task (Morris et al., 2000).  Indeed, Nybo and 
Nielsen (2001C) found a correlation between core temperature and RPE, and 
also electroencephalogram activity in the frontal, central and occipital cortex. 
 
1.4.1.2 Substrate utilisation 
Exercise during heat exposure has been suggested to up-regulate the flux 
through the pyruvate dehydrogenase pathway, possibly because some of the 
pyruvate formed is being oxidised (Febbraio et al., 1994; Febbraio, 2001).  
While fatigue during prolonged exercise in temperate conditions is often 
attributed to depletion of muscle glycogen (Bergstrom et al., 1967), this 
relationship does not appear to hold true at high ambient temperatures.  
Parkin et al. (1999) found that despite no differences in resting muscle 
glycogen concentration; at the point of exhaustion following cycling at 70 % 
 ̇O2peak there was significantly more muscle glycogen remaining after the 
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trials that took place in 40 °C (299 ± 33 mmol / kg) compared to either 20 °C 
(153 ± 27 mmol / kg) or 3 °C (116 ± 28 mmol / kg). 
 
Exercise in the heat per-se does not affect oxygen uptake in the muscle 
(Gonzalez-Alonso et al., 1998).  Indeed, even if blood flow to the working 
muscles is reduced, as seen during exercise when hypohydrated (Gonzalez-
Alonso et al., 1998), there does not appear to be a compromise in oxygen 
delivery or muscle metabolism, since the oxygen extraction by the working 
muscles can increase as a means of compensating for the reduced muscle 
blood flow (Gonzalez-Alonso et al., 1999A).  
 
Nielsen and colleagues have shown that at the point of fatigue there is no 
reduction in cardiac output, mean arterial pressure, muscle or skin blood flow 
(Nielsen et al., 1993; Nielsen et al., 1997) and in Galloway and Maughan’s 
(1997) experiment investigating exercise capacity at varying ambient 
temperatures, the carbohydrate oxidation rate was lower after forty five 
minutes cycling in 31 °C, where fatigue occurred earliest, compared to the 
same exercise performed in 4 °C, 11 °C or 21 °C. 
 
1.4.1.3 Thermoregulation and cardiovascular responses 
Hyperthermia or heat strain during exercise in warm or hot ambient 
temperatures places a strain on the cardiovascular system.  During exercise 
the volume of blood sent to the working muscles increases to provide them 
with fuel and oxygen, and to remove waste products.  However, at a given 
cardiac output during exercise in the heat, more blood will flow to the skin and 
less to the muscles than in lower environmental temperatures (Astrand et al., 
2003B).  Cardiac output increases, through an increase in heart rate, in an 
attempt to maintain muscle blood flow.  Often added into this situation is a 
falling blood volume due to dehydration, resulting from the loss of body fluids 
through sweating if no, or insufficient, fluids are consumed.  This reduces 
stroke volume leading to a compensatory increase in heart rate to maintain 
cardiac output (Wyndham, 1973).   
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Although skin blood flow increases during exercise in the heat, the reduced 
gradient between the skin temperature and the environmental temperature 
means that the efficacy of this avenue of heat loss is reduced and core 
temperature rises.  If core body temperature continues to rise, hyperthermia 
ensues.  This is thought to be a key factor in the development of fatigue as it 
reduces the motivation to continue with exercise (Bruck and Olschewski, 
1987).  This can be viewed as the body’s built-in safety mechanism to ensure 
that there is no further increase in core body temperature which could put the 
individual at risk of permanent damage. 
 
There have been suggestions that exhaustion during prolonged exercise in 
the heat may be related to a critically high core temperature of around 40°C 
(39.7 ± 0.15 °C), above which exercise cannot be sustained (Nielsen et al., 
1993).  It has been shown that by lowering initial core temperature, exercise 
capacity can equally also be increased, suggesting that time to fatigue is 
inversely related to initial core temperature (Gonzalez-Alonso et al., 1999B).   
 
However, it appears that critical core temperature, if such a phenomenon 
even exists, may be related to physical fitness and must vary between 
individuals, as core temperatures of well below 40 °C are frequently seen at 
the point of exhaustion, after prolonged exercise in the heat (Cheung and 
McLellan, 1998; Sawka et al., 1992; Bridge et al., 2003A; Bridge et al., 2003B; 
Hobson et al., 2009; Watson et al., 2004).  Furthermore, core temperature 
readings at the point of exhaustion after prolonged exercise in the heat have 
been reported to be in excess of 40 °C in some individuals (Pugh et al., 1967).  
A confounding factor in this debate, however, is the range of techniques and 
sites used to measure core temperature.  Recently it has also been shown 
that during hypohydration (4 %), every 1 °C increase in skin temperature 
results in a decrement in aerobic performance of around 1.6 % (Kenefick et 
al., 2010), despite no differences in core temperature. 
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1.4.2 The brain 
1.4.2.1 Blood flow and activity 
Exercise and heat stress, when combined, have serious implications for 
metabolism and circulation within the brain.  Blood flow to the brain increases 
during exercise in normal, temperate environments (Ide and Secher, 2000), 
but declines with hyperthermia, which is likely to occur during prolonged 
exercise in the heat (Nybo and Nielsen, 2001A).  Increased global cerebral 
metabolism in response to hyperthermia suggests that the overall levels of 
neuronal activity are increased (Nybo et al., 2002) although the underlying 
causes of this effect remain unclear as it could be attributed to increased 
exertion during prolonged exercise, or to the elevated core body temperature 
leading to increased rates of enzymatic processes (the Van’t Hoff Q10 effect), 
coupled with increasing cerebral metabolic rates of oxygen and glucose, both 
seen by Nybo and colleagues (2002). 
 
Through the use of positron emission tomography scans, Nunneley et al. 
(2002) demonstrated that at rest the cerebral metabolic rate of several brain 
regions, including the hypothalamus, thalamus, cerebellum and corpus 
callosum, was increased by systemic hyperthermia eliciting core temperatures 
of 38.6 °C and skin temperatures of 39 – 40 °C, compared to during 
normothermic conditions.  Within the central nervous system, temperature 
control is regulated by the hypothalamus, the brain stem and the spinal cord, 
and more specifically by the pre-optic area of the anterior hypothalamus 
(POAH; Boulant, 2000).  It is likely that similar activation occurs during 
passive heat exposure and exercise.  It is important to note however, that 
several brain regions showed increases in cerebral activity in the study by 
Nunneley and colleagues, not just the hypothalamus, implying that 
thermoregulation is not controlled by the hypothalamus alone and that several 
brain regions may co-operate in the perception of heat and the autonomic and 
behavioural responses to alterations in environmental and body temperature.  
 
1.4.2.2 Neurotransmitters 
Serotonin is known to be involved in thermoregulation (Jacobs and Azmitia, 
1992).  The 5-HT2c reuptake inhibitor Paroxetine increases core temperature 
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compared to when a placebo is administered, both at rest and during exercise 
in the heat (32 °C), although this did not influence exercise time to exhaustion 
nor ratings of perceived exertion (Strachan et al., 2004).  Serotonin is a major 
excitatory neurotransmitter for prolactin release (Struder and Weicker, 
2001A). Therefore, increases in serum prolactin levels can be associated with 
increases in serotonin release.  Serum prolactin levels are higher during 
exercise in the heat (30 °C) than during exercise in the cold (10 °C; Pitsiladis 
et al., 2002), but they do not correlate to plasma tryptophan, free tryptophan, 
branched-chain amino acids or the ratio of free tryptophan to branched-chain 
amino acids, all of which have been purported as peripheral modulators of the 
serotonin system.  Serum prolactin concentration did however relate to rectal 
temperature during exercise in the heat (Pitsiladis et al., 2002). 
 
Increased ratings of perceived exertion during exercise in the heat are not 
related to the cerebral balance of dopamine or tryptophan assessed by 
arterial and venous sampling (Nybo et al., 2003).  However dopamine has 
also been shown to be involved in thermoregulation.  Based on studies into 
the relationship between dopaminergic pathways and thermoregulation by 
Hasegawa et al. (2000) coupled with their own findings, Bridge et al. (2003A) 
suggest that an individual’s ability to exercise in the heat is enhanced by a 
high activity level in the dopaminergic pathways of the preoptic anterior 
hypothalamus. 
 
1.4.2.3 Muscle activation 
In rats (Fuller et al., 1998) and goats (Caputa et al., 1986) brain temperature 
has been shown to be a major factor affecting movement.  Although not 
directly related to endurance exercise in the heat, several studies have 
investigated the influence of hyperthermia on muscle activation.  
 
Nybo and Nielsen (2001B) found that exercise-induced hyperthermia (core 
temperature 40.0 ± 0.1 °C) caused a marked reduction in force generation 
capacity, both in exercised muscle groups and non-exercised muscle groups.  
However, Martin et al. (2005) and Saboisky et al. (2003) both found that while 
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hyperthermia caused a marked reduction in force generation capacity of 
exercised muscle, no such reduction was seen in non-exercised muscle.  
 
These results suggest that although an elevated core temperature decreases 
the central drive to activate muscles, it is unlikely to be the sole factor.  Once 
again, methodological differences between studies in the duration of 
activation required may also be the cause of the discrepancy in the findings.  
Either way, these studies offer clear evidence that hyperthermia, induced by 
exercise, reduces the brain’s drive to recruit active skeletal muscle. 
 
1.4.2.4 Brain temperature manipulation 
Several animal models have been used to investigate the role of various brain 
regions in the autonomic control of thermoregulation.  The temperature of the 
POAH has been reduced to induce heat saving (peripheral vasoconstriction) 
and heat producing (shivering) responses (Boulant and Gonzalez, 1977) or 
warmed to induce heat loss responses (increased skin blood flow; Jacobson 
and Squires, 1970).  Local warming of the hypothalamus has also been 
shown to evoke panting and cause vasodilation in cats and dogs (Magoun et 
al., 1938; Hemingway et al., 1940). 
 
The concept of being able to selectively cool the brain has been widely 
accepted in most mammals.  However, the application of this theory to the 
human brain is a source of much debate.  Cabanac (1993) suggests that 
selective brain cooling offers a better explanation of the benefits seen through 
head cooling, such as improved comfort, and increased exercise capacity, 
than does afferent nervous input to the brain from the skin.  
 
Unfortunately, there are several theories as to why selective brain cooling 
cannot exist in humans.  Physiologically, humans do not ‘pant’ as a 
thermoregulatory mechanism, neither do they have a carotid rete, which in 
some non-human mammals is a counter-current heat exchanger between 
arterial and venous bloods flowing to and from the brain (Brengelmann, 1993).  
Furthermore, selective brain cooling would effectively remove the protective 
error signal against potentially harmful hyperthermic conditions in the rest of 
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the body.  Also, the low tympanic temperatures, seen in hyperthermic 
individuals are purported not to be a sign of brain cooling but rather a 
consequence of low head skin temperature contaminating the temperature 
reading (Shiraki et al., 1988).  
 
1.4.3 The skin and the brain 
1.4.3.1 Integration of information 
The POAH is highly sensitive to changes both centrally (as evidenced above 
in section 1.4.2.4) and peripherally (Boulant, 2000).  Although the core 
temperature seems to be the strongest stimulus for the initiation of 
thermoregulatory responses, there can be little doubt that the temperature of 
the skin also plays a significant role.  The POAH receives afferent sensory 
input from the warm and cold receptors in the skin (Boulant and Hardy, 1974).  
Therefore, the POAH can affect the most appropriate thermoregulatory 
response considering the internal and external environmental temperatures. 
 
Simmons et al. (2008) assessed several parameters including alertness and 
calmness whilst at rest, and demonstrated that heat-related fatigue is a 
function of a combination of an elevated core and skin temperature.  They 
found that elevated skin temperature did not negatively influence cognitive 
performance (using measures of accuracy and reaction time assessed from a 
battery of cognitive tests), but when core temperature was also increased 
cognitive performance was negatively affected.  They also found that cooling 
of the head and neck, through use of a cold water perfused balaclava, did not 
improve cognitive performance when skin temperature was elevated, nor did it 
blunt the decrement in cognitive function seen when skin and core 
temperatures were elevated. 
 
1.4.3.2 Facial cooling 
Lowering of skin temperatures and facial cooling during exercise in the heat 
greatly reduces the perception of effort associated with elevated core 
temperatures (Armada-da-Silva et al., 2004).  Lowered skin temperature has 
also been suggested to modulate the effects of high core temperatures on 
cardiovascular (Riggs et al., 1981) and hormonal responses to exercise in the 
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heat (Bridge et al., 2003B; Ansley et al., 2008), and possibly even improve 
endurance exercise capacity (Ansley et al., 2008) as detailed below.  
 
Riggs et al. (1981) found that facial cooling, using wind at 10 °C during 
progressively intense exercise lasting sixteen minutes, evoked a lower heart 
rate than when no facial cooling occurred.  The blunted heart rate response 
appeared to be associated with a declining skin temperature: no differences 
were seen in the blood pressure or core temperature of the participants.  The 
authors suggested that the heart rate response was not a reflex mediated by 
increased stroke volume, but was mediated through a central 
thermoregulatory response.  There have since been many studies looking at 
the effects of cooling the skin during exercise, often performed in the heat.  
Brisson et al. (1989) showed that facial cooling, using wind at 10 °C, during 
submaximal exercise in the heat (27 ± 0.5 °C) caused bradycardia, to such an 
extent that workload had to be increased by an average of twenty watts to 
elicit the same response as when there was no facial cooling.  
 
Facial cooling in the study by Brisson et al. (1989) also caused a blunting (31 
% increase from basal resting values) in the plasma prolactin response seen 
with no facial cooling (450 % increase from basal resting values).  Bridge and 
colleagues (2003B) investigated this further by comparing the prolactin 
response to exhaustive exercise at 73 %  ̇O2max in 20 °C and 35 °C.  The 
prolactin concentration was elevated from baseline levels after forty minutes 
of exercise and remained elevated at the point of fatigue when the exercise 
was done in 20 °C.  In 35 °C the prolactin concentration was elevated from 
baseline levels by twenty minutes of exercise and was greater than the values 
in 20 °C after ten minutes of exercise (Bridge et al., 2003B).  Prolactin release 
has been purposed to be a marker of central serotonergic activity.  These 
findings therefore suggest that central serotonergic activity is increased by 
exercise in the heat and suppressed by head cooling during exercise in the 
heat. 
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Head cooling was again found to attenuate the increase in prolactin release 
seen in response to exhaustive exercise at 75 %  ̇O2max in a warm 
environment (29 ± 1 °C), reducing the elevation from a six-fold increase in the 
control condition to a two-fold increase in the head cooling condition (Ansley 
et al., 2008).  Their head cooling protocol, achieved through wind and cool 
water application, also resulted in a 51 % (21 – 65 %) improvement in 
exercise time to exhaustion at 75 %  ̇O2max in 29.0 ± 1.0 °C from 24 (22 - 
47) minutes in the control condition to 45 (29 – 61) minutes in the head 
cooling condition. 
 
1.4.3.3 Thermal comfort 
Weiss and Laties (1961) suggested long ago that thermal comfort is the factor 
that leads to the initiation of behavioural thermoregulation such as heat 
seeking behaviour.  The integration of peripheral or cutaneous thermal 
information with core temperature has been shown to be a key factor in the 
determination of thermal comfort (Frank et al., 1999; Gibson et al., 1980).  
Frank and colleagues (1999) demonstrated that skin temperature was directly 
linked to thermal comfort and that lowering skin temperatures to ~30 °C 
lowered thermal comfort ratings compared to the ratings given at skin 
temperatures of ~34 °C while increasing skin temperatures to ~36 °C 
increased thermal comfort ratings, all whilst core temperatures were 
maintained at ~37 °C. 
 
Frank et al. (1999) also showed that core temperature and skin temperature 
contribute equally to levels of thermal comfort in men, assessed by a ten point 
visual analogue scale.  By artificially manipulating the perception of skin 
temperature to lower than the true physiological temperature, it may be 
possible to manipulate thermal comfort and, as a result, improve heat 
tolerance.  If this hypothesis holds true during exercise in a warm 
environment, endurance exercise performance or capacity may be improved.  
Equally, by artificially manipulating the perception of skin temperature to 
higher than the true value, endurance exercise performance or capacity may 
be reduced.  
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1.5 Manipulation of thermal sensation using menthol 
1.5.1 Mechanism of action 
Cool sensations can be caused by either the stimulation of cold receptors or 
the inhibition of warm receptors.  Conversely, warm sensations can be caused 
by either the stimulation of warm receptors or the inhibition of cold receptors 
(Eccles, 2000).  According to Eccles (2000), as far back as the nineteenth- 
century the warming and cooling sensations elicited by the plant extract 
menthol were suggested to be the result of stimulation of sensory nerve 
endings (Goldscheider, 1886).  Therefore, the application of menthol to the 
skin results in a cooling or a warming sensation without a concomitant 
alteration in actual skin temperature. 
 
It is now known that menthol exerts its effects on cold receptors by interfering 
with the movement of calcium across the cell membrane in thermoreceptors 
(Schafer et al., 1986).  However, the mechanisms of the action of menthol are 
more complex than a simple stimulation of cold receptors, since menthol also 
modulates feelings of warmth and, in high concentrations, can cause irritation 
and local anaesthesia (Eccles, 1994). 
 
The transient receptor potential melastatin-8 (TRPM8), also known as cold 
and menthol receptor one (CMR1) is the ion channel with the most advocated 
role in cold transduction (McKemy et al., 2002).  It is activated by voltage, low 
temperature and cooling compounds.  Its expression is also thought to be 
restricted to small sensory neurons (Malkia et al., 2007).  Further support for 
the role of TRPM8 in cold transduction comes from the use of the compound 
BCTC as a potent and full blocker of these channels, resulting in a lack of a 
response to the application of menthol in mice and guinea pigs (Madrid et al., 
2006).  However, menthol has also been shown to activate transient receptor 
potential vanilloid-3, a heat activated ion channel (Macpherson et al., 2006). 
 
1.5.2 Responses in animals 
When mice had menthol (1 – 10 %) applied to the skin of their whole trunk 
they demonstrated both behavioural and autonomic responses.  These 
included heat seeking behaviour, shivering-like muscle activity and peripheral 
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(tail) vasoconstriction (Tajino et al., 2007), as well as increases in core 
temperature of 1 – 2 °C (Tajino et al., 2008).  This suggests that in mice, 
when a large percentage of TRPM8 receptors are activated a cooling 
response ensues.  Indeed, TRPM8 deficient mice exhibit diminished 
responses to cold, assessed by measuring acute flinching responses using 
acetone-evoked evaporative cooling, and an impaired ability to distinguish 
between warm and cold surfaces (Bautista et al., 2007). 
 
1.5.3 Responses in humans 
Existing research on topically applied menthol has predominantly been carried 
out in temperate environments of 18 - 23 °C (Yosipovitch et al., 1996; 
Kozyreva and Tkachenko, 2008).  It is probable however, that the actual skin 
temperature rather than the ambient temperature plays a greater role in the 
perception of skin temperature after an application of menthol.  Kozyreva and 
Tkachenko (2008) found that some people show an increase in the number of 
functioning cold receptors, while others show a decrease and some show no 
change when applying a 1 % menthol solution to the forearm at a skin 
temperature of 32.3 ± 0.1 °C (30.5 – 33.7 °C). 
 
The most comprehensive and systematic study into the sensory effects of 
menthol application to the skin at different temperatures was done by Green 
(1992).  When skin temperature was maintained at 31 °C, the application of 5 
% or 10 % menthol to the skin had an excitatory effect.  He also showed that 
at lower skin temperatures (21 °C), menthol solutions had a proportionally 
smaller effect on the perceived intensity of cooling than at 29 °C, or than when 
they were compared to a 0 % menthol control solution.  These findings were 
mirrored with higher skin temperatures where the proportional intensity of the 
warming sensation of menthol was reduced compared to a 0 % menthol 
control as skin temperature increased from 33 °C to 41 °C, but as skin 
temperature increased so did the perceived intensity of the warming sensation 
in all trials. 
 
Different areas of the body surface have different densities of thermoreceptors 
and Watson and colleagues (1978) showed that the eyes and buccal region 
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are most sensitive to the effects of menthol, while the palms and soles are 
least sensitive.  Despite this, Nakamura et al. (2008) suggest that the 
qualitative differences in the thermal comfort of various body areas seen in 
their study (preferential cooling of the head in the heat and maintaining the 
warmth of the core in the cold) cannot be solely explained by the distribution 
of peripheral thermoreceptors, thereby implicating processing mechanisms 
within the central nervous system. 
 
1.5.4 Performance responses 
In a recent study by Mundel and Jones (2010) it was shown that cycling 
exercise capacity in the heat (34 °C) was improved by 9 ± 12 % when swilling 
a menthol solution around the oral cavity (63 ± 14 minutes) compared to 
swilling a placebo solution (58 ± 16 minutes).  Central RPE (defined by the 
authors as the rating of perceived exertion for the cardiopulmonary system) 
was significantly lower for the initial forty minutes of exercise, and pulmonary 
ventilation was greater after twenty and forty minutes of exercise on the 
menthol trials compared to the placebo trials.  
 
Mundel and Jones (2010) postulated that the mechanism of the improvement 
in exercise capacity was an alteration in the sensation of oropharyngeal 
temperature through alterations in psychophysical processes.  The reduction 
in central RPE was likely due to the improved ventilation, as there were no 
differences in any of the circulatory or metabolic parameters measured.  As 
suggested by Watson et al., (1978), the oropharyngeal cold receptors of the 
mouth are highly sensitive to menthol and this may have altered the 
perception of the effort required to breath.  Anecdotal evidence from 
comments made by their participants also suggested that the menthol caused 
a sensation that was described as ‘refreshing’ and ‘stimulating’ (Mundel and 
Jones, 2010).  
 
1.5.5 Overview 
There are clear physiological and performance effects of actual skin, head 
and facial cooling.  In recent years there has been an increase in the 
availability of commercially available, menthol infused, sports clothing 
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claiming to improve performance.  Further to this there is also evidence for 
alterations in thermal sensation evoked by cutaneous menthol application, 
coupled with the improvements in exercise capacity found when mouth-rinsing 
with menthol.  These factors all contribute to the necessity to further 
investigate the effects of manipulating thermal sensation without altering body 
temperature during exercise in the heat. 
 
 
1.6 Assessment of the efficacy of interventions 
There has always been a need within exercise physiology to perform 
reproducible, accurate and precise exercise tests to determine changes 
induced by various interventions.  Indeed, within sports science research, 
exercise tests are one of the most commonly used tools (Hinkson and 
Hopkins, 2005).  Therefore, it is important to use the most appropriate test to 
enable the correct interpretation of results.  
 
Two main distinctive types of protocol are employed to assess possible 
changes in the outcome of endurance exercise.  They are exercise capacity 
tests (time to fatigue at a constant workload), and exercise performance tests 
(time taken to complete a set amount of work, or completing as much work as 
possible in a set duration).  Both of these methods offer useful opportunities to 
investigate the efficacy of various interventions upon exercise, but equally 
both have drawbacks.  It is therefore important to understand these so that 
the most appropriate method can be employed. 
 
The more traditionally used test involves exercise at a fixed workload, 
maintained to the point of exhaustion.  This is a useful tool for the 
measurement of changes that may occur within the physiology of the 
participant due to various pharmacological, training, nutritional or dietary 
manipulations over the course of an exercise bout (Bergstrom et al., 1967; 
Cogan and Coyle, 1987; Gleeson et al., 1986; Coyle et al., 1986; Wilson and 
Maughan, 1992).  However, time to exhaustion tests are really tests of 
exercise capacity or fatigue, rather than being a direct assessment of 
performance. 
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Historically, time to exhaustion was the test of choice and was widely utilised.  
However, as reports began to appear from some researchers presenting  very 
large variations within individual performances of the protocol (up to 56 %, 
Krebs and Powers, 1989; up to 40 % Jeukendrup et al., 1996), there has been 
a shift in favour of time-trial protocols This was despite further researchers 
finding much lower variations in performance measured by time to exhaustion 
than these reported values (3 ± 15 %, Watson et al., 2004; 7.0 ± 5.1 %, 
Maughan et al., 1989; 7.9 % Coyle et al., 1986 according to Hopkins et al., 
2001).  
 
Time-trials are direct measures of exercise performance and involve the 
assessment of a participant’s ability to perform a set distance, duration or 
amount of work. They are widely reported to have fairly low variability 
(Laursen et al., 2003; Jeukendrup et al., 1996; Marion et al., 2002).  This tool 
is often utilised in such a way that the results can be applied to actual sporting 
settings (Coyle et al., 1991), leading to suggestions that they are the more 
appropriate exercise tests for athletes, as they are more race specific 
(Jeukendrup et al., 1996).  However, with a time-trial protocol the participants 
are required to pace themselves, which is often cited as a potentially 
confounding factor (Hinkson and Hopkins, 2005). 
 
The choice of which test is most appropriate to use in a certain experiment is 
often dictated by the research question, and it can also be important in the 
investigators’ subsequent interpretation of their findings.  During this thesis 
both forms of exercise test were employed.  The variability data for each 
exercise protocol are reported in the appropriate experimental chapters. 
 
 
1.7 Summary 
From the literature outlined above it can be seen that there are still a plethora 
of unanswered questions with regard to the role of the brain in fatigue during 
exercise.   
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Support for the probably overly simplistic Newsholme theory of central fatigue 
appears to be diminishing.  However, before dismissing the theory completely 
there are still a couple of avenues which pose interesting opportunities for 
research. Watson et al. (2004) suggested, based upon their results and those 
of others, that the use of branched-chain amino acids to manipulate 
endurance exercise capacity may be an effective ergogenic aid in some 
individuals while others will not.   
 
Furthermore, psychology research shows that there is more than one way of 
influencing tryptophan uptake into the brain.  Acute tryptophan depletion is a 
technique which removes as much tryptophan as possible from the 
circulation, thereby reducing tryptophan uptake into the brain.  This aim is 
shared by the technique of feeding branched-chain amino acids.  Therefore, 
investigating the exercise capacity response to acute tryptophan depletion 
warrants investigation. 
 
The availability of the serotonin precursor tryptophan is just one factor in the 
synthesis of serotonin.  Once the serotonin has been produced it then fulfils 
many other roles within the central nervous system.  The concentration of 
serotonin in the synaptic cleft is carefully regulated, with serotonin being 
transported out of and into neurons by transporters.  The density and activity 
levels of these transporters may influence the rate of change of the 
concentration of serotonin in the synaptic clefts, which may in turn effect the 
actions of the serotonin.  Therefore, the density and activity of these 
transmitters may be important in the aetiology of fatigue.  Unfortunately it is 
impossible to study the neuronal serotonin transporters of athletes.  However, 
peripheral models may offer and interesting insight into this aspect of fatigue.  
A study by Strachan and Maughan (1998) found that endurance trained 
individuals have more serotonin transporters on their blood platelets than 
sedentary people.  This information poses many interesting questions, which 
warrant further investigation. 
  
Serotonin is not the only central factor involved in fatigue.  During heat 
exposure feelings of lethargy often increase, and it is well documented that 
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endurance exercise performance and capacity are detrimentally affected.  
Skin temperature and core temperature have been shown to equally 
contribute to thermal comfort (Frank et al., 1999).  Applying menthol to the 
skin alters thermal sensation without altering skin temperature.  The menthol 
acts upon peripheral thermoreceptors which originate in the hypothalamus.  
Applying menthol to the skin during heat exposure could alter the thermal 
comfort and thermal sensation of the skin.  If this is the case then applying 
menthol to the skin during exercise in the heat may alter endurance exercise 
performance.  Swilling menthol around the oral cavity has been shown to 
improve endurance exercise performance, and the advent of menthol infused 
clothing means that this is an emerging area of research which warrants 
further investigation. 
 
 
1.8 Aims of the experimental chapters 
1.8.1 Chapter Three 
The aim of Chapter Three was to determine if inter-individual differences exist 
in the response to branched-chain amino acid supplementation on endurance 
cycling capacity in a warm environment.  
 
1.8.2 Chapter Four 
The aim of Chapter Four was to examine the responses to prolonged 
exhaustive cycling exercise in a warm environment when participants were 
either tryptophan depleted through amino acid supplementation or fed a 
control dose of amino acids. 
 
1.8.3 Chapter Five 
The aim of Chapter Five was to look for differences in platelet serotonin 
transporter density in former and current sprint and distance runners, and 
sedentary controls in order to discover if this is a state or a trait marker. 
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1.8.4 Chapter Six 
The aim of Chapter Six was to elucidate the physiological and psychophysical 
responses to the application of a 1 % menthol solution to the skin whilst 
resting in the heat. 
 
1.8.5 Chapter Seven 
The aim of Chapter Seven was to determine if the manipulation of thermal 
sensation, without alterations in core or skin temperatures through the 
application of menthol to the skin, would alter endurance exercise 
performance in the heat.  
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CHAPTER TWO 
 
General methods. 
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2.1 Introduction  
This chapter outlines the methodologies used in the experimental research 
reported in subsequent chapters.  The individual experimental protocols are 
detailed in the methods section of each chapter.  With the exception of the 
sample collection undertaken in Chapter Five, all data collection and all 
sample analyses in this thesis were conducted in the exercise physiology 
laboratories at Loughborough University, UK. 
 
2.2 Ethics approval 
All experiments were approved by the Loughborough University Ethical 
Advisory Committee; Chapter Three reference number R06-P97, Chapter 
Four reference number R07-P121, Chapter Five reference number R08-P91, 
Chapter Six and Seven reference number R09-P92.  The nature and the 
purpose of each study were clearly documented in the participant information 
sheets and were also verbally explained to all participants.  Participants were 
informed of the procedures and demands of the study as well as any risks or 
discomforts they might experience.   
 
Participants were always given opportunities to ask questions and only once 
they were satisfied with what was required were they accepted into the study.  
Each participant completed a health screen questionnaire to assess their 
suitability to take part.  Participants then gave both verbal and written consent 
but also retained the right to withdraw from the study at any time and for any 
reason.   
 
2.3 Participants 
The participants recruited for all investigations were male.  With the exception 
of Chapter Five, all participants were students or staff at Loughborough 
University or residents of the local community.  Participants in Chapter Five 
were members of the wider community and were living in the United Kingdom.  
For all investigations participants were recruited mainly by word of mouth and 
through personal contacts, although posters and emails were also 
occasionally used.  Participants were aged between 18 and 35 years for all 
investigations except Chapter Five, which due to the nature of the experiment 
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had a maximum age for participation of 70 years.  All participants were free 
from known illness which would have prevented them from participation in the 
testing, and were considered as healthy individuals.   Activity levels that 
covered a broad spectrum were required for Chapter Five, from being 
sedentary up to international competitors, but all other investigations used 
recreationally active individuals.  Within each experimental chapter the activity 
level of the participants was kept as similar as possible.  All participants in the 
investigations conducted in the heat were unaccustomed to exercise in a hot 
environment preceding the experiments.   
 
2.4 Preliminary trials  
2.4.1 Anthropometry 
During the first visit to the laboratory in Chapters Three, Four and Seven nude 
body mass was measured to the nearest 0.02 kg using a digital floor weighing 
scale (AFW-120K or AFW-150K, Adam Equipment Co Ltd, Milton Keynes, 
UK).  Nude body mass was measured at the start of the second visit in 
Chapter Six using the equipment as previously stated.  Height was measured 
to the nearest one centimetre using a wall mounted stadiometer (Seca 202, 
SECA Ltd. Birmingham, UK).  Body mass and height were self-reported in 
Chapter Five. 
 
2.4.2 Peak oxygen uptake testing 
In Chapters Three, Four and Seven peak oxygen uptake ( ̇O2peak) was 
determined for each participant at least 48 hours prior to the start of the 
familiarisation trials.  A discontinuous incremental protocol was performed on 
an electromagnetically braked cycle ergometer (Gould Corival 300, Holland or 
Lode BV Corival V3, Groningen, The Netherlands) set in hyperbolic mode. 
This meant that participants could pedal at any cadence and the workload 
would remain constant. 
 
Participants were given the opportunity to warm up if they wished to, though 
this was rarely done as the test always started at a low workload of 100 W for 
4 minutes.  They were then free to choose the progression of the increase in 
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work load in increments from 15 to 100 W based on their performance in, and 
perception of, the previous stage.  Each sub maximal exercise bout lasted 
four minutes, with approximately six minutes between bouts.  During the final 
bout of exercise, if participants felt they could not complete the four minute 
bout they indicated when they were only able to continue for one more 
minute, so that a final gas sample could be taken.   
 
The test was finished at the point of volitional exhaustion.  The test was 
considered valid if one of the following two criteria were met: 1) heart rate was 
within 10 % of the age predicted maximum heart rate, 2) respiratory exchange 
ratio was above 1.15 (ACSM, 2000).  Based on the  ̇O2 – work rate 
relationship, the required power output was then calculated for use during the 
subsequent trials.  
 
2.4.3 Collection and analyses of expired air 
Oxygen uptake was determined using the Douglas bag method (Astrand et 
al., 2003C).  Expired gas was collected into a Douglas bag through Falconia 
tubing attached to a two-way non-rebreathing valve, which was in turn 
attached to a mouth piece through which participants breathed.  Participants 
also wore a nose clip to prevent any expired air being lost to the environment.  
Expired gas was collected for sixty seconds each sample, for the last minute 
of every stage in the  ̇O2peak test and at predetermined times during 
Chapters Three, Four and Seven.   
 
The expired gas was analysed for oxygen concentration by sampling through 
a paramagnetic transducer and carbon dioxide concentration was determined 
through an infra-red carbon dioxide analyser (Servomex 1440c, Crowborough, 
UK).  The gas analysers were calibrated with gases of known concentration 
(British Oxygen Company, London, UK).  The volume of gas expired was 
measured through a dry gas meter (Harvard dry gas meter, Harvard 
Apparatus Ltd, Kent, UK) and the temperature of the expired gas was 
recorded using an electronic temperature sensor at the dry gas meter inlet 
(Edale Instruments Ltd, Cambridge, UK).  All expired gas volumes were 
48 
 
corrected to standard temperature and pressure for dry gas (STPD).  
Barometric pressure was measured using a standard mercury barometer.  
Oxygen consumption, carbon dioxide production and the respiratory 
exchange ratio, as well as estimations of the rate of carbohydrate and fat 
oxidation and energy expenditure, were calculated using the equations put 
forward by Frayn (1983) which are detailed in the Appendix A. 
 
2.5 Familiarisation trials 
Prior to starting trials in Chapters Three, Four and Seven, participants were 
given food and activity diaries to complete for the forty eight hours prior to the 
first familiarisation.  They were then asked to reproduce this dietary and 
activity pattern prior to each subsequent familiarisation and experimental trial. 
This method of dietary standardisation is commonly used before intervention 
studies in an attempt to limit external influences on the exercise test due to its 
low cost and its simplicity for both participant and researcher (Jeacocke and 
Burke, 2010). 
 
Participants were also asked to avoid alcohol and unaccustomed strenuous 
exercise for twenty four hours prior to each familiarisation and experimental 
trial.  No restrictions were placed upon caffeine intake at any time.  For 
Chapter Six participants were asked to replicate diet and activity patterns of 
the twenty four hours prior to trial one before trial two.  During Chapter Four 
participants were given a list of suitable and unsuitable foods to consume in 
the twenty four hours prior to coming into the laboratory in order to minimise 
their dietary tryptophan intake.   
 
During the exercise trials in Chapters Three, Four and Seven, participants 
undertook two familiarisation trials, after the  ̇O2peak test before the main 
data collection trials.  The familiarisation trials offered the participant an 
opportunity to become accustomed to and comfortable with their surroundings 
prior to the collection of the data.  Furthermore, familiarisation trials allow an 
investigator to fully understand a participant’s response to the exercise test, 
ensuring that both the participant and the investigator enter the main trials 
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fully prepared.  The familiarisation trials followed exactly the same protocol as 
the main trials, other than the blood sampling protocol which was done only 
on the second familiarisation.  Familiarisation trials were completed at the 
same time of day and on the same day of each week as the main trials.  The 
familiarisation trials also allowed an opportunity to verify that the correct 
workload was set.  Often workload was adjusted within twenty minutes of the 
start of the exercise bout in the first familiarisation in order to ensure that 
participants were working at the correct intensity.   
 
During the exercise in Chapters Three and Four, exhaustion was defined as 
the point at which participants could not maintain a pedal cadence above 50 
rpm despite verbal encouragement from the investigator.  A cut-off rpm of 50 
provided a 10 rpm cushion because below approximately 40 rpm the cycle 
ergometer used could not maintain the relationship between the workload and 
pedal cadence. 
 
2.6 Experimental trials 
Trials in Chapters Three, Four, Six and Seven were randomised in an attempt 
to eliminate any order effect.  All were separated by at least seven days to 
allow for adequate recovery time, and in the exercise trials to minimise any 
training effect.  Seven days has also been shown to be a sufficient time gap to 
prevent the development of heat acclimation (Barnett and Maughan, 1993).  
The time of day at which all familiarisation and main trials started was kept 
constant through the experiment to eliminate the effect of diurnal variation in 
core temperature (Reilly and Brooks, 1986).  Due to the nature of the 
participants used in Chapter Five this was not possible and is discussed 
further in Chapter Five.     
 
In Chapters Three, Four, Six and Seven all treatments and experimental 
hypotheses were blinded to the participants. The treatment was also blinded 
to the experimenter in Chapter Three and Chapter Four.  At the start of each 
main trial a urine sample was collected.  A small aliquot was retained for the 
analyses of urine osmolality.  Participants were asked to empty their bladders 
as fully as possible and nude body mass was measured.   
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All of the cycling exercise was done on electrically braked cycle ergometers 
(Chapters Three and Four Gould Corival 300, Groningen, Holland, Chapter 
Seven: Lode BV Corival. Groningen, Holland) operating in a hyperbolic 
manner to allow the workload to be independent of the pedal cadence.  This 
allowed participants to exercise at a pedal cadence at which they felt 
comfortable, without affecting the work done.  During exercise trials verbal 
encouragement was offered to the participants by the same investigator each 
time.  During the exercise trials participants were provided with a small 
amount of water (100 – 150 ml) at fifteen minute intervals in an attempt to 
minimise the effects of hypohydration and also minimise the alteration in 
blood brain barrier permeability which may arise due to exercise in the heat 
(Watson et al., 2005B).   
 
At the end of the trials participants were promptly removed from the heated 
environment.   All instrumentation was removed from the participants and final 
nude body mass was measured again to allow the estimation of body water 
loss during the trials.  Body water losses were not corrected for respiratory 
water loss or metabolic water production since measurement of body water 
losses to this degree of accuracy were not deemed necessary in any of the 
following investigations, as this was not the focus of this thesis. 
 
2.7 Experimental protocols 
2.7.1 Time to exhaustion 
When the participant was ready they started to pedal.  The resistance was 
quickly set to the required power output (55 % of their  ̇O2peak) and the clock 
was started.  Participants were given no feedback of any kind throughout the 
protocol.  Participants exercised until volitional exhaustion, which was defined 
as the inability to sustain a pedal cadence of 50 rpm or greater, despite verbal 
encouragement.  Participants were given two warnings if pedal cadence 
dropped below 50 rpm.  If they failed to respond, or it dropped below 50 rpm 
on a third occasion, the clock was stopped and the trial was deemed to be 
completed. 
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2.7.2 Preloaded time trial 
When the participant was ready they started to pedal.  The resistance was 
automatically applied to elicit the pre-determined workload over approximately 
six seconds, although for consistency the clock was always started when the 
resistance reached 100 W.  During both the preload and the time-trial phases 
of the protocol participants had no feedback other than the duration for which 
they had been exercising.  
 
The preload phase required participants to cycle for sixty minutes at 55 % of 
their  ̇O2peak.  After a short break of approximately five minutes, the twenty 
minute time-trial commenced.  Participants were told to complete as much 
work as possible within the twenty minutes and were reminded that pedal 
cadence would not influence work done.  An initial workload equivalent to 75 
% of  ̇O2peak was set but, immediately after the start of the time-trial, 
participants had control of their workload, which could be manually adjusted 
using the touch sensors on the cycle ergometer.  
 
2.8 Deep body and skin temperatures 
Rectal temperature (Chapters Three and Four used a 46TUC tele-
thermometer and Chapters Six and Seven used a precision 4000A 
thermometer, both YSI, Ohio, USA) was monitored as an index of body core 
temperature using a rectal probe (YSI 400 series, Ohio, USA) inserted 10 cm 
beyond the rectal sphincter, held in place by a fixed knob in order to provide 
stable readings.  Prior to the start of each study the rectal probes were 
calibrated using a water bath and a mercury in glass thermometer.  
Unfortunately, no firm link has been made between rectal temperature and 
brain temperature in humans although this has been established in animal 
studies (Fuller et al., 1998).  
 
Another criticism of this method is the suggestion that the measurement of 
rectal temperature may lag behind the true value of core temperature when 
rapid changes occur (Moran and Mendal, 2002).  However, rectal temperature 
probably represents the best option for the measurement of core body 
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temperature in these experiments, since tympanic temperature has been 
shown to both accurately reflect brain temperature (Mariak et al., 1994), and 
be unrelated to brain temperature (Shiraki et al., 1988) and can be painful 
when measured, while orally ingested temperature pills would be unreliable in 
view of the ingestion of drinks before and during the exercise in Chapters 
Three, Four and Seven. 
 
Measurement of skin temperature in Chapters Three and Four used skin 
thermistors (YSI UK Ltd, Hampshire, UK) positioned on the right hand side of 
the body on the chest, triceps, thigh and calf and held in place with Transpore 
medical tape (3M, Loughborough, UK).  Again, prior to the start of each of the 
experimental trials the skin thermistors were calibrated using a water bath and 
a mercury in glass thermometer.  In Chapters Six and Seven, an infra-red 
laser site thermometer (thermometer LS, Micro-epsilon, Ortenburg, Germany) 
was used to determine skin temperature at the same four sites.  For this 
measurement the emissivity was set to 0.97 for the measurement of skin 
surface temperature (Mitchell et al., 1967).  For Chapter Six each site was 
measured with a beam of 1 mm diameter and the mean temperature sited 
was reported. For Chapter Seven, due to the exercise the participants were 
performing during the measurements, a larger surface area reading was used 
and the maximum sited temperature was reported, in case clothing or 
peripheral temperatures falsely influenced the mean value.  This instrument 
was also calibrated prior to the start of the experimental trials using calibrated 
skin thermistors.  Matsukawa and colleagues (2000) have shown that a good 
level of association exists between analysis of skin temperature using an 
infra-red thermometer and a thermocouple system.  Evans et al. (2010) also 
presented data showing that average weighted mean skin temperature, 
calculated using skin thermistors, correlated (R = 0.832, P<0.001) with values 
obtained when using the same type of infrared thermometer used in this 
thesis, over a range of skin temperatures.  Furthermore, pilot data generated 
before the use of this instrument for data collection in the thesis also backs up 
these published findings.  
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Weightings for the four skin temperature sites were applied using the 
equations of Ramanathan (1964) to compute mean skin temperature as 30 % 
chest temperature, 20 % thigh temperature, 30 % tricep temperature and 20 
% calf temperature.  This equation has been developed from the original 
formula proposed by Hardy and Dubois (1938) involving seven skin 
temperature sites.  Although this is an imperfect method of calculation due to 
its inability to account for thermal sensitivity of different skin surface areas 
(Nadel et al., 1973), it is the most commonly used equation and therefore its 
use allows comparisons to be made to the values observed in other studies.  
 
Mean body heat content was calculated using the equation of Burton (1935) in 
which 65 % is contributed from the core temperature and 35 % is contributed 
from the mean weighted skin temperature, corrected for body mass.  
However, this equation has also come under criticism, as the specific heat of 
the body is related to body composition, which is impossible to standardise.  
Also, during exercise in the heat there is no clear ratio between the 
contribution of skin temperature and core temperature to body heat comfort, 
thereby impairing the analysis of mean body heat content (Wyndham, 1973).  
 
2.9 Heart rate 
Heart rate was measured using a Polar Electro heart rate monitoring system 
(Polar Electro Oy, Kempele, Finland). A transmitter positioned on the chest 
and held in place with an elastic strap.  A Polar FS-1 wrist receiver was 
positioned near to the participant to note the heart rate whenever this 
information was required. 
 
2.10 Subjective ratings 
The ratings of perceived exertion scale (RPE; Chapters Three, Four and 
Seven; Appendix B) and the rating of thermal comfort scale (TC; Chapters 
Three and Four; Appendix C) were explained to all participants before the 
start of the familiarisation trials.  Rating of perceived exertion was assessed 
using the Borg scale (1982) and rating of thermal comfort was assessed using 
a 21-point scale from -10 (cold impossible to bear) through 0 (neutral) up to 
+10 (heat impossible to bear) (Parsons, 2003C).  
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Visual analogue scales were used to assess thermal sensation (Chapters Six 
and Seven; Appendix D) and thermal comfort (Chapter Six only; Appendix D).  
Participants had the scales fully explained to them prior to the start of the 
trials.  The scales consisted of a 10 cm line with verbal anchors at either end 
(‘Cold’ to the left, ‘Hot’ to the right on the thermal sensation scales, and ‘Too 
much cold’ to the left and ‘Too much hot’ to the right on the thermal comfort 
scales; Parsons, 2003C). Participants were asked to mark the line at the point 
they felt best reflected their rating of thermal sensation or thermal comfort, 
with each millimetre representing a 1 % change.  Chapter Six asked 
participants to consider the thermal sensation on their right forearm, their left 
forearm and their body overall, as well as their overall thermal comfort.  
Chapter Seven asked participants to consider the same three thermal 
sensation scales as in Chapter Six.  Visual analogue scales were used in 
Chapters Six and Seven as these allow participants a wider choice of 
response options. With numbered scales when a participant becomes hotter 
between samples, the number stated may rise to indicate feeling hotter, but 
may not rise if the increased sensation is not deemed to be large enough to 
increase the rating by an entire category. A visual analogue scale eliminates 
such uncertainties. 
 
2.11 Fluid provision 
During the peak oxygen uptake tests participants were allowed to drink either 
water, squash or sports drinks ad libitum.  During the exercise trials small 
amounts of the test drink (Chapter Three) or water (Chapters Four and 
Seven) were provided for the participants.  In Chapter Three this acted to 
provide more branched-chain amino acids and, as in Chapters Four and 
Seven, also aimed to stave off severe hypohydration and avoid this being a 
major limiting factor to exercise capacity or performance.  During Chapters 
Three and Four the fluids were kept in a water bath (23 °C) prior to 
consumption and were served every fifteen minutes during the exercise 
protocol.  During Chapter Seven fluids were kept and served at room 
temperature (30 °C) immediately prior to, and every fifteen minutes during, 
exercise. These fluid temperatures were chosen purely due to logistical 
reasons and not physiological reasons.  
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2.12 Blood sampling 
Participants were seated for fifteen minutes prior to any blood samples being 
drawn to stabilise the effects of postural change on blood volume.  Blood 
samples were taken in every experiment with the exception of Chapter Six. In 
Chapter Five cannulation was not necessary and a single venepuncture 
sample was taken from an anticubital vein of each participant.  A 
venepuncture was also used for the first sample taken from each participant in 
Chapter Four, as this was done the evening before the exercise trial.  In 
Chapters Three and Four, one hand was immersed in warm (42-44 °C) water 
for ten minutes prior to cannulation while in Chapter Seven the participant was 
resting in a warm environment and therefore this was deemed unnecessary.  
An indwelling 21 g cannula needle (Surflo winged infusion set, Terumo. 
Tokyo, Japan) was inserted into a superficial forearm vein and a three way 
tap (Luer-Loc 360, BD Connecta. Heidelberg, Germany) was attached to the 
end to allow repeated blood sampling.  
 
The indwelling cannula was kept patent by flushing with a small volume (2 – 3 
ml) of heparinised saline (~25 Units / ml) after each sample.  In Chapter Three 
each blood sample was a 10 ml volume, in Chapter Four a 7 ml volume, in 
Chapter Five a 40 ml volume and in Chapter Seven a 5 ml volume was taken.   
Immediately after sampling the blood was dispensed as appropriate and 
deproteinised where necessary.   
 
2.13 Blood analyses 
For the following analysis techniques, Table 2.1 in Section 2.18 contains 
information on the coefficient of variation of the methods. 
 
2.13.1 Haemoglobin (Hb)  
This was done using the Cyanmethaemoglobin method.  In duplicate, 10 µl of 
whole blood treated with an anticoagulant (K2EDTA) was added to 2.5 ml of 
Drabkins reagent.  This was left at room temperature, out of direct sunlight, for 
thirty minutes after which time the optical density was measured 
spectrophotometrically using an ultraviolet light at 540 nm.  The values 
obtained from a blank sample and a known standard were used to formulate a 
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straight line equation which allows the calculation of the haemoglobin in the 
samples.  In the rare instances where the measured concentration was 
slightly greater than the known standard it was assumed that the linear 
relationship held true.  The mean of each duplicated pair was reported.  All 
haemoglobin analyses were done on the day the samples were collected.   
 
Drabkins reagent contains potassium ferricyanide (K3Fe(CN)6) and potassium 
cyanide (KCN).  Oxidation of the haem groups in haemoglobin, 
oxyhaemoglobin and carboxyhaemoglobin, by ferricyanide forms 
methaemoglobin, which then combines with the ionized form of cyanide to 
produce the red coloured, stable, cyanmethaemoglobin that is analysed.  
  
2.13.2 Haematocrit (Hct)  
Also called the packed cell volume, this was measured using whole blood 
treated with an anticoagulant (K2EDTA).  The blood was drawn up into a 50 µl 
capillary tube, sealed at one end and then centrifuged at approximately 
12,000 g for five minutes.  The packed cell volume is the percentage of the 
volume in the column occupied by the erythrocytes.  These analyses were 
done in triplicate and the median value reported.  All haematocrit analyses 
were done on the day the samples were obtained. 
 
2.13.3 Blood volume calculations 
From the values obtained for haemoglobin and haematocrit it is possible to 
calculate changes in blood, plasma and red cell volumes using the equations 
proposed by Dill and Costill (1974). These can be seen in Appendix E. The 
values reported throughout this thesis are as a percentage change relative to 
the first sample collected. This calculation is also listed in Appendix E.  
 
2.13.4 Blood glucose  
Using the GOD/PAP method, 100 µl of whole blood, treated with the 
anticoagulant K2EDTA, was deproteinised in 1 ml of ice cold 0.3 N perchloric 
acid (PCA) and centrifuged for one minute and the resulting supernatant was 
used in the assay.  100 µl of the supernatant was added to 1 ml of glucose 
reaction mix and left to incubate at room temperature for thirty minutes.  
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During this time the enzymatic oxidation of glucose in the presence of glucose 
oxidase, forms gluconate and hydrogen peroxide.  The hydrogen peroxide 
reacts, under the catalysis of peroxidase, with phenol and 4-aminophenazone 
to form a red-violet quinoneimine dye as an indicator of the presence of 
glucose.  The absorbance was measured photometrically at a wavelength of 
500 nm.  These analyses were done using the Randox kit (Randox 
Laboratories Ltd, Crumlin, UK), performed in duplicate and the mean value is 
reported. 
 
2.13.5 Blood lactate  
This assay is based on the method as described by Maughan (1982).  The 
assay required 100 µl of K2EDTA treated whole blood to be deproteinised in 1 
ml of ice cold 0.3 N PCA and centrifuged to obtain supernatant.  This 
supernatant was then stored at -20 °C until analysis when it was defrosted 
and centrifuged again for one minute.  The assay, done in duplicate and 
reporting the mean values, uses 20 µl of supernatant added to 200 µl of 
reaction mix and is left to incubate at room temperature for thirty minutes.  
The reaction mix contains nicotinamide-adenine dinucleotide (NAD), lactate 
dehydrogenase and hydrazine buffer.  The hydrazine buffer solution contains 
hydrazine sulphate, hydrazine hydrate, Na2EDTA and distilled water.  The 
assay works on the principle that the lactate present in samples will be 
oxidised to form pyruvate, and the NAD+ will be reduced to NADH and 
hydrogen ions in the presence of lactate dehydrogenase.  This reaction is 
reversible, but by adding an alkaline reagent (hydrazine) that removes 
hydrogen ions the reaction will go to completion, which is when all the lactate 
is oxidised.  It is the fluorescence of NADH that is measured at a wavelength 
of 340 nm.  At the end of the incubation period 1 ml of distilled water is added 
to each sample to increase the volume.  The fluorescence of the samples is 
read alongside a blank and three separate known concentration standards of 
1.0, 3.0 and 5.0 mmol / L that provide a calibration curve. 
  
2.13.6 Serum osmolality  
Serum osmolality was measured by freezing point depression using a 300 
mosmol / kg standard.  To determine the osmolality of an aqueous solution, 
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the freezing point is compared to that of pure water.  It is known that pure 
water has a freezing point of 0 °C, and a solution containing 1 osmol / kg 
sodium chloride has a freezing point of -1.858 °C.  The method involves a 
monitored cooling of the sample solution until, at a temperature below the 
freezing point of water, the crystallisation of the solution is automatically 
initiated.  At the same time a stainless steel needle is held well below 0 °C so 
that the water vapour in the air freezes as tiny ice crystals on the tip.  The 
needle tip is then plunged into the super cooled solution.  The initiation of 
crystallisation occurs and immediately after this the temperature of the 
solution begins to rise spontaneously as the heat of crystallisation is released 
during the freezing process.  The rise in temperature of the solution is 
measured to an accuracy of 1.858 x 10-3 °C. The cryoscopic constant (Kf) for 
water is 1.858 K * kg / mol.  Therefore, 1 mole of solute dissolved in a 
kilogram of water has a freezing point depression of 1.858 Kelvin.   
 
Untreated blood samples were collected and dispensed into plain Z5 tubes 
and left to clot at room temperature for at least two hours.  They were then 
spun for fifteen minutes at 1600 g in 4 °C.  The resulting serum was extracted 
and kept refrigerated in Eppendorf tubes until analyses.  Samples were 
analysed in duplicate and the mean value reported. 
 
2.13.7 Serum free fatty acids 
Done in duplicate this assay used 50 μl of serum obtained from whole blood 
left to clot at room temperature for at least two hours before being centrifuged 
at 1600 g for fifteen minutes.  The resulting serum was extracted and stored in 
duplicate at -80 °C for analyses.  This assay works on the principle that free 
fatty acids combine with coenzyme A and ATP, in the presence of acyl-CoA 
synthetase, to form acyl-Coenzyme A and other by-products.  The acyl-
Coenzyme A then reacts with oxygen in the presence of acyl-CoA oxidase to 
form 2,3-trans-enoyl-CoA and hydrogen peroxide.  Two molecules of the 
hydrogen peroxide convert 3-methyl-N-ethyl-N(β-hydroxyethyl) aniline and 4-
aminophenazone into a red dye (Quinoneimine-colour) and four water 
molecules in the presence of the enzyme peroxidase.  The intensity of the dye 
is proportional to the free fatty acid concentration in the sample. It is 
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measured spectrophotometrically at a wavelength of 500 nm.  This assay was 
done on a Pentra (ABX Pentra 400, Horiba ABX, Diagnostics, UK), using the 
Wako NEFA C assay kit (Wako Chemicals GmbH, Germany). 
 
2.13.8 Plasma amino acids 
The plasma samples were stored at -80 °C due to the findings of Van Eijk et 
al. (1994), who found that although TRP levels were not influenced by storage 
at -20 °C or -70 °C, the branched-chain amino acids were more stable when 
stored at -70 °C.  They also found no difference in the analyses between the 
samples being stored deproteinised or as plasma. 
 
The amino acid concentrations of plasma collected in Chapters Three, Four 
and Five were analysed by high pressure liquid chromatography (HPLC) 
using a diode array detector set at 338 nm wave length within a Prominence 
HPLC System (Shimadzu Corporation, Kyoto, Japan).  Whole blood (5 ml) 
was treated with the anticoagulant heparin.  This was then centrifuged for 
fifteen minutes at 1600 g and the resulting plasma was extracted and stored 
at -80 °C until analyses.  Upon defrosting, 500 µl of each plasma sample was 
deproteinised by adding 100 µl of 24 % 5-sulphosalicylic (2-hydroxy-5-sulfo-
benzoic) acid, containing 2 mmol / L of norvaline and homoserine acting as an 
internal standard (Fekkes et al., 1995).   
 
After immediate vortex mixing and subsequent standing for fifteen minutes in 
a refrigerator at 4 °C, the precipitate was spun down for fifteen minutes at 
18,400 g.  Next, 400 µl of the resulting supernatant was mixed with 100 µl of 
0.3 M lithium hydroxide in order to adjust the pH to 2.5.  After this 
deproteinisation process the samples were refrigerated for a maximum of 
twelve hours before being prepared for analyses.   
 
The analyses of the samples used a method developed by Henderson et al. 
(2000) for Agilent Technologies.   The derivatisation procedure was performed 
by hand with the FMOC reagents omitted and with the fluorescence detector 
switched on, though not used for the analyses.   
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The column used was 4.6 x 75 mm in length with 3.5 µm particle size for 
analysis with routine sensitivity and high throughput.  A guard column was 
also used.  Both were provide by Agilent Technologies (Cheshire, UK).  Pre-
formulated standards of 900, 225 and 90 pmol / µl were used, with the 
appropriate concentration of extended amino acid stock solution and internal 
standard stock solution added.  Multiple preliminary runs were performed to 
ensure that pipetting error could be minimised for the derivatisation process 
and also to ensure there was no degradation in the amino acids within the 
samples, due to the derivatisation process being conducted well in advance of 
the sample being injected into the column for analyses.  
 
Similarly to the plasma samples, plasma ultrafiltrate samples were also 
analysed.  A 500 µl aliquot of the plasma yielded through centrifugation was 
then used to isolate free tryptophan by centrifugal ultra-filtration with a 
cellulose tri-acetate membrane to retain the molecules with a molecular 
weight of >10,000 (Whatman International Ltd, Kent, UK).  The tube was 
capped and centrifuged for two hours at 1500 rpm in 4 °C and the supernatant 
was then stored at -80 °C until the time of analyses.  Due to the small volume 
of the sample, and also the ultrafiltration process, no deproteinisation was 
required.  The standards used for this analyses were 90, 22.5 and 9 pmol / µl, 
again with the appropriate concentrations of both stock solutions used.  
 
For the interpretation of all chromatograms the area under the peak was 
calculated by the instrument software (Shimadzu LCsolution; Chromatography 
data system, Shimadzu corporation. Kyoto, Japan).  Identification of the peaks 
was done by hand.  No samples were run in duplicate due to the time and 
financial implications of this.  Therefore the values reported are those 
generated from each individual sample.  Where a result was generated which 
appeared to be exceptionally high or low the sample was re-run with fresh 
standards to check the value. 
 
2.13.9 Platelet count and mean platelet volume 
The mean platelet volume and the platelet count were determined using a 
haematology analyser (Ac.T 5diff, Beckman Coulter. High Wycombe, UK). 
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Volume and count of platelets are done based on the coulter principle.  This 
principle is based on the knowledge that cells will disrupt a flow of electricity 
due to their poor conductive properties. 
 
2.13.10 Paroxetine binding to blood platelets 
For the analyses of the platelets yielded from the blood samples collected in 
Chapter Five, liquid scintillation counting of tritiated Paroxetine was used as a 
peripheral model for investigating serotonin transporter density.  The details of 
this method are presented in Chapter Five. 
 
2.13.11 Sample protein content 
The determination of the protein content of the samples used in the 
Paroxetine binding assay was done using the test-tube method of the Pierce 
BCA protein assay kit (ThermoScientific, Loughborough, UK).  A 50 µl aliquot 
of the same sample used in the Paroxetine binding assay, or standards 
diluted as appropriate in the same incubation buffer as the samples for the 
Paroxetine binding assay, is added to 1 ml of working stock, which contains, 
among other things, bicinchoninic acid and cupric sulphate.  The assay is then 
left to incubate at room temperature for two hours.  The absorbance of all the 
standards and samples are then read spectrophotometrically at 562 nm within 
ten minutes of each other.  The method combines the reduction reaction of 
CU2+ to Cu1+ by protein in an alkaline medium with the highly sensitive and 
selective colorimetric detection of Cu1+ using a reagent containing 
bicinchoninic acid.  
 
2.14 Urine collection and analyses  
The urine samples collected from participants for each trial tended to be the 
second void of the day.  The measurement of pre-trial urine osmolality aimed 
to ensure that participants were in a similar state of hydration prior to each 
trial.  Samples (5 ml) were stored in the fridge and 50 µl samples were 
analysed in duplicate against a calibration curve generated from a blank of 
distilled water and a standard solution of 1200 mosmol sodium chloride per 
kilogram employing the same principles laid out in section 2.12.6.  The mean 
value is reported. 
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2.15 Skin blood flow 
Skin blood flow was measured qualitatively using a laser Doppler flow meter 
(Moor Instruments, Axminster, UK).  A laser Doppler probe was positioned on 
both dorsal forearms of the participants at the same place on each arm on 
each occasion.  From the beginning of the trials participants’ forearms were 
placed on stools at heart level and they were instructed to keep their arms 
relaxed and as still as possible during the trial and particularly during the 
measurement period.  Skin blood flow was measured continuously and ten 
second segments were used in the analysis.  The laser Doppler flow meter 
was interfaced with a computer and data were displayed and analysed using 
data-acquisition software (moorSOFT, Moor Instruments, Axminster, UK).  
 
Maintaining posture and the position of the Doppler probes is of critical 
importance to generate reproducible results and due to several 
methodological problems with the technique (including thickness of the skin), 
it is most appropriately employed to investigate relative changes in blood flow, 
as in this thesis, rather than to generate quantitative data (Swain and Grant, 
1989). 
 
2.16 Menthol solution and patch configuration 
Chapters Six and Seven used patches containing menthol in an attempt to 
manipulate skin and overall thermal sensation.  The patches used consisted 
of commercially available craft felt soaked in either a 1 % menthol solution 
(Menthol), made with 50 % methylated spirit and 50 % water, or the same 
solution with no menthol added (Control).  To avoid possible evaporative 
cooling the felt patches were covered with non-porous adhesive tegaderm film 
(3M, Bracknell, UK).  In Chapter Six the patches were positioned on either 
side of the upper back (12 x 10 cm), on the underside of each forearm (10 x 5 
cm) and on the forehead (7 x 2.5 cm).  In Chapter Seven the patches were 
positioned on either side of the spine on the upper and lower back ( 4 patches 
of 12 x 10 cm each), on the underside of both the right and left forearms (10 x 
5 cm each) and on the forehead (7 x 2.5 cm). 
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Menthol is not soluble in water and therefore an ethanol based solution must 
be used.  Other investigators have used ethanol as the vehicle for applying 
menthol to the skin (Tajino et al., 2007; Yosipovitch et al., 1996).  However, a 
combination of methylated spirits and water were used in the present studies 
partly due to the cost implications of using ethanol, but mainly as the colour 
and smell of methylated spirits allowed the participants to be blinded as far as 
possible to the test solution being used.  A 1 % menthol solution was chosen 
for the investigations as pilot tests revealed that thermal sensations did not 
intensify with higher concentrations of menthol, but feelings of discomfort, 
such as itching and pain, did increase. 
 
2.17 Statistical analyses  
The specific analysis performed on the data in each investigation is detailed in 
the appropriate chapter.  Briefly, all data were tested for normality of 
distribution using the Shapiro-Wilk test and data were then investigated for 
skewness and kurtosis.  For normally distributed data, a one-way or two-way 
(time x trial) repeated measures analysis of variance (ANOVA) was used to 
test for differences.  Where appropriate, post hoc tests were done using 
paired t-tests with a Bonferroni correction for multiple comparisons.  Where 
different groups of participants were used, a one-way independent ANOVA 
was performed with Bonferoni post hoc tests.  Where data were not normally 
distributed, the Kruskal-Wallis non-parametric ANOVA was used and where 
appropriate pair-wise differences were investigated using the Wilcoxon 
matched-pair sign rank test. For any correlations either a Pearson’s product-
moment correlation coefficient was used of parametric data, or a one-tailed 
Spearman’s correlation coefficient test was used for non-parametric data.  
Data are clearly presented as mean ± SD when parametric and median 
(range) when non-parametric. Statistical tests used the SPSS program, 
version 14.0 or version 17.0, and significance was set at P < 0.05, while a 
tendency was defined as P < 0.09.  
 
2.18 Coefficient of variation of methods 
The coefficient of variation for each method is shown in Table 2.1. 
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Table 2.1.  The method, mean values and coefficient of variation for the analytical methods 
employed.  
Measure Method Mean CV (%) 
Arm sensation  Visual  
analogue 
scale 
57 % 4.3 
Overall sensation 59 % 3.9 
Overall comfort 58 % 5.0 
Haemoglobin Cyanmethaemoglobin 17.6 g / 100 ml 0.9 
Haematocrit Microcentrifugation 45.4 % 0.8 
Glucose GOD-PAP 4.9 mmol / L 1.8 
Lactate Fluorometric 1.2 mmol / L 5.0 
Serum osmolality Freezing point depression 290 mosmol / L 0.3 
Free fatty acids NEFA C 0.7 mmol / L 7.5 
Tyrosine  
 
 
 
HPLC 
 
64.6 µmol / L 0.7 
Valine 254.5 µmol / L 2.7 
Methionine 29.2 µmol / L 0.3 
Tryptophan 49.6 µmol / L 1.9 
Free-Tryptophan 10.5 µmol / L 5.4 
Phenylalanine 78.0 µmol / L 3.4 
Isolecuine 153.3 µmol / L 0.9 
Leucine 126.1 µmol / L 2.3 
Platelet count 
Coulter 
240 x103 / µL  2.4 
Platelet volume 9.1 fL 4.1 
Paroxetine binding Liquid Scintillation  942 fmol / mg protein 4.6 
Protein assay Pierce BCA 1680 µg / ml 1.4 
Urine osmolality Freezing point depression 571 mosmol / L 0.2 
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CHAPTER THREE 
 
Inter-individual differences in the response to 
branched-chain amino acid supplementation 
during endurance cycling capacity tests in a 
warm environment. 
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3.1 Abstract 
 
Branched-chain amino acid supplementation has been proposed to improve 
exercise capacity by delaying the onset of central fatigue.  Several studies 
have failed to find an effect of supplementation, although a study by Watson 
et al., (2004) suggested that the response to supplementation may vary 
between individuals.  Therefore, the aim of this investigation was to determine 
if inter-individual differences exist in the response to branched-chain amino 
acid supplementation on endurance cycling capacity in a warm environment.  
 
Eight males cycled to volitional exhaustion at 55 %  ̇O2peak in an ambient 
temperature of 30.0 ± 0.6 °C and 47 ± 6 % relative humidity on four separate 
occasions.  In two of the trials they consumed a drink containing 12 g / L of 
branched-chain amino acids (BCAA) and in the other two trials they 
consumed a taste matched control drink (CON).  Participants were fed the 
appropriate drink for two hours before the start of exercise and then every 
fifteen minutes during exercise.  Blood samples were taken before the drink 
was consumed, before the exercise commenced, every fifteen minutes during 
exercise and at the point of exhaustion.  Core (Tc) and skin (Tsk) 
temperatures, heart rate (HR), rating of perceived exertion (RPE) and thermal 
comfort (TC) were recorded every ten minutes.  
 
Plasma branched-chain amino acid concentration was higher (P < 0.001) and 
the free tryptophan to branched-chain amino acid ratio was lower (P = 0.006) 
in the branched-chain amino acid trials.  However, the exercise time to 
exhaustion was not different between the two test drinks (CON: 105.8 ± 31.1 
minutes, BCAA: 105.8 ± 31.3 minutes; P = 0.993).  The variability of the 
exercise capacity for CON was 12.6 ± 13.4 %, while for BCAA it was 8.9 ± 9.4 
%.  There were no differences in Tc (P = 0.675), Tsk (P = 0.361), HR (P = 
0.292), RPE (P = 0.636), TC (P = 0.805) or the respiratory exchange ratio (P 
= 0.691) between treatments.  This experiment adds further weight to the 
argument that nutritional manipulation of the serotonergic system with 
branched-chain amino acids does not improve endurance exercise capacity. 
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3.2 Introduction 
The synthesis of the neurotransmitter serotonin, which is widely accepted to 
influence feelings of lethargy, largely relies on the availability of the essential 
amino acid tryptophan.  Tryptophan, or more specifically free tryptophan, 
entering the brain is thought to be directly responsible for determining the rate 
of serotonin synthesis (Fernstrom, 1977).  Newsholme and colleagues (1987) 
hypothesised that during prolonged exercise, due to alterations in substrate 
utilisation, an increase in the availability and cerebral uptake of free 
tryptophan would occur, resulting in an increase in the synthesis of serotonin.  
This elevated level of serotonin could explain fatigue during prolonged 
exercise in the absence of any other peripheral factors. 
 
As discussed in Chapter One, tryptophan transport across the blood brain 
barrier is open to competition from the large neutral amino acids including the 
branched-chain amino acids valine, leucine and isoleucine.  During prolonged 
exercise there is a reduction in the concentration of circulating branched-chain 
amino acids (Blomstrand et al., 1988), therefore allowing an increase in the 
uptake of tryptophan across the blood brain barrier.  Theoretically, this will 
increase serotonin synthesis which may, at least in part, be responsible for 
the cessation of exercise. 
 
It was suggested that if individuals were supplemented with branched-chain 
amino acids during exercise, the availability of tryptophan for transportation 
across the blood brain barrier would decrease, leading to a reduction in 
serotonin synthesis (Newsholme et al., 1987).  This theory of the development 
of central fatigue sparked much interest, partly due to the opportunity it 
offered to improve prolonged exercise capacity and performance by nutritional 
manipulation.  Although there is support for the Newsholme theory of central 
fatigue in animal models, the evidence for the efficacy of nutritional 
manipulations influencing exercise capacity is conflicting in humans. 
  
Micro-dialysis in rats showed that when valine (2 mg / 100 g) was injected by 
a venous catheter prior to exercise, there was no increase in the extracellular 
serotonin concentration in the hippocampus during subsequent exercise, 
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compared to the steady increase during (123.7 ± 6.4 %) and after (133.9 ± 6.4 
%) exercise that was seen when saline placebo was infused (Gomez-Merino 
et al., 2001).  Furthermore, there was a clear increase in exercise capacity in 
rats injected with 30 mg of branched-chain amino acids compared to those 
injected with saline (99 ± 9 minutes vs. 76 ± 4 minutes respectively; Calders 
et al., 1997).  This was again shown when rats receiving an injection of 
branched-chain amino acids (250 mg / kg) improved their run time to 
exhaustion by twofold compared to those receiving saline (Yamamoto and 
Newsholme, 2000).  However, it is important to note that the rats used by 
Yamamoto and Newsholme had a genetically controlled lack of plasma 
albumin which may confound the interpretation of these results.  Indeed, a 
study by Verger et al. (1994) in rats has found no difference in time to 
exhaustion between branched-chain amino acids and placebo supplements. 
 
Human-based trials have generated even more contradictory results, and the 
interpretation and comparison of these is further confounded by the variety of 
exercise protocols used.  These have included exercise to exhaustion tests 
(Blomstrand et al., 1995; Blomstrand et al., 1997; Galiano et al., 1991; Struder 
et al., 1998; Van Hall et al., 1995; Watson et al., 2004), time-trials (Hassmen 
et al., 1994), incremental exercise tests (Varnier et al., 1994), intermittent 
shuttle running tests (Davis et al., 1999) and actual running races (Blomstrand 
et al., 1991A). Details of these studies can be found in Table 1.1. 
 
An early field-based experiment by Blomstrand et al., (1991A) showed 
positive support for the theory.  They tested experienced runners in a 
marathon or a cross country race and supplemented them with branched-
chain amino acids and carbohydrate vs. carbohydrate alone (cross country 
running event) or branched-chain amino acids and water vs. water alone 
(marathon running event).  Those who ran in a slower time (marathon time 3 
hours 5 minutes to 3 hours 30 minutes) with branched-chain amino acid 
supplementation were found to run faster than those with a slower time who 
were given the placebo beverage.   Cognitive function tests (Stroop Colour 
and Word Tests; Stroop, 1935) were also performed one to two hours before, 
and one to two hours after the race, and performance in the tests improved in 
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those supplemented with branched-chain amino acids compared to those 
given the placebo beverages. 
 
To further strengthen the case for the Newsholme theory, Mittleman et al., 
(1998) found, in an apparently well-controlled laboratory based experiment, 
that branched-chain amino acid supplementation increased exercise time to 
exhaustion in 34 °C by around 16 minutes (153.1 ± 13.3 minutes on the 
branched-chain amino acid trial and 137.0 ± 12.2 minutes on the placebo 
trial).  However, other studies which also looked at exercise performance 
when acutely supplementing participants with branched-chain amino acids 
failed to find any ergogenic effect for exercise in the heat (Watson et al., 
2004) or exercise in temperate environmental conditions (Blomstrand et al., 
1995; Struder et al., 1998; Van Hall et al., 1995; Madsen et al., 1996). 
 
It has been suggested that hyperthermia may accelerate the onset of central 
fatigue (Bruck and Olschewski, 1987).  Indeed, it is now widely accepted that 
exercise performance (Tatterson et al., 2000) and capacity (Galloway and 
Maughan, 1997) are both negatively affected in a warm environment.  
However, the exact mechanisms of this remain unclear.  Work has shown that 
elevated core temperature alters brain activity (Nielsen et al., 2001) and 
increases the perception of effort (Nybo and Nielsen, 2001C).  By setting the 
exercise trials in the heat, the double stressor of heat and exercise was 
imposed, therefore increasing the chances of showing an effect of branched-
chain amino acid supplementation, if such an effect exists. 
 
The study by Watson et al. (2004), despite not finding a significant response 
to branched-chain amino acid supplementation, presented the idea that there 
may be inter-individual differences in the responses to branched-chain amino 
acid supplementation, where some individuals do experience an ergogenic 
effect, while others do not.  Their data showed that, when glycogen depleted 
through prior exercise, there was a mean non-significant improvement of 7.1 ± 
11.6 minutes when branched-chain amino acids were fed (111.0 ±  29.2 
minutes on the branched-chain amino acid trial; 103.9 ± 26.9 minutes on the 
placebo trial).  Four of the eight participants showed an improvement in 
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exercise capacity when consuming branched-chain amino acids, three 
showed no improvement and one individual exercised longer on the placebo 
trial.  This led the authors to form the hypothesis that only some individuals 
may see an improvement in exercise capacity due to the ingestion of 
branched-chain amino acids, thereby giving an overall non-significant result 
when in fact branched-chain amino acid supplementation could still, 
potentially, improve exercise capacity in some individuals.  However, the 
authors did not hypothesise any physiological mechanisms that might lead to 
a divergence in the effects seen between individuals,  
 
Therefore, the aim of this investigation was to determine if inter-individual 
differences exist in the response to branched-chain amino acid 
supplementation during endurance cycling capacity in a warm environment. 
 
3.3 Methods 
3.3.1 Participants 
Eight healthy, recreationally active males (Mean ± SD: age 25 ± 3 years; body 
mass 84.1 ± 8.9 kg;  ̇O2peak 48.9 ± 10.0 ml / kg/ min; Median (range) height 
1.82 m (1.78 - 2.01 m) were recruited to participate in the study. 
 
3.3.2 Experimental protocol 
Participants came to the laboratory on seven separate occasions.  The initial 
visit was to determine the participants’  ̇O2peak (detailed in Chapter Two).  
The following two visits to the laboratory were for familiarisation trials.  Details 
of these and of pre-trial conditions can be found in Chapter Two.  There were 
four experimental trials, all of which followed the same protocol, during which 
different drinks were provided on two occasions each to the participants, in a 
randomised, double blinded, cross-over design.  A schematic of the protocol 
can be seen in Figure 3.1.   
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Figure 3.1. A schematic representing the protocol employed in the main trials of Chapter Three. 
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Participants reported to the laboratory at the same time each week between 
0600 and 0900 hours.  After arriving, participants emptied their bladder and a 
sample was retained (detailed in Chapter Two).  Post-void nude body mass 
was recorded and the participants then positioned a rectal thermometer to 
allow the measurement of core body temperature.  Skin thermistors were 
positioned on the chest, tricep, thigh and calf.  A heart rate telemetry band 
was also worn around the chest to allow the continuous measurement of heart 
rate (see Chapter Two for details).  
 
Participants were then seated in a comfortable environment (25.4 ± 1.4 °C) 
and one hand was immersed in warm (42 – 44 °C) water for ten minutes.  At 
this point a cannula was inserted and baseline 10 ml blood sample was drawn 
(for details see Chapter Two), after which participants consumed 250 ml of 
either the flavoured control (Control; no added sugar lemon squash; Tesco 
Stores Ltd. Cheshunt, UK) or the branched-chain amino acid drink (BCAA; no 
added sugar lemon squash with 6 g / L leucine, 3 g / L isoleucine and 3 g / L 
valine; SHS International, Liverpool, UK).  Participants drank a further 250 ml 
of the appropriate drink at thirty minute intervals throughout the two hour rest 
period. All drinks were served at 22 – 24 °C.   Resting blood samples were 
drawn at one and two hours.  Heart rate, core temperature and skin 
temperature were recorded every fifteen minutes during the resting phase. 
 
Following this period, the participants moved into a warm environment (30.0 ± 
0.6 °C, 47 ± 6 % RH) and exercised on a cycle ergometer at a workload 
corresponding to 55 %  ̇O2peak until volitional exhaustion (details given in 
Chapter Two).  Blood samples were taken at fifteen minute intervals during 
exercise and participants consumed 150 ml of the appropriate beverage 
(Control or BCAA) immediately after each blood sample.  Heart rate, core 
temperature, skin temperature, and ratings of perceived exertion and thermal 
comfort were recorded every ten minutes during exercise.  Expired gas 
samples were collected every thirty minutes (see Chapter Two for details).  A 
final blood sample and temperature readings were taken at the point of 
volitional exhaustion.  Participants were then moved back into a comfortable 
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ambient temperature.  Final recordings of heart rate, core temperature and 
skin temperature were made fifteen minutes after the cessation of exercise.  
At this point all probes and the cannula were removed and the participant was 
reweighed to allow the calculation of body mass loss over the duration of the 
trial (see Chapter Two for details).  They then showered and were provided 
with food and beverages before leaving the laboratory.   
 
3.3.3 Blood handling and analyses 
All blood samples (10 ml) were collected into dry syringes.  Samples were 
analysed for the determination of blood lactate and glucose concentrations, 
haemoglobin and haematocrit values, plasma amino acid and plasma free 
tryptophan concentrations.  Details of the techniques used can be found in 
Chapter Two.  
 
3.3.4 Statistical analysis 
Data are presented as mean ± standard deviation (SD) unless otherwise 
stated.  Data were tested for normality of distribution using the Shapiro-Wilk 
test.  Data were then investigated for skewness and kurtosis.  Where data 
were not normally distributed, a Kruskal-Wallis ANOVA was performed and, if 
appropriate, pair-wise differences were investigated using the Wilcoxon 
matched-pair sign rank test.  Statistical analysis for normally distributed data 
was done using a two way (time x trial) repeated measures analysis of 
variance test, followed, where appropriate, by a paired t-test with Bonferroni 
correction for multiple comparisons, in order to identify differences between 
trials.  Where there was no difference between trials further analysis to 
investigate the effect of treatment was not undertaken.  The absolute values 
and percentage change in exercise time were used to identify any statistically 
significant differences between trials for time to exhaustion.  The difference in 
the control trials was compared to the difference in the branched-chain amino 
acid trials to investigate if there was greater variation in response on the 
treatment trial.  This was done using paired samples t-tests and the 
Bonferroni correction for multiple comparisons where necessary.  This was 
also performed for variables measured at a single time point.  Statistical 
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analysis was performed using the SPSS program, version 14.0, and 
significance was set at P < 0.05. 
 
3.4 Results 
3.4.1 Hydration status 
Each participant started the trials in a similar state of hydration between 
weeks (Control 1, 448 ± 285 mosmol / L; Control 2, 612 ± 289 mosmol / L; 
BCAA 1, 433 ± 259 mosmol / L; BCAA 2, 585 ± 288 mosmol / L ;P = 0.472).  
 
3.4.2 Time to exhaustion protocol 
Due to the experimental design of this chapter it was possible to investigate 
the influence that the number of trials had on the reproducibility of the 
protocol.  The co-efficient of variation after two trials (between the first and 
second familiarisations) was 21.7 ± 20.4 % (r = 0.613).  The co-efficient of 
variation after three trials (between the second familiarisation and the first 
Control trial) was 11.0 ± 11.2 % (r = 0.934).  This shows the importance of a 
first familiarisation when performing exercise time to exhaustion tests.  The 
coefficient of variation after four trials (between the two Control trials) was 
12.6 ± 13.4 % (r = 0.916), suggesting that there is no additional advantage in 
performing two familiarisation trials before the start of the main data collection.  
 
3.4.3 Time to exhaustion data 
There was no order effect of the trials (Trial 1, 107.8 ± 32.8 minutes; Trial 2, 
105.1 ± 28.1 minutes; Trial 3, 104.4 ± 33.1 minutes; Trial 4, 105.8 ± 33.4 
minutes; P = 0.817).  There was no difference in the time to exhaustion 
between the Control trials (105.8 ± 31.1 minutes) and the BCAA trials (105.8 ± 
31.3 minutes; P = 0.993; Figure 3.2) when the mean times to exhaustion were 
analysed as a complete group.  When the data were analysed as the 
percentage change from the time achieved during the first Control trial there 
was also no difference (Control 1, 100 ± 0 %; Control 2, 101 ± 16 %; BCAA 1, 
104 ± 13 %; BCAA 2, 98 ± 7 %; P = 0.973).  When the difference between the 
two Control trials (11.5 ± 10.5 minutes) was compared to the difference 
between the two BCAA trials (8.5 ± 5.2 minutes) there was also no noteworthy 
difference (P = 0.498).  Taken together these analyses show the branched-
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chain amino acid supplementation protocol did not improve exercise capacity 
in a warm environment and did not show a greater variability in response than 
the Control trial. 
 
When the data are interpreted on an individual, case by case level, only one 
individual appears as if he may have responded positively to the 
supplementation of branched-chain amino acids (Figure 3.3).  This participant 
cycled for an average of 157.9 minutes on the Control trials (158.3 and 157.4 
minutes) and 168.5 minutes on the BCAA trials (172.3 and 164.6 minutes).  
However, this participant had the lowest absolute work load, and the longest 
time to exhaustion compared to the overall group mean of 105 minutes.  The 
variability in exercise capacity was 12.6 ± 13.4 % on the Control trials and 8.9 
± 9.4 % on the BCAA trials.   
 
 
Figure 3.2.  Mean group times to exhaustion for the Control and BCAA drinks. No difference 
was found between treatments or trials for cycling time to exhaustion. 
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Figure 3.3.  Individual cycling times to exhaustion on both of the Control and both of the 
BCAA trials.  
 
3.4.4 Thermoregulatory measures 
As expected, there was an effect of time on core temperature (P < 0.001).  
Core temperature increased at the onset of exercise, and it continued to rise 
steadily throughout the test, peaking at the point of fatigue (38.5 ± 0.4 °C).  It 
then started to decrease during the subsequent fifteen minutes of monitored 
recovery.  There was no effect of the treatments on core temperature (P = 
0.675; Figure 3.4). 
 
There was a significant effect of time (P = 0.023) on skin temperature but the 
trials did not differ (P = 0.361; Figure 3.5).  Skin temperature followed a similar 
pattern to core temperature, rising during the exercise to a peak at the point of 
exhaustion, and once exercise had ceased skin temperature fell.  
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Figure 3.4.  Mean core temperature over the duration of the experimental trials.  There was a 
significant effect of time on core temperature, but there were no differences between any of 
the trials.  The error bars above the data displays the variability in the data.  
 
 
 
Figure 3.5.  Mean of skin temperatures over the duration of the experimental trials.  There 
were no statistically significant effects of time or trial.  The error bars above the data displays 
the variability in the data.  
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Estimated body heat content showed a similar pattern to core and skin 
temperatures over the trials.  Body heat content increased with exercise, 
peaking at the point of exhaustion and then falling during the initial recovery 
period.  Body heat content was not affected by the different trials, but there 
was a significant effect of time (P = 0.001). 
 
Mean body mass loss was 1.11 ± 1.24 kg on the BCAA trials and 1.12 ± 1.01 
kg on the Control trials, despite receiving 150 ml of the required beverage 
every fifteen minutes during exercise.  This was not significantly different 
between trials (P = 0.969). 
 
3.4.5 Cardiovascular and metabolic measures 
Heart rate increased by about 70 beats per minute during the initial ten 
minutes of exercise.  It then increased steadily during the exercise session 
and peaked at around 170 beats per minute at the point of exhaustion 
(P<0.001).  During the initial fifteen minutes of recovery heart rate fell rapidly 
to around 95 beats per minute.  However, there was no difference between 
any of the trials (P = 0.292; Figure 3.6).  
 
Ratings of perceived exertion increased slowly over the initial hour of exercise 
(P < 0.001), but again there was no effect of the trials (P = 0.636; Figure 3.7).  
The same pattern was apparent for the participants’ ratings of thermal 
comfort, which increased steadily during the exercise (P = 0.001), but for 
which there was no effect of the different trials (P = 0.805; Figure 3.8). 
 
There was no effect of time or trial on the use of carbohydrate (CHO) during 
exercise (P = 0.104; P = 0.897 respectively), nor on the use of fat during 
exercise (P = 0.202; P = 0.843 respectively).  Energy expenditure (EE) did 
increase over time (P = 0.018), but did not vary between the trials (P = 0.325). 
Respiratory exchange ratio (RER) was not significantly different over time (P = 
0.150) or between trials (P = 0.691; Table 3.1). 
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Figure 3.6.  Mean heart rate over the duration of the experimental trials.  The error bars above 
the data displays the variability in the data.  
 
 
 
Figure 3.7.  Ratings of perceived exertion during the exercise phase of the trials.  There was 
no difference between trials, and a significant increase over time.  The error bars above the 
data displays the variability in the data.  
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Figure 3.8.  Ratings of thermal comfort during the exercise phase of the trials.  This increased 
significantly during exercise, but was not different between trials.  The error bars above the 
data displays the variability in the data.  
 
Table 3.1.  Carbohydrate and fat oxidation rates at two time points during the trials, the 
energy expenditure calculated from these and the RER value (see Chapter Two for details).  * 
indicates a significant increase over time. 
 
Time (minutes) Control 1 Control 2 BCAA 1 BCAA 2 
30 60 30 60 30 60 30 60 
CHO oxidation rate 
(g / min) 
Mean ± SD 
2.45 
0.81 
2.88 
1.44 
2.54 
0.88 
3.15 
1.74 
2.45 
0.67 
2.90 
1.41 
2.54 
0.89 
2.83 
1.17 
Fat oxidation rate 
(g / min) 
Median (range) 
0.17 
0-0.61 
0.08 
0-0.43 
0.13 
0-0.41 
0.01 
0-0.44 
0.22 
0-0.55 
0.17 
0-0.51 
0.17 
0-0.31 
0.17 
0-0.40 
RER 
Mean ± SD 
0.96 
0.05 
0.97 
0.07 
0.96 
0.05 
0.99 
0.10 
0.93 
0.05 
0.97 
0.08 
0.96 
0.04 
0.96 
0.06 
EE 
(kJ / min) 
Mean ± SD 
45.5 
12.4 
48.3 
13.4 
* 
45.7 
10.6 
49.4 
13.3 
* 
47.6 
10.9 
50.2 
12.7 
* 
45.7 
12.3 
50.0 
13.1 
* 
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Table 3.2.  Blood glucose and lactate concentrations over the duration of the trials.  * 
indicates a significant increase over time. 
 
 
 
 
Blood 
Glucose 
(mmol / 
L) 
Mean 
SD 
Trial Rest Pre 
60 
Pre 
120 
15 30 45 60 Exh 
P1 5.30 
0.52 
5.37 
0.54 
5.29 
0.48 
5.22 
0.57 
5.61 
0.52 
5.64 
0.56 
5.49 
0.68 
5.56 
0.88 
P2 5.00 
0.48 
4.87 
0.57 
4.91 
0.47 
5.04 
0.51 
5.00 
0.61 
4.96 
0.57 
4.96 
0.64 
5.37 
1.10 
B1 5.36 
0.22 
4.95  
0.31 
4.86 
0.44 
5.02 
0.35 
5.06 
0.52 
5.20 
0.53 
5.18 
0.62 
5.29 
0.68 
B2 5.28 
0.42 
4.92 
0.53 
4.94 
0.54 
5.15 
0.56 
5.24 
0.57 
5.32 
0.64 
5.33 
0.73 
5.68 
0.66 
 
Blood 
Lactate 
(mmol / 
L) 
Mean 
SD 
P1* 0.74 
0.36 
0.75 
0.33 
0.81 
0.32 
2.03 
1.00 
2.22 
1.05 
2.17 
1.15 
2.47 
1.91 
2.87 
2.37 
P2* 0.83 
0.32 
0.86 
0.32 
0.78 
0.30 
2.03 
0.93 
2.06 
0.98 
1.78 
1.02 
1.79 
0.72 
2.42 
1.00 
B1* 0.62 
0.33 
0.75 
0.22 
0.82 
0.26 
2.05 
0.88 
1.98 
0.83 
1.96 
0.76 
2.03 
0.97 
2.32 
1.34 
B2* 0.91 
0.50 
0.96 
0.41 
0.88 
0.30 
2.34 
0.78 
2.25 
0.88 
2.35 
0.85 
2.54 
1.49 
3.01 
1.54 
 
Plasma 
Volume 
Change 
(%) 
Mean 
SD 
P1 
 
0 
0 
0.2 
1.9 
-2.1 
2.8 
-12.5 
3.2 
-12.8 
2.8 
-13.4 
2.6 
-13.4 
3.0 
-15.0 
2.7 
P2 
 
0 
0 
0.9 
2.0 
-0.4 
2.0 
-10.2 
4.2 
-10.1 
4.8 
-10.6 
5.1 
-11.3 
6.5 
-13.1 
6.8 
B1 
 
0 
0 
1.9 
3.2 
0.9 
2.8 
-11.2 
2.9 
-11.5 
3.5 
-11.3 
3.7 
-11.6 
3.5 
-13.5 
4.6 
B2 
 
0 
0 
1.0 
2.2 
-0.6 
2.7 
-11.4 
3.0 
-11.1 
4.4 
-11.5 
3.3 
-10.8 
7.0 
-14.7 
5.6 
 
Plasma amino acid concentrations are displayed in Figures 3.9A and 3.9B, 
and the free tryptophan to branched-chain amino acid ratio is shown in Figure 
3.9C.  For the statistical analysis of the amino acids the values obtained on 
the two Control trials have been combined and the mean value reported, and 
the same has been done for the BCAA trials at each time point.  The 
concentration of all of the large neutral amino acids were significantly higher 
82 
 
(P < 0.001 tyrosine; P = 0.028 methionine; P = 0.012 tryptophan; P = 0.023 
phenylalanine) during the Control trials than the BCAA trials (Figure 3.9A).  
 
Valine, isoleucine and leucine concentrations were all significantly greater on 
the BCAA trial compared to the Control trial from one hour after the first bolus 
of drink was consumed.  For each branched-chain amino acid, the plasma 
concentration was significantly elevated from baseline by sixty minutes after 
the first drink was consumed and remained elevated for the duration of the 
trials (Figure 3.9B). 
 
Free tryptophan levels tended to differ over time (P = 0.055) but did not differ 
between trials (P = 0.166).  However, the ratio between free tryptophan and 
the branched-chain amino acids was significantly (P = 0.006) higher on the 
Control trials than the BCAA trials.  There was only a slight tendency for the 
values to differ over time (P = 0.069), though it can be seen that they were 
very similar between trials before the start of the supplementation protocol 
(Figure 3.9C). 
 
 
Figure 3.9A.  Large neutral amino acid concentrations over the duration of the trials.  (P) 
symbolises the Control trials and (B) symbolises the BCAA trials. 
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Figure 3.9B.  Branched-chain amino acid concentrations over the duration of the trials.  (P) 
symbolises the control trials and (B) symbolises the branched-chain amino acid trials. 
 
 
 
Figure 3.9C.  The ratio between free tryptophan and the total branched-chain amino acids 
over the duration of the trials.   
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3.5 Discussion 
The aim of this investigation was to determine whether there are inter-
individual differences in the response to branched-chain amino acid 
supplementation on endurance exercise capacity in a warm environment.  
The data presented show there is no greater variability in the response to 
branched-chain amino acid supplementation compared to that seen when a 
control is administered, and that no individual appeared to perform markedly 
better with a BCAA drink than with the Control drink.  
 
One participant did exercise for longer on both of the BCAA trials than on the 
Control trials (Figure 3.3).  This individual exercised for longer than all other 
participants: approaching three hours.  An effect of supplementation with 
branched-chain amino acids in exercise lasting over three hours was found by 
Blomstrand et al. (1991A).  They found that branched-chain amino acid 
supplementation improved exercise performance in ‘slower’ (3 hours 5 
minutes to 3 hours 30 minutes for a marathon) runners by around 3 %, 
equating to 5 - 6 minutes.  The participant in this study increased his mean 
exercise time to exhaustion by 10.6 minutes (6.7 %) with the branched-chain 
amino acid supplementation.  However, in the study by Blomstrand et al. 
(1991A) the supplementation protocol did not improve performance in faster 
(less than 3 hours 5 minutes) runners, the duration of exercise which is closer 
to the individual discussed here.  Therefore, it is likely that these results do 
not originate from the same physiological mechanism. 
 
However, it is important to note the differences between the participants used 
by Blomstrand and colleagues (1991A) and the individual who appeared to 
improve due to the present supplementation protocol.  The participant in this 
study had an absolute  ̇O2 of 2.7 L (32 ml / kg / min).  It is highly unlikely that 
anyone with this level of fitness would be able to complete a marathon run 
within the time scale of the ‘slow’ runners (3 hours 5 minutes to 3 hours 30 
minutes) in the study by Blomstrand and colleagues (1991A).  Also, it is 
important to remember that studies undertaken in the field, like that of 
Blomstrand and colleagues, are open to many confounding and uncontrollable 
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factors.  These include weather conditions, the appropriate matching of 
participants when assigning to experimental groups, blinding of the 
participants to their test group, exercise intensity or dietary and fluid intakes 
before the event.  This means that there may be no relevant effect of 
branched-chain amino acid supplementation on exercise over three hours in 
duration.  
 
It seems highly improbable that the reason for fatigue in the present trials was 
a simple peripheral factor.  Core temperatures at the point of exhaustion were 
not elevated close to the proposed ‘critical’ core temperature in humans of 
approximately 40 °C (Nielsen et al., 1993; Figure 3.4), above which exercise 
may cease due to uncompensable thermoregulatory demands.  Nor was the 
fatigue likely to have been caused by hypohydration since research has 
shown that performance decrements due to hypohydration occur at around a 
2 % loss in body mass (Armstrong et al., 1985).  Most of the participants (6 of 
8) in the present study were hypohydrated to a lesser extent (1.4 ± 0.6 %), 
meaning that this is an unlikely cause of fatigue.  Blood glucose levels were 
also maintained over the duration of the trials.  In the present study the heart 
rates of the participants at the end of exercise were not elevated to estimated 
maximum levels (195 ± 3 beats per minute), being 169 ± 13 beats per minute 
for the Control trials and 170 ± 15 beats per minute for the BCAA trials. 
 
While the results of the present study may agree to some extent with the 
findings of Blomstrand et al. (1991A), they conflict with those of Mittleman and 
colleagues (1998), who performed an apparently well-controlled laboratory 
based study into the effect of supplementation of branched-chain amino acids 
on exercise (40 %  ̇O2max) capacity in the heat (34.4 ± 1.8 °C).  They found 
that exercise time to exhaustion was longer (153.1 ± 13.3 vs. 137.0 ± 12.2 
minutes; 14 % improvement) when the participants were given drinks (5 ml / 
kg body mass) containing 5.88 g / L of branched-chain amino acids (54 % 
leucine; 19 % isoleucine; and 27 % valine) compared to when they were given 
the same volume of a placebo drink.  Although the composition of the drinks 
between the Mittleman et al. (1998) study and the present study differed 
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slightly, this is unlikely to be a major contributing factor for the different 
findings.  The total amount of branched-chain amino acids administered for 
the male participants of the Mittleman study was 15.8 ± 1.1 g.  Mittleman and 
colleagues purported that the cause of the improved exercise capacity seen 
was due to the alteration in the free tryptophan to branched-chain amino acid 
ratio as a result of branched-chain amino acid supplementation.  The present 
study administered between 19.2 g and 31.8 g dependent on exercise 
duration, and the ratio of free tryptophan to branched-chain amino acid was 
even further reduced.  Therefore, an improvement in exercise capacity should 
have been even clearer in the present investigation, but this was not the case. 
 
The ratio of tryptophan to branched-chain amino acids has been shown to be 
correlated with the brain tryptophan concentration (Leathwood, 1987).  
Therefore, this ratio is likely to be more important than the absolute values.  
By altering the free tryptophan to branched-chain amino acid ratio in the 
blood, there would be a reduced uptake of the serotonin precursor into the 
brain and therefore a reduction in the production of serotonin and 
consequently, theoretically, a delay in the onset of fatigue.  Indeed, the values 
seen here for plasma branched-chain amino acid concentration or the free 
tryptophan to branched-chain amino acid ratio are representative of the trend 
seen in Mittleman et al. (1998), Blomstrand et al. (1991A), Watson et al. 
(2004), and Cheuvront et al. (2004).   
 
A time delay is thought to exist between peripheral amino acid availability and 
the uptake of free tryptophan into the brain.  Therefore, it is important that 
supplementation starts a sufficient length of time before exercise to allow for 
the increased availability of free tryptophan to be realised (Knott and Curzon, 
1972).  In this study the supplementation protocol was introduced two hours 
before exercise commenced and as a result the greatest difference in the free 
tryptophan to branched-chain amino acid ratio was seen at the onset of the 
exercise protocol.  During the initial thirty minutes of exercise there was a 
drop in the concentration of amino acids in the plasma.  It is possible that this 
initial reduction was due to the uptake of the branched-chain amino acids into 
the muscles at the onset of exercise for use as a fuel source.  
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Although brain serotonin levels could not be directly measured here, it has 
been shown using micro-dialysis in rat brain that infusion with L-valine (2 mg / 
100 g) prevented the exercise-induced serotonin release that was seen when 
a placebo (saline) was infused (Gomez-Merino et al., 2001).  The values 
reported in the above experiment reflect those seen in the current 
investigation, despite the different species used.  Valine in this study was 
given equating to an average of 7 mg / 100 g.  The valine plasma 
concentrations were similar before and after the valine administration between 
species (196 ± 14 µM / L in rats and 254 ± 17 µM / L in humans before valine 
was administered and 406 ± 15 µM / L in rats and 701 ± 111 µM / L in humans 
after valine was administered). Changes in tryptophan levels due to the valine 
supplementation (19 % reduction in rats and 22 % reduction in humans) were 
also similar. 
 
Branched-chain amino acid supplementation led to a reduction in the plasma 
concentrations of all of the other large neutral amino acids in the present 
study.  This is in line with the findings of Blomstrand et al. (1991A), although 
in their study the concentrations of tryptophan, tyrosine, phenylalanine, and 
methionine, were all reduced after branched-chain amino acid 
supplementation during a prolonged running race.  However, it was only the 
reductions in tryptophan and methionine that were statistically significant.  
This shows that branched-chain amino acid supplementation, as well as 
increasing the competition for transport across the blood brain barrier also 
reduces the absolute plasma concentration of tryptophan which, along with 
the ratio of free tryptophan to branched-chain amino acids, has also been 
suggested to be important.  Pardridge (1983) suggested that the large neutral 
amino acid transporter at the blood brain barrier may be able to disassociate 
tryptophan from albumin, thereby making bound tryptophan available for 
transport across the blood brain barrier.   
 
The ratings of perceived exertion in this investigation were not different 
between trials  (P = 0.636), though it might have been expected that they 
would have been lower on the branched-chain amino acid trials, as central 
serotonergic activity has been associated with reductions in arousal levels 
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and increases in the perception of tiredness and lethargy.  Indeed, 
Blomstrand and colleagues found that during supplementation with branched-
chain amino acids participants overall rating of perceived exertion was 
reduced by 7 % and their ratings of mental fatigue were reduced by 15 % 
during a sixty minute cycle at approximately 70 %  ̇O2max (Blomstrand et al., 
1997).  However, other investigations have also failed to find any differences 
in perceived exertion (Watson et al., 2004; Mittleman et al., 1998; Struder et 
al., 1996).   
 
Blomstrand’s group also found that cognitive function (Stroop Colour and 
Word Test; Stroop, 1935) was improved one to two hours after a 30 km cross 
country running race compared to one to two hours before the race when 
supplemented with branched-chain amino acids, while those receiving a 
placebo drink did not improve performance (Blomstrand et al., 1991A).  
Similar findings were also reported by the same investigators for the same 
cognitive tests using female football players tested before and after a match 
when consuming either a 6 % carbohydrate drink or the same drink with 7.5 g 
/ L of branched-chain amino acids added (Blomstrand et al., 1991B)   
However, another well controlled laboratory-based investigation found no 
effect of branched-chain amino acid supplementation on cognitive function, 
assessed by a battery of five tests, including those used in other studies 
investigating branched-chain amino acid administration, or exercise 
performance, assessed by a thirty minute pre-loaded time-trial performance in 
the heat (40 °C; Cheuvront et al., 2004). 
 
Performing exercise in the heat reduces exercise capacity, with 11 °C being 
optimum for exercise capacity at approximately 70 %  ̇O2max (Galloway and 
Maughan, 1997).  Exercise in a warm environment (32 °C) has also been 
shown to reduce mean power output of elite road cyclists by 6.5 % over a 
thirty minute time-trial, compared to when the same exercise was performed 
in an environment only 9 °C cooler (23 °C), despite no differences in rectal 
temperatures between the trials (Tatterson et al., 2000).   
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In the current study the exercise intensity was low (55 %  ̇O2peak), thereby 
allowing the participants to exercise for a fairly long duration without core 
temperature becoming a limiting factor; core temperature at exhaustion was 
38.5 ± 0.3 °C for the Control trials and 38.5 ± 0.4 °C for the BCAA trials.  
Participants’ core temperature was not elevated close to the proposed ‘critical’ 
core temperature of approximately 39.7 ± 0.15 °C, above which exercise may 
cease due to uncompensated  thermoregulatory demands, or as a protective 
mechanism within the body (Nielsen et al., 1993).  Elevated core temperature 
has been postulated to accelerate the onset of central fatigue through signals 
originating in the active muscles and/or the central nervous system, and the 
critical core temperature hypothesis has been supported by further research 
(Gonzalez-Alonso et al., 1999B).  However, there are many cases in the 
published literature where fatigue occurs at a core temperature well below this 
threshold (Watson et al., 2004; Sawka et al., 1992; Mittleman et al., 1998).   
 
There is a vast volume of literature on the peripheral physiological effects of 
varying environmental conditions in which exercise is performed, but the 
central mechanisms behind the reduction in performance are yet to be fully 
clarified.  What is known, is that the increase in perceived effort seen during 
exercise in the heat, compared to the same exercise in a more temperate 
environment, is not related to the cerebral balance of tryptophan or dopamine 
measured by the arterial-venous differences in the blood, neither of which 
differed between exercise in an ambient environment, and the same exercise 
with heat exposure (Nybo et al., 2003).  There was no difference between the 
trials for the ratings of thermal comfort in the present study.  Serotonin has 
been suggested to play a role in thermoregulation and therefore by altering 
the synthesis rate of serotonin, a difference in the thermal comfort scores 
reported between the two treatments might have been expected. 
 
The intensity of the exercise performed in the present study was low and 
there was no difference between the trials for the RER values (P = 0.691), nor 
any effect of time (P = 0.150), showing that the supplemented branched-chain 
amino acids were not being metabolised as a fuel source.  There is also no 
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evidence that carbohydrate supply was a limiting factor to exercise, as shown 
by the stable blood glucose concentrations seen throughout the exercise 
protocol.  Indeed the supplementation of branched-chain amino acids did not 
alter the blood glucose (P = 0.562) or lactate (P = 0.072) levels between trials, 
a finding that is in line with other BCAA supplementation protocols (Watson et 
al., 2004; Mittleman et al., 1998; Blomstrand et al., 1997). 
   
3.6 Conclusion 
The results of this study do not support the theory of inter-individual 
differences in the response to branched-chain amino acid supplementation 
proposed by Watson et al. (2004).  Nor does it support previous findings that 
BCAA supplementation improves exercise capacity in the heat (Mittleman et 
al., 1998), despite the large amount of branched-chain amino acids ingested, 
and the consequent reduction in the free tryptophan to branched-chain amino 
acid ratio.  The BCAA drink did not cause any differences in the physiological 
responses to exercise compared to the Control drink.  With the growing 
number of published studies showing no response to nutritional manipulations 
using branched-chain amino acids on the serotonergic system, it should be 
concluded that this is not a successful approach to improving exercise 
capacity or performance. 
 
Although using branched-chain amino acids to manipulate tryptophan uptake 
into the brain does not seem to produce an improvement in exercise capacity, 
there is another nutritional manipulation that could reduce tryptophan uptake 
into the brain.  By acutely depleting the body’s circulating tryptophan 
concentration, this may reduce the uptake of tryptophan across the blood 
brain barrier and therefore prevent or reduce the production of serotonin.  
Based on the same theory as branched-chain amino acid supplementation, a 
reduced rate of serotonin production could improve exercise capacity. This 
principle provides the basis of the next chapter. 
91 
 
CHAPTER FOUR 
 
Effect of acute tryptophan depletion on 
endurance cycling capacity in a warm 
environment. 
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4.1 Abstract 
 
Reducing the availability of tryptophan for transport across the blood brain 
barrier has been proposed to reduce the rate of production of serotonin, 
thereby improving endurance exercise capacity.  Acute tryptophan depletion 
has never been tested as a method for improving endurance exercise 
capacity.  The aim of this investigation was to assess the effect of acute 
tryptophan depletion on endurance cycling capacity in a warm environment.  
 
Eight males cycled to volitional exhaustion at 55 %  ̇O2peak in an ambient 
temperature of 30.1 ± 0.5 °C and 30 ± 7 % relative humidity, on two separate 
occasions. They did these tests seven hours after consuming either an amino 
acid load designed to deplete their circulating tryptophan concentration (TD), 
or a Control amino acid load (CON).  Blood samples (7 ml) were taken before 
ingesting the amino acids, before the start of exercise, every fifteen minutes 
during exercise, and at the point of exhaustion.  Heart rate (HR), core (Tc) 
and skin (Tsk) temperatures and ratings of perceived exertion (RPE) and 
thermal comfort (TC) were also monitored every ten minutes during the 
experiment.  Gas samples were collected every thirty minutes.  
 
Tryptophan (P = 0.003) and free tryptophan (P < 0.001) plasma 
concentrations, and the ratio of free tryptophan to branched-chain amino 
acids (P = 0.004) were all lower on the TD trials.  However, there was no 
difference in the time to exhaustion between the two treatments (TD: 99.2 ± 
24.4 minutes, CON: 108.4 ± 21.6 minutes; P = 0.088).  There was also a 
tendency for HR and Tc to be higher on the TD trials (HR P = 0.053, Tc P = 
0.069). There were no differences for any of the other parameters measured 
(Tsk, P = 0.597; RPE, P = 0.195; TC, P = 0.422; Blood [glucose], P = 0.666; 
Plasma [FFA], P = 0.695; Change in plasma volume, P = 0.211).  It is possible 
the TD did reduce serotonin production, but that this actually increased HR 
and Tc, potentially causing the tendency for a reduction in endurance exercise 
capacity.  The results of this study show that exercise capacity in a warm 
environment is not improved by acute tryptophan depletion. 
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4.2 Introduction 
Exercise capacity is significantly reduced in a warm environment (Galloway 
and Maughan, 1997).  In contrast to temperate conditions, during heat stress 
fatigue may be mediated through mechanisms residing within the central 
nervous system (CNS), with the development of hyperthermia thought to play 
a key role (Nybo and Nielsen, 2001B).  Specifically, the neurotransmitter 
serotonin is thought to be of importance in the development of fatigue as it is 
involved in the control of arousal, sleepiness and mood (Blomstrand, 2001).  
Prolonged strenuous exercise increases serotonin synthesis and release 
which has led to suggestions that serotonin impairs exercise capacity 
(Newsholme et al., 1987). 
 
Serotonin, or 5-hydroxytryptamine (5-HT), is synthesised in the body using the 
essential amino acid precursor tryptophan.  After the transportation of free 
tryptophan across the blood brain barrier, tryptophan is converted in the brain 
to serotonin through two enzymatic reactions.  One of the enzymes, 
tryptophan hydroxylase, is only around 50 % saturated in normal 
circumstances, meaning that the main determinant of serotonin production is 
the availability of the substrate, i.e. tryptophan.  
 
Tryptophan is found in protein rich foods such as meat, fish and dairy 
produce.  The National Academy of Sciences (2005) has suggested that, 
based on RDA-level of protein intakes, males aged over eighteen years 
should be consuming 392 mg of tryptophan a day.  Not all of the dietary 
tryptophan ingested crosses the blood brain barrier, as tryptophan in the brain 
usually ranges from 10 – 30 mg, but this is undoubtedly an important fate of 
tryptophan (Leathwood, 1987).  Indeed, research is on-going about which 
protein sources offer the best tryptophan availability with a view to altering 
serotonin production and improving mood (Markus et al., 2008).  Completely 
removing tryptophan from the diet reduces plasma tryptophan by only around 
20 %, and consequently has few behavioural consequences (Bell et al., 
2001).  To induce greater falls in plasma tryptophan concentration, feeding an 
amino acid load with the particular omission of tryptophan achieves about an 
80 % reduction in plasma free and total tryptophan levels five to seven hours 
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after consumption: a technique known as rapid or acute tryptophan depletion 
(Delgado et al., 1990).  Such a reduction may therefore inhibit the synthesis 
and release of serotonin (Bell et al., 2001).  
 
Acute tryptophan depletion works by loading the system with amino acids 
causing protein synthesis to be stimulated in the liver (Bell et al., 2001).  This 
process requires tryptophan which, since it was not ingested, is utilised from 
the stores within the body.  Administering the amino acid load also increases 
the systems’ large neutral amino acid content, thereby further reducing the 
amount of tryptophan passing across the blood brain barrier, due to increased 
competition for the same energy requiring, active transport mechanism 
(Pardridge, 1983).  The most successful brain tryptophan depletion protocols 
combine a low tryptophan diet with the ingestion of an amino acid load.  
 
Acute tryptophan depletion is a popular, well documented technique and has 
been used extensively in clinical studies into depression (Neumeister et al., 
2004), anxiety (Bell et al., 2001), aggression (McCloskey et al., 2009), sleep 
patterns (Bhatti et al., 1998), memory (Schmitt et al., 2000), eating disorders 
(Weltzin et al., 1995) and cognitive function (Gallagher et al., 2003).  Through 
the combined effects of a tryptophan free diet and acute tryptophan depletion, 
the lowered brain serotonin concentrations could, theoretically, lead to an 
improvement in exercise capacity based on the principals proposed in 
Newsholme’s theory of central fatigue (1987).   
 
Therefore, the aim of this investigation was to compare the response to 
prolonged exercise in a warm environment when participants were tryptophan 
depleted to when they were fed a control amino acid load. 
 
4.3 Methods 
4.3.1 Participants 
Eight healthy, recreationally active males (Mean ± SD: age 24 ± 3 years; 
height 1.84 ± 0.07 m; mass 84.4 ± 9.9 kg;  ̇O2peak 52.8 ± 7.1 ml / kg / min) 
were recruited to participate in the study.  
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4.3.2 Experimental protocol 
The initial visit was to complete a discontinuous, incremental cycle ergometer 
test to volitional exhaustion in order to determine the participants’  ̇O2peak 
(details in Chapter Two).  All subsequent visits to the laboratory were 
separated by at least one week and were performed at the same time of day.  
The following two visits to the laboratory were for familiarisation trials.  Details 
of these and of the pre-trial conditions are in Chapter Two.  There were then 
two experimental trials, both of which followed the same protocol, but during 
which slightly different amino acid loads were provided to the participants, in a 
randomised, double blinded, cross-over design. A schematic of the protocol 
used can be seen in Figure 4.1.   
 
Each trial involved two visits to the laboratory.  Participants were asked to 
attend the laboratory between 1700 and 1900 hours the day before the 
exercise trial, having consumed nothing but plain water for the previous four 
hours.  Participants were seated in a comfortable room for fifteen minutes 
before a resting blood sample (7 ml) was taken by venepuncture.  Participants 
were then given the amino acid load to take away and consume at 2330 hours 
that night.  The amino acid load consisted of either 104.4 g of amino acids 
including tryptophan (CON: alanine (5.5 g), arginine (4.9 g), cysteine (2.7 g), 
glycine (3.2 g), histidine (3.2 g), isoleucine (8 g), leucine (13.5 g), lysine 
monohydrochloride (11 g), methionine (3 g), phenylalanine (5.7 g), proline 
(12.2 g), serine (6.9 g), threonine (6.5 g), tyrosine (6.9 g), valine (8.9 g) and 
tryptophan (2.3 g); SHS International ltd, UK), or the same amino acid load 
excluding tryptophan (TD).  In order to make the amino acids consumable 
they were divided into a drink and capsules.  The gelatine capsules (TAAB, 
UK) contained the isoleucine, tyrosine and methionine, while the drink 
contained all the remaining amino acids along with 8.25 g of intensive 
pineapple flavouring (SHS International ltd, UK) in 350 ml of tap water. 
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Figure 4.1. A schematic representing the protocol employed during the main trials in Chapter Four. 
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Participants reported to the laboratory at 0500 hours the following morning 
after an overnight fast and 500 ml of water at 0430 hours.  After arriving, 
participants emptied their bladder and a sample was retained (details in 
Chapter Two).  Participants’ post-void, nude body mass was noted and they 
then positioned a rectal thermometer to allow the measurement of core body 
temperature.  Skin thermistors were positioned on the chest, tricep, thigh and 
calf.  A heart rate telemetry band was also worn (see Chapter Two for details).  
 
Participants were then seated in a comfortable environment (22.9 ± 0.4 °C), 
and one hand was immersed in warm (42 - 44 °C) water for ten minutes.  An 
indwelling cannula was inserted (detailed in Chapter Two) and a baseline 
blood sample (7 ml) was drawn.  Baseline measures of heart rate and core 
and skin temperatures were taken before participants were moved into a 
warm environment (30.1 ± 0.5 °C, 30 ± 7 % relative humidity) and exercised 
on a cycle ergometer at a workload corresponding to 55 %  ̇O2peak until 
volitional exhaustion (details in Chapter Two).  
 
Blood samples (7 ml) were taken at fifteen minute intervals during exercise 
and participants consumed 100 ml of plain water immediately after each 
sample.  Heart rate, core temperature, skin temperature and ratings of 
perceived exertion and thermal comfort were recorded every ten minutes 
during exercise; expired gas samples were collected every thirty minutes (see 
Chapter Two for details).  A final blood sample and temperature readings 
were taken at the point of exhaustion.  Participants were then moved back 
into a comfortable environment and their recovery was monitored.  Final 
recordings of heart rate, core temperature and skin temperature were made 
fifteen minutes after the cessation of exercise.  At this point, all probes and 
the cannula were removed and the participant was reweighed to allow the 
calculation of body mass loss over the trial (see Chapter Two for details).  
Participants then showered and were provided with food and drinks before 
leaving the laboratory.   
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4.3.3 Blood handling and analysis 
All blood samples were collected into dry syringes.  Samples were analysed 
for the determination of blood glucose and haemoglobin concentrations, 
haematocrit values and free fatty acid, free tryptophan and large neutral 
amino acids concentrations.  Details of the techniques used can be found in 
Chapter Two.  
 
4.3.4 Statistical analysis 
Data are presented as mean ± standard deviation (SD) unless otherwise 
stated.  Data were tested for normal distribution using the Shapiro-Wilk test.  
Data were then investigated for skewness and kurtosis.  Where appropriate, 
statistical analysis was done by either a two-way repeated measures ANOVA 
with a Bonferroni correction or a paired sample t-test.  Statistical analysis was 
done using the SPSS program, version 14.0, and significance was set at P < 
0.05.  
 
4.4 Results 
4.4.1 Hydration status 
There were no differences in hydration status between the two trials (P = 
0.427).  The mean urine osmolality for TD was 637 ± 308 mosmol / L and for 
CON it was 667 ± 369 mosmol / L.  The body mass loss from the two trials 
was not different (1.43 ± 0.40 kg on TD and 1.53 ± 0.32 kg on CON; P = 
0.148).  
 
4.4.2 Time to exhaustion protocol 
The co-efficient of variation between the first and second familiarisations was 
14.4 ± 14.8 % (r = 0.781).  The co-efficient of variation between the second 
familiarisation and the Control trial was 11.5 ± 12.4 % (r = 0.834).  This backs 
up the findings of Chapter Three by again showing the importance of a first 
familiarisation when performing exercise time to exhaustion tests, in order to 
improve the reproducibility of the test.   
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4.4.3 Time to exhaustion data 
There was no effect of trial order in the exercise times to exhaustion (Trial 1 
102.0 ± 23.4 minutes, Trial 2 105.6 ± 23.6 minutes; P = 0.540).  There was no 
effect of acute tryptophan depletion on exercise capacity as the mean time to 
exhaustion was 99.2 ± 24.4 minutes on the TD trial and 108.4 ± 21.6 minutes 
on the CON trial (P = 0.088; Figure 4.2).  When the data are expressed as a 
percentage change from the second familiarisation trial there is still no effect 
of acute tryptophan depletion (P = 0.066), although there is a tendency for 
duration to be shorter on the TD trials (95.5 ± 7.4 %) compared to the CON 
(105.5 ± 10.7 %) trials relative to the second familiarisation. 
 
 
Figure 4.2.  Mean cycling time to exhaustion (n = 8) for the TD and CON trials.  There was no 
difference in the time to exhaustion between the two trials (P = 0.088). 
 
4.4.4 Thermoregulatory measures 
Core temperature increased during the exercise test (P < 0.001) from resting 
values of 37.0 ± 0.1 °C to 38.3 ± 0.3 °C on the TD trial and 36.9 ± 0.2 °C to 
38.2 ± 0.2 °C on the CON trial at the point of exhaustion (Figure 4.3).  The 
difference between the trials failed to reach statistical significance (P = 0.069).  
The core temperature then fell during the initial period of recovery on both 
trials. 
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As with core temperature, skin temperature increased during the exercise test 
(P < 0.001; Figure 4.4) but did not differ between trials (P = 0.597).  Skin 
temperature increased from 32.5 ± 0.9 °C at rest to 35.0 ± 0.8 °C at the point 
of exhaustion on the TD trial, and from 32.3 ± 0.7 °C to 35.2 ± 0.9 °C on the 
CON trial.  It then fell in the fifteen minute recovery period (to 33.2 ± 1.6 °C 
and 33.4 ± 1.2 °C for TD and CON respectively).  Again, estimated body heat 
content followed a similar pattern to both core and skin temperatures, with no 
difference between the trials (P = 0.960), but a significant increase during the 
exercise bout (2471 ± 299 kJ and 2451 ± 283 kJ pre exercise increasing to 
2587 ± 322 kJ and 2598 ± 318 kJ at the point of exhaustion for the TD and 
CON trials respectively; P < 0.001). 
 
 
Figure 4.3.  Core temperature over the duration of the TD and CON trials. There was a 
tendency for a core temperature to be higher on the TD trial than the CON trial.   
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Figure 4.4.  Skin temperature over the duration of the TD and CON trials.   
 
4.4.5 Cardiovascular and metabolic measures 
Rating of perceived exertion increased over time during the exercise (P < 
0.001), but was not affected by the trials (P = 0.195; Table 4.1).  Rating of 
thermal comfort also increased during the exercise bout (P < 0.001), but 
again, was not affected by the trials (P = 0.422; Table 4.1). 
 
Table 4.1.  Ratings of perceived exertion and thermal comfort over the exercise test. 
 
 
Time (minutes) 
10 20 30 40 50 60 70 
Perceived 
Exertion 
TD 
11  
± 2 
12  
± 2 
13  
± 2 
14  
± 2 
15  
± 2 
17  
± 2 
18  
± 2 
CON 
11  
± 2 
12  
± 2 
13  
± 2 
14  
± 2 
14  
± 2 
16  
± 2 
16  
± 1 
Thermal 
Comfort 
TD 
3  
± 1 
4  
± 1 
4  
± 1 
5  
± 1 
6  
± 1 
6  
± 1 
7  
± 2 
CON 
3  
± 1 
4  
± 1 
5  
± 1 
5  
± 1 
6  
± 1 
6  
± 1 
6  
± 1 
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Heart rate tended to be higher on the TD trials (P = 0.053), but it did rise over 
the duration of the exercise (P < 0.001) to peak at the point of exhaustion (165 
± 11 and 161 ± 14 beats per minute on the TD and the CON trials 
respectively; Figure 4.5). 
 
 
 
Figure 4.5.  Heart rate over the duration of the TD and CON trials.   
 
There was no effect of time (P = 0.840, P = 0.471) or trial (P = 0.636, P = 
0.667) on the contributions of carbohydrate (CHO) or fat respectively during 
the exercise.  Consequently, there was no effect of time (P = 0.172, P = 
0.622) or trial (P = 0.881, P = 0.264) on energy expenditure (EE) or 
respiratory exchange ratio (RER) respectively (Table 4.2). 
 
Plasma volume did change with time (P < 0.001).  It increased initially 
between the pre-supplementation sample and the pre-exercise sample, 
however, it then fell during exercise and reached its lowest at the point of 
exhaustion.  There was no difference between the trials (P = 0.211; Figure 
4.6).  Blood glucose changed significantly with time (P = 0.007), but again, 
there was no difference between the trials (P = 0.666; Figure 4.7).  Free fatty 
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acid concentration also changed significantly over time (P < 0.001) increasing 
through exercise, but again there was no effect of trial (P = 0.695; Figure 4.8). 
 
Table 4.2.  Contributions of different energy sources during the exercise performed and the 
respiratory exchange ratio and energy expenditure values. 
 
 TD CON 
30 minutes 60 minutes 30 minutes 60 minutes 
CHO oxidation 
rate (g / min) 
2.42  
± 0.83 
2.57  
± 1.31 
2.42  
± 0.55 
2.35  
± 0.87 
Fat oxidation 
rate (g / min) 
0.26  
± 0.29 
0.30  
± 0.18 
0.26  
± 0.14 
0.33  
± 0.16 
RER 
 
0.93  
± 0.06 
0.92  
± 0.06 
0.93  
± 0.03 
0.91  
± 0.05 
EE 
 (kJ / min) 
48.4  
± 10.6 
51.5  
± 12.8 
49.0  
± 6.5 
50.4  
± 9.2 
 
 
 
Figure 4.6.  Plasma volume, presented as the percentage change from the initial blood 
sample, over the duration of the study.  There was no difference between trials (P = 0.211). 
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Figure 4.7.  Blood glucose concentration varied over the duration of the TD and CON trials (P 
= 0.007), but was not different between trials (P = 0.666).   
 
 
Figure 4.8.  Free fatty acid concentration over the duration of the TD and CON trials.  There 
was no difference between the trials (P = 0.695). 
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Plasma branched-chain amino acid concentrations are shown in Figure 4.9A 
and plasma concentrations for the other large neutral amino acids are shown 
in Figure 4.9B.  Other than leucine, all demonstrated significant changes over 
time (P ≤ 0.024), with the majority rising either after drinking or during the 
exercise, none were different between the trials.  Figure 4.10A shows plasma 
tryptophan and free tryptophan concentrations at the time points sampled.  
Tryptophan (P = 0.003) and free tryptophan (P < 0.001) concentrations are 
lower on the TD trials compared to the CON trials.  Figure 4.10B shows the 
ratio of free tryptophan to branched-chain amino acids during the trials.  The 
ratio was lower on the TD trials than the CON trials (P = 0.004) and there was 
also a significant effect of time on the ratio (P = 0.048), decreasing after 
consuming the amino acid load and then increasing during the exercise 
phase. 
 
 
 
Figure 4.9A.  Plasma branched-chain amino acid concentrations over the durations of the TD 
and CON trials.  Valine (P = 0.003) and isoleucine (p = 0.024) were influenced by time over 
the duration of the trials but the treatment did not have any influence on any of the branched-
chain amino acids. 
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Figure 4.9B.  Plasma large neutral amino acid concentrations over the durations of the TD 
and CON trials.  Tyrosine (P = 0.001), methionine (P = 0.038) and phenylalanine (P = 0.004) 
were all affected by time during the trials but the treatment did not have any influence. 
 
 
Figure 4.10A.  Plasma tryptophan and plasma free tryptophan concentrations at the time 
points sampled over the TD and CON trials.   
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Figure 4.10B.  The ratio of free tryptophan to branched-chain amino acids at the time points 
sampled over the TD and CON trials.   
 
4.5 Discussion 
The main finding of this investigation was that there was a tendency for 
exercise capacity to be impaired on the TD trials (99.2 ± 24.4 minutes) 
compared to the CON trials (108.4 ± 21.6 minutes; P = 0.088).  This was also 
reflected when the data were expressed as a percentage change from the 
time to exhaustion generated in the second familiarisation (TD 95.5 ± 7.4 %, 
CON 105.5 ± 10.7 %; P=0.066).  This is the opposite response to the one 
which may have been expected given the hypothesis for the mechanism of 
action of the tryptophan depletion protocol, however, potential explanations 
for this finding are presented below. 
 
In a recent study, Van der Veen and colleagues (2008) found that acute 
tryptophan depletion, using a slightly smaller amino acid load to the one used 
in the present study, did not affect participants' mood levels or their 
performance in a response test designed by Miltner et al. (1997).  The test 
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negative feedback based on their ability to estimate a one second interval.  In 
the placebo trial, heart rate (continuously monitored by ECG) slowed when 
participants received negative feedback and this response was attenuated in 
the tryptophan depleted trial.  The acute tryptophan depletion did not have 
any effect on heart rate compared to the placebo when positive feedback was 
given.  This implies that phasic heart rate responses are sensitive to lowered 
serotonin and serotonin is known to play a critical role in the control of heart 
rate (Jordan, 2005).  When Ramage and Fozard (1987) administered a 5-
HT1A receptor agonist, they found that this evoked a vagally mediated fall in 
heart rate in anaesthetised cats.   
 
It is possible therefore, that the administration of an amino acid load designed 
to deplete the serotonin precursor tryptophan, may lead to a relative increase 
in heart rate.  Put another way, the increases seen in heart rate during normal 
exercise, such as in the CON trial, may be slightly attenuated due to the 
presence of serotonin in greater concentrations than on trials where this is 
reduced by some means, such as through acute tryptophan depletion.  This 
hypothesis is backed up by the trend throughout the TD trials in the present 
study for a higher heart rate than on the CON trials (P = 0.053).  It should also 
be considered that serotonin is known to have vaso-active properties (Yildiz et 
al., 1998) and therefore if a reduction in serotonin were to lead to vasodilation, 
heart rate could increase to maintain cardiac output. 
 
The trend for an elevated heart rate on the TD trials may have subsequently 
led to the trend (P = 0.069) seen for a slightly elevated core temperature 
throughout the TD trials.  The reduction in the time available for the diffusion 
of excess heat from the peripheral circulation to the skin, due to an increased 
heart rate, may have led to the trend for an elevated core temperature.  
However, the lack of any differences in skin temperature between the TD and 
CON trials means that this is unlikely to be the cause of the elevated core 
temperatures seen with tryptophan depletion. 
 
If acute tryptophan depletion did cause a reduction in serotonin activation, 
then this could have led to the tendency for rectal temperatures to be higher, 
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independent of the effect on heart rate.  This was seen when a 5-HT2C 
receptor antagonist (Pizotifen) was administered to healthy human 
participants, resulting in an elevated resting core temperature (Strachan et al., 
2005).  However, the opposite was seen in rats where, by elevating the levels 
of 5-HT in the hypothalamus, synaptic 5-HT2 receptors were activated, 
resulting in hyperthermic effects (Lin et al., 1998).  Of course, care must be 
taken in the interpretation of these results as the investigation was conducted 
in rats not humans and no exercise was involved  Furthermore, the 5-
hydroxytryptophan was directly perfused into the hypothalamus rather than 
tryptophan being ingested and transferred over the blood brain barrier for 
synthesis into 5-hydroxytryptophan. 
 
It is also possible that the tendency for a higher heart rate and core 
temperature on the TD trials may have actually lead to the tendency for 
exercise capacity to be impaired on the TD trials (99.2 ± 24.4 minutes) 
compared to the CON trials (108.4 ± 21.6 minutes; P = 0.088).  It is likely that 
any benefit which may have been seen due to the influences of the acute 
tryptophan depletion on serotonin production and metabolism are overridden 
by the trends for higher heart rates and core temperatures that acute 
tryptophan depletion appears to evoke.  It is possible that any positive effect 
of acute tryptophan depletion on exercise capacity may be clearer in more 
temperate environments. 
 
It is important to note that the core temperatures seen at the point of 
exhaustion in these trials (38.3 ± 0.3 °C on the TD trials and 38.2 ± 0.2 °C on 
the CON trials) are low in comparison to those reported in the wider literature 
on prolonged exercise in the heat.  As discussed in Chapter One, a critical 
core temperature of 39.7 °C has been proposed, above which exercise cannot 
be sustained (Nielsen et al., 1993).  Although there are several reports of 
exhaustion during prolonged exercise in the heat occurring at core 
temperatures lower that the ‘critical’ level, [38.8 ± 0.3 °C Cheung and 
McLellan, (1998); 39.1 ± 0.3 °C Sawka et al., (1992); 38.8 ± 0.1 °C Bridge et 
al., (2003A); 38.7 ± 0.9 °C Hobson et al., (2009); 38.9 ± 0.5 ° C Watson et al., 
(2004)], the temperatures reported here are still very low.  However, the pre-
110 
 
exercise resting core temperatures are consistent with early morning core 
temperatures reported in the literature (Hobson et al., 2009; Faria and 
Drummond, 1982) suggesting that the reason for this was not due to the 
instruments used or the methodology employed to measure core temperature.   
 
In humans, the response to tryptophan depletion in the cerebrospinal fluid is 
delayed, with peak depletion occurring seven to ten hours after consuming an 
amino acid load (Carpenter et al., 1998), compared to the maximum level of 
plasma tryptophan depletion, occurring five to seven hours post ingestion of 
an amino acid load (Delgardo et al., 1990).  Due to the timing of the present 
study, participants will have started exercise approximately six hours after 
consuming the amino acid load, which should have corresponded with the 
peak time for the depletion of plasma tryptophan.  Data shown in Figure 4.9A 
supports this.  For all participants the point of exhaustion will have been 
reached between seven and nine hours after consuming the amino acid load, 
which should have corresponded with the peak time of tryptophan depletion in 
the cerebrospinal fluid.   
 
Laboratory tests on humans have shown that tryptophan depletion specifically 
reduces cerebrospinal fluid concentration of both tryptophan (by 80 – 90 %; 
Carpenter et al. 1998) and the serotonin metabolite 5-HIAA (24 – 40 %; 
Williams et al., 1999).  In animal studies acute tryptophan depletion leads to 
extremely rapid changes in plasma tryptophan and brain serotonin content 
and also influences behaviour through increased pain sensitivity and 
aggression, and reduced rapid eye movement sleep (Bell et al., 2001).  
Therefore, if this translates into the human brain, the point of exhaustion 
should have coincided with the maximum level of tryptophan depletion in the 
cerebrospinal fluid, eliciting the highest chance of influencing the serotonergic 
system. 
 
Tryptophan supplementation (1.2 g over approximately fifteen hours) has 
previously been shown to improve treadmill running time to exhaustion in 
humans running at 80 %  ̇O2peak with a 5 % incline gradient, by, on average, 
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49 % (5 minutes 40 seconds on the placebo trial and 7 minutes 40 seconds 
on the supplementation trial; Segura and Ventura, 1988).  However, the 
equivocal improvements in two of the participants (5 minutes to 18 minutes 
(260 %) and 2 minutes 30 seconds to 6 minutes 30 seconds (160 %)), 
coupled with the very short duration of the exercise test, despite fairly low 
running speeds (11.8 ± 2.0 km / hour), and the use of apparently active males 
(VO2peak 53.9 ± 8.2 ml / kg / min), leaves the findings open to speculation 
(Segura and Ventura, 1988).   
 
Furthermore, the protocol employed by Segura and Ventura (1988) was later 
repeated but with the addition of two familiarisation trials preceding the 
experimental trials.  No difference in exercise capacity was seen between the 
tryptophan and the placebo trials (Stensrud et al., 1992).  Indeed, applying the 
Newsholme theory of central fatigue (1987), supplementing tryptophan would 
be expected to elicit a decrement in exercise capacity and this has been 
shown to be the case in horses (Farris et al., 1998) and rats (Soares et al., 
2004; Soares et al., 2007).  However, in a well-controlled study in humans, 
the consumption of a 6 % sucrose solution containing 3 g / L of tryptophan 
(average total intake 3.9 g) by endurance trained males failed to limit cycle 
exercise capacity at 70 – 75 % of maximum power, despite greater than six-
fold increases in plasma tryptophan concentrations (Van Hall et al., 1995). 
 
It can be seen that some of the participants may have started the exercise 
test slightly hypohydrated.  However, none of the individual participants’ urine 
osmolality’s were more than 55 mosmol / L different between trials and the 
500 ml of water they consumed before coming to the laboratory should have 
helped to minimise this. Therefore, it is unlikely that this will have influenced 
the results of the exercise capacity test.   
 
An increase in brain tryptophan uptake during prolonged exercise is 
suggested to contribute to an elevation in central serotonin activity 
(Blomstrand et al., 1989).  This increase in serotonergic activity increases the 
perception of effort during exercise and therefore hastens the onset of fatigue 
(Blomstrand et al., 1997).  However, in this study acute tryptophan depletion 
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did not cause a concurrent lowering of perceived exertion ratings during the 
exercise, as the RPE values seen were not different between trials (P = 
0.195) and if anything actually tended to be higher on the TD trial towards the 
point of fatigue (RPE at 70 minutes 18 ± 2 for TD and 16 ± 1 for CON).  
However, it may be possible to explain this as there was a tendency for a 
shorter exercise duration on the TD trials, meaning that participants were 
nearer the point of exhaustion after seventy minutes of the TD trial than at the 
same time point on the CON trial. 
 
Tryptophan depletion has been shown to increase aggression in animals (Bell 
et al., 2001) and in humans (Bjork et al., 1999).  Bjork and colleagues (1999) 
conducted an experiment in which money was taken from participants who 
were either tryptophan depleted or food restricted as a control.  Participants’ 
aggression levels were monitored by recording the number of retaliatory 
responses the participants made ostensibly to reduce the earnings of other, 
fictitious, participants.  Based on these findings, improvements in exercise 
capacity with acute tryptophan depletion may be more likely to be seen in 
directly competitive environments, where aggression is likely to play an 
influential role in overall performance, compared to a solitary lab based 
exercise time to exhaustion test as used here.   
 
A tryptophan depletion study, conducted to look at the effects on executive 
function, showed an improvement on only one (Trail-Making Test) of four (The 
Wisconsin card sorting test; Verbal fluency; Stroop colour-word test) 
neurocognitive tests, when participants were acutely tryptophan depleted in 
the same way as in the present experiment (Gallagher et al., 2003).  
However, since there was a learning effect on the tests and participants had 
not been familiarised with them, the true effects of tryptophan depletion on 
cognitive function cannot be seen.  Gallagher and colleagues (2003) also 
found that the acute tryptophan depletion had no effect on subjective ratings 
of mood when measured on a battery of 16 visual analogue scales.  However, 
women appear to be more susceptible to the mood lowering effects of 
tryptophan depletion compared to men, even when plasma tryptophan 
concentration is depleted to the same extent (Booij et al., 2005).  Therefore, 
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gender differences may exist in serotonin metabolism meaning that acute 
tryptophan depletion, which causes no negative effects in males, does 
produce mood lowering in females (Nishizawa et al., 1997).  
 
4.6 Conclusion 
There was no difference in exercise capacity when participants received a 
control amino acid load compared to a load designed to acutely deplete 
plasma tryptophan concentrations.  Therefore, it seems likely that central 
fatigue is influenced by another factor, or, more likely, several other factors.  
The availability of tryptophan as a precursor to serotonin production is not the 
sole reason for fatigue during prolonged exercise in a warm environment.  
However, there seems little doubt that the neurotransmitter serotonin does 
have a role to play in the development of central fatigue.  Therefore, the 
following chapter will investigate the transport of serotonin, rather than the 
synthesis of serotonin. 
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CHAPTER FIVE 
 
Differences in platelet serotonin transporter 
density in former and current sprint and 
distance runners, and sedentary controls. 
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5.1 Abstract 
 
Serotonin is thought to be of importance in the development of fatigue.  
Transporters remove serotonin from the synaptic cleft, actively lowering the 
concentration to a point at which maintaining the activation in the post-
synaptic receptors becomes impossible.  A reduction in the concentration of 
serotonin could be achieved by an increased number of serotonin 
transporters.  Unfortunately, it is not possible to study the serotonergic 
neurons directly, but they share many similarities with blood platelets which 
represent a simple and accessible peripheral model.  Therefore, the aim of 
this study was to investigate serotonin transporter density on the platelets of 
current and former athletes in sprint and endurance disciplines to discover if 
this is a state or a trait marker. 
 
Thirty three healthy males [6 current international endurance runners (CE), 6 
retired international endurance runners (RE), 9 current international sprinters 
(CS), 6 retired international sprinters (RS), and 6 sedentary controls (I)] all 
provided a resting 40 ml venous blood sample.  From the blood samples the 
platelets were isolated, washed and the membranes were prepared.  They 
were then incubated in eight different concentrations of [3H]Paroxetine (10 – 
500 pM) and specific binding was determined using Citalopram (1 µM).  
Membrane-bound radioactivity was analysed by liquid scintillation counting. 
 
The maximum number of binding sites was significantly greater in the CE 
group (1090 ± 76 fmol / mg protein) than in any of the other groups (P ≤ 
0.008).  The maximum number of binding sites (Bmax) for the CS group (953 
± 68 fmol / mg protein) was also greater than that of the RS group (P = 0.042).  
There were no differences between the RE, RS and I groups for Bmax (892 ± 
88, 866 ± 58, 885 ± 58 fmol / mg protein respectively).  The data show that 
the CE group have a greater number of serotonin transporters on their platelet 
membranes.  This suggests that training, particularly for endurance events, 
may increase the number of serotonin transporters on the serotonergic 
neuron of the brain, aiding serotonin reuptake, and possibly altering the 
perception of fatigue. 
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5.2 Introduction 
The brain appears to play a significant role in the development of fatigue 
during prolonged exercise.  Specifically, the neurotransmitter serotonin is 
thought to be of importance in the development of fatigue as it has been 
shown to be responsible for, among other things, feelings of lethargy (Cooper 
et al., 2003A).  Chapters Three and Four, coupled with the wider literature, 
suggest that reducing the synthesis of serotonin through the minimising the 
amount of tryptophan crossing the blood brain barrier does not influence 
exercise capacity.  Unfortunately, the direct examination of the central 
serotonergic neurons is obviously restricted in humans.  However, the blood 
platelets share several commonalities with the serotonergic neuron, the site of 
serotonin synthesis within the brain (Da Prada et al., 1988).  Therefore, it is 
possible to use the blood platelet as a simple, accessible peripheral model for 
the examination of the serotonergic neuron to further investigate the 
development of fatigue within individuals.  
 
Platelets have sub-cellular organelles that contain ATP and they actively store 
serotonin and other biological monoamines in preparation for their release by 
exocytosis.  There are similarities between platelets and the serotonergic 
neurones; they are both active transporters of serotonin and they are both 
active storage vesicles for serotonin.  In addition, both contain monoamine 
oxidase B and both also have 5-HT2 receptors (Da Prada et al., 1988).  
Although there are many similarities between the blood platelets and the 
serotonergic neuron which can be exploited in further study of the central 
nervous system, there are also several differences.  Platelets do not contain 
monoamine oxidase A and they also lack tyrosine hydroxylase, meaning that 
they are unable to synthesise serotonin.  Platelets are also anucleate and 
therefore have no capacity for protein synthesis (Pletscher, 1988). 
 
The half-life of a blood platelet is approximately five days, meaning that the 
entire original population is eliminated from the circulation within 
approximately three weeks.  This implies that the chronic action of 
antidepressant drugs is that they act on the platelet synthesising cells 
(megakaryocytes), rather than the platelet receptors themselves (Lawrence, 
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1991).  Blood platelets vary in size and in age; younger platelets are larger 
and more dense and metabolically active, but the functional properties of the 
platelets are believed to be independent of size and density (Thompson et al., 
1983).  Acute exercise increases blood platelet counts by the alpha-
adrenergic stimulation of the spleen.  The spleen contains approximately ⅓ of 
the exchangeable platelet population (Chamberlain et al., 1990), and the age 
of these platelets is similar to that of the population circulating in the blood 
stream (Chamberlain et al., 1990). 
 
Serotonin transporters on the serotonergic pre-synaptic neuron remove 
serotonin from the synaptic cleft in order to rapidly terminate synaptic 
transmissions (Rudnick and Clark, 1993).  The serotonin transporter removes 
the serotonin and therefore actively lowers the synaptic serotonin 
concentration levels to the point at which it becomes incapable of maintaining 
the activation in the post-synaptic receptors.  A reduction in the concentration 
of serotonin could be achieved by an increased number of serotonin 
transporters, an increase in their activity levels, or a combination of these two 
factors.  During exercise, if there is an increased activity level of the central 
serotonergic system, a reduction in the concentration of serotonin could delay 
or stop synaptic transmissions and therefore alter the perception of fatigue.  
Wilson and Maughan (1992) indirectly supported this theory by demonstrating 
that a serotonin reuptake inhibitor reduced prolonged exercise capacity.  
 
There is previous research in healthy athletic populations investigating platelet 
serotonin transporter density (Strachan and Maughan, 1998).  The 
investigators showed that the density of the serotonin reuptake transporter is 
greater on the platelet membranes of endurance trained participants than in 
sedentary controls.  However, Struder et al., (1999) found that acute 
endurance exercise reduced the density of platelet 5-HT2A receptor 
[3H]Ketanserin binding sites.   
 
Due to the nature of investigations into the actions of the serotonergic neuron, 
the changes that may occur within the brain can only be hypothesised 
because all measures must be made peripherally.  One of the few ways of 
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directly assessing the brain is by using cadavers.  Lawrence et al. (1997) 
looked at [3H]Paroxetine binding in ten brain regions in thirteen clinically 
depressed suicide victims who were being prescribed antidepressants and 
compared this to ‘healthy’ control cadavers.  They found no difference in nine 
brain regions, and a lower number of binding sites in the putamen of the 
suicide victims.  This corresponds well to previous research by the same 
group suggesting that there is no difference in the Bmax values, assessed 
using platelet membranes, of depressed and control participants (Lawrence et 
al., 1993). 
 
The non-tricyclic selective serotonin reuptake inhibitors (including Paroxetine 
and Citalopram) are over a thousand times more selective for serotonin-
uptake inhibition than noradrenalin-uptake inhibition (Magnussen et al., 1982).  
The binding proteins for the tritiated forms of Paroxetine and Citalopram have 
the same molecular weight (Plenge et al., 1990), making them suitable for use 
when investigating binding to serotonin transporters. 
 
The serotonin transporters in humans are encoded by a single gene on the 
chromosome 17q11.2, and are expressed in both brain and blood platelet 
cells.  Genetic differences have been identified within healthy human 
participants for the expression and function of serotonin transporters in 
platelets.  The insertion point of the serotonin transporter regions can be in 
either the long (l) or short (s) forms, and this will affect transporter expression 
and function.  Greenberg et al. (1999) found that the long form allele was 
associated with a rapid initial rate of platelet serotonin uptake (Vmax).  This is 
the inheritable index of platelet serotonin transporter function.  They also 
found that the short form of the allele was dominant.  Genotype had no effect 
on platelet [3H]Paroxetine binding (Bmax).  
 
Therefore, the aim of this chapter was to look for differences in platelet 
serotonin transporter density in former and current sprint and distance 
runners, and sedentary controls in order to discover if this is a state or a trait 
marker. Within the same running discipline (endurance or sprint), current 
athletes were compared to retired athletes to investigate whether notable 
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differences occur due to training.  Comparing endurance and sprint running 
athletes allowed adaptations to specific types of training to be investigated.  A 
sedentary control group provided a baseline ‘norm’ for comparison. 
 
5.3 Methods 
5.3.1 Participants 
Thirty three healthy males were recruited to take part in this experiment.  They 
were split into five experimental groups; current international level endurance 
(5 kilometres to marathon) runners (CE, n = 6), retired international level 
endurance runners (RE, n = 6), current international level sprint (60 meters to 
400 meters) runners (CS, n = 9), retired international level sprint runners (RS, 
n = 6), and sedentary controls (I, n = 6).  Details of the competitive levels of 
the participants are presented below in Table 5.1.  Participant anthropometric 
information is presented in Table 5.2.  
 
Table 5.1.  Event and personal best time of athlete participants. 
 
CE RE CS RS 
Event P.B. Event P.B. Event P.B. Event P.B. 
Marathon 2:14:30 Marathon 2:10:12 100m 10.18 100m 10.17 
Half 1:09:00 Marathon 2:10:48 100m 10.28 200m 20.31 
Half 1:06:45 Half 1:05:31 100m 10.51 200m 21.32 
10 mile 51:30 10 mile 49:46 100m H 13.53 200m 22.6 
5,000m 13:25 5,000m 13:00 200m 20.87 400m 45.22 
1,500m 3:45 5,000m 13:40 400m 45.84 400m H 52.5 
    400m 46.21   
    400m H 50.2   
    400m H 50.4   
 
After giving signed informed consent, participants filled out a health screen 
questionnaire.  Exclusion criteria for the study were any known 
haematological or metabolic disorders, or the consumption of any depression 
medication.  Participants were then asked to complete a questionnaire on 
basic information which included details such as age, height and body mass 
120 
 
and also their sporting event, their current (and past for retired participants) 
training activities, highest sporting achievements and the number of years of 
training for top level competition.  Due to restrictions in the availability for 
sampling of the elite athlete participants recruited to the study, diet and 
activity prior to the blood sample were not standardised. 
 
5.3.2 Sample preparation 
Whilst participants were seated, a single blood sample (40 ml) was taken from 
the antecubital vein (see Chapter Two for details).  The blood sample was 
immediately mixed with 4 ml of the anticoagulant acid-citrate-dextrose.  The 
mean platelet volume and the platelet count were determined using a 
haematology analyser as discussed in Chapter Two (Ac.T 5diff, Beckman 
Coulter. High Wycombe, UK). 
 
Platelets and platelet-rich plasma (PRP) were isolated by centrifugation using 
a modified version of the original method for platelet isolation by Healy et al. 
(1990).  Briefly, the blood samples were left overnight to separate and they 
were then gently centrifuged for ten minutes at 100 g.  The platelet-rich 
plasma was removed and 500 µl was retained for the analysis of amino acid 
content in the plasma.  The remaining platelet-rich plasma was then 
centrifuged at 2,500 g for fifteen minutes.  Of the platelet-poor plasma (PPP) 
produced, 500 µl was retained for the analysis of amino acid content and a 
further 500 µl was centrifuged in an ultraflitrate tube (Whatman International 
Ltd, Kent, UK)  for two hours at 400 g for the analysis of free tryptophan.  The 
ultrafiltrate and the aliquots of plasma were all stored at -80 °C until analysis 
using HPLC, as detailed in Chapter Two. 
 
The remaining platelet-poor plasma was removed, leaving a pellet of platelets.    
Very gently, a 3 ml volume of ice cold saline was added to wash the pellet.   
This was then removed and the wash step repeated once more before the 
pellet was flash frozen in liquid nitrogen and stored at -80 °C until the day of 
the assay.  The freezing and subsequent thawing of membranes has been 
shown to have no effect on the Bmax values seen for [3H]Imipramine binding 
compared to the results obtained when the assay is performed when the 
121 
 
membranes are fresh, suggesting no detrimental effect of freezing on the 
binding sites (Lawrence, 1991). 
 
On the day of the assay the platelet pellet was allowed to defrost before 5 ml 
of ice cold wash buffer (50 mM Tris-HCl, 110 mM NaCl and 20 mM EDTA, pH 
6.4) was added.  This was then left on ice for five minutes before being 
homogenised (6 strokes at 800 rpm), then centrifuged at 18,400 g for ten 
minutes at 4 °C.  The supernatant was then discarded and the wash process 
repeated.  After this the platelets were re-suspended in 5 ml of ice cold lysing 
buffer (5 mM Tris-HCl, 5 mM EDTA, pH 7.4) and homogenised (12 strokes at 
1,200 rpm).  They were then left on ice for twenty minutes before being 
centrifuged at 42,000 g for ten minutes at 4 °C.  All supernatant was 
discarded and the membranes were re-suspended in 5 ml of ice cold 
incubation buffer (50 mM Tris-HCl, 120 mM NaCl and 5 mM KCl, pH 7.5). 
They were then centrifuged at 42,000 g for ten minutes at 4 °C.  All the 
supernatant was discarded and the membranes were re-suspended in 500 µl 
of ice cold incubation buffer.  Of this, 100 µl was retained and stored at -80 °C 
for the analysis of the protein content of the sample (Pierce BCA protein 
assay kit, Pierce Biotechnology, Rockford, IL, USA; for details see Chapter 
Two). 
 
5.3.3 Sample analysis 
The assay performed was based on the original method established by 
Lawrence and colleagues (1993).  The membranes were added to glass tubes 
(30 – 48 µg protein / tube) containing incubation buffer and eight 
concentrations (10 – 500 pM) of [3H]Paroxetine (specific activity 22.9 Ci / 
mmol, PerkinElmer, Cambridge, UK) at a total volume of 2 ml per tube.  The 
assay was incubated in a water bath at 23 °C for ninety minutes.  Specific 
binding was defined as the radioactivity displaceable by an excess (1 µM) of a 
competitor drug (Citalopram hydrobromide, Tocris Bioscience. Bristol, UK). 
 
The incubation period was stopped with the addition of 5 ml of ice cold 
incubation buffer.  Membrane bound radioactivity was recovered by filtration 
under pressure (Brandel cell harvester, Alpha Biotech Ltd. London, UK) 
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through Whatman glass-fibre filters (Whatman International Ltd, Kent, UK). 
Filters were then washed with a further 15 ml of ice cold incubation buffer. 
Radioactivity was determined by standard liquid scintillation spectroscopy 
using 6 ml of scintillation cocktail (Gold Star multi-purpose liquid scintillation 
cocktail, Meridian, Surrey, UK) on a scintillation counter (LKB Wallac1219 
scintillation counter, Turku, Finland) with a counting efficiency of 42 – 47 %. 
 
5.3.4 Data analysis 
Specific binding was determined from the measured values of non-specific 
binding subtracted from the total binding.  The maximum number of binding 
sites (Bmax; fmol / mg protein) and the equilibrium dissociation constant (Kd; 
pM) were determined by non-linear regression analysis fitting to a one site 
binding model using GraphPad (Prism. San Diego, USA).  
 
5.3.5 Statistical analysis 
All analysis was performed on SPSS version 17.0 and statistical significance 
was set at P < 0.05.  All data sets were investigated for normality of 
distribution using the Shapiro-Wilk test and for skewness and kurtosis.  A one-
way independent ANOVA was then used to investigate differences between 
groups for all of the measured parameters with the exception of Kd, for which 
the data was found to be non-parametric and therefore was analysed using a 
Kruskal-Wallis test.  Where appropriate, Bonferroni post hoc tests were 
performed to compare the data between groups.  For the correlation between 
age and Bmax a one-tailed Spearman’s correlation coefficient was performed 
as the data were non-parametric. All data is presented as the mean ± 
standard deviation, unless otherwise stated. 
 
5.4 Results 
Within the five experimental groups there were differences in age (P = 0.005), 
body mass (P = 0.002) and BMI (P = 0.027) as shown in Table 5.2.  As 
expected, current athletes (CE and CS) were younger than the retired athletes 
(RE and RS).  The current endurance athletes (CE) were also significantly 
lighter than the current sprint athletes (CS) or the retired sprint athletes (RS).  
The height of the participants was not significantly different between groups, 
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although there was a tendency for sprinters (CS and RS) to be taller 
(P=0.060).  
 
Table 5.2.  Participant Information.  * symbolises a difference between the current and retired 
groups within the same distance discipline (P ≤ 0.005).  
+
 symbolises a difference between 
the retired and current groups in opposite distance disciplines (P ≤ 0.039).  ^ symbolises a 
difference between the distance disciplines within the current groups (P = 0.033). 
 
Group Age  
(y) 
Height  
(m) 
Body Mass 
(kg) 
BMI  
(kg / m2) 
CE (n = 6) 26 ± 4* 1.78 ± 0.04 63.8 ± 3.9 20.1 ± 0.8 
RE (n = 6) 52 ± 11+ 1.77 ± 0.08 74.0 ± 10.6 23.8 ± 4.5 
CS (n = 9) 24 ± 4* 1.86 ± 0.06 75.0 ± 7.2^ 22.3 ± 1.7 
RS (n = 6) 45 ± 13+ 1.84 ± 0.05 83.8 ± 5.7+ 24.8 ± 1.6+ 
I (n = 6) 38 ± 16 1.78 ± 0.06 76.9 ± 11.2 24.3 ± 3.3 
 
Figure 5.1 shows a scatter graph of the individual Bmax values for 
participants in each group.  The maximum number of binding sites was 
significantly greater in the CE group than in any of the other groups (P ≤ 
0.008).  The Bmax for the CS group was also greater than that of the RS 
group (P = 0.042).  There were no differences between the RE, RS and I 
groups.  Table 5.3 also shows the mean values of Bmax for each group.  
Figure 5.2 demonstrates an example of saturation binding and the use of total 
binding and non-specific binding to calculate specific binding values. The 
equilibrium dissociation constant (Kd) data was not normally distributed in the 
CE, CS or RS groups. There were no differences in the Kd values between 
any of the groups (P = 0.182; Table 5.3).  
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Figure 5.1.  Maximum number of binding sites (fmol / mg protein) for each individual in each 
group, and the mean of each group. 
 
 
Table 5.3.  Average maximum binding capacity and average equilibrium dissociation constant 
for each group. 
 
 CE RE CS RS I TOTAL 
Bmax  
fmol / mg protein 
Mean ± SD  
1090  
± 76 
892  
± 88 
953  
± 68 
866  
± 58 
885  
± 58 
936  
± 104 
Kd  
pM  
Median (range)  
63 
(50–66) 
62 
(43–70) 
61 
(45–70) 
73 
(58–74) 
55 
(47–76) 
62 
(43–76) 
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Figure 5.2.  An example of the saturation binding of [
3
H]Paroxetine to platelet membranes in 
one participant (CE).  
 
There were no differences in the platelet count or in the mean platelet volume 
between any of the groups.  The analysis of the platelet-rich plasma amino 
acid concentration showed that the only difference between the groups was in 
the concentration of phenylalanine present.  The concentration found in I (201 
± 35 µmol / L) was significantly greater than that found in either CE (108 ± 2 
µmol / L; P = 0.031), RE (107 ± 13 µmol / L; P = 0.029) or RS (107 ± 36 µmol 
/ L; P = 0.029), but was not different from the concentration in CS (151 ± 84 
µmol / L).   
 
There were no differences between any of the groups for the concentrations 
of the measured amino acids in the platelet-poor plasma.  Furthermore, there 
were no differences between any of the groups for total branched-chain amino 
acid concentration in either the platelet-rich or the platelet-poor plasma (Table 
5.4).  The ratio of free tryptophan to branched-chain amino acids analysed 
using platelet-poor plasma was also not different between groups (Figure 5.3). 
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Table 5.4.  Branched-chain amino acid concentration in platelet-rich and platelet-poor plasma. 
There were no differences between any of the groups. 
 
 CE RE CS RS I 
PRP [BCAA] 
 (µmol / L) 
Mean ± SD 
431.9  
± 69.4 
443.2  
± 74.1 
496.9  
± 103.6 
464.1  
± 73.6 
480.8  
± 90.4 
PPP [BCAA] 
(µmol / L) 
Mean ± SD 
460.0  
± 63.0 
481.6  
± 73.3 
510.4  
± 109.3 
468.1  
± 59.4 
455.0  
± 50.8 
 
 
 
Figure 5.3.  The ratio of free tryptophan to branched-chain amino acids in platelet-poor 
plasma. There were no differences between any of the groups. 
 
5.5 Discussion 
The main finding of this investigation was that those who follow an elite level 
endurance training program, have a greater number of serotonin transporters 
on their platelet membranes compared to those who used to train to a similar 
standard in a similar discipline, or in fact, those who have never done any 
previous training.  The influence of endurance activity on the number of 
binding sites for serotonin is further supported by closer analysis of the data 
within the RE group.  Two of the six retired runners recruited to this study still 
completed thirty to fifty minutes of endurance running every day and the Bmax 
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value for these individuals were greater than the group average.  In Figure 5.1 
they are the two individuals in the RE group with Bmax values of 
approximately 1000 fmol / mg protein compared to the group average of 892 ± 
88 fmol / mg protein.   
 
The current activity levels of the RE group as a whole were greater than those 
of the RS group.  In the RS group, the participants were involved in infrequent 
recreational activity, whereas in the RE group all participants except one 
reported that they were recreationally active at least four times per week.  
Indeed the Bmax value for the RE group was higher, and the data are more 
widely distributed than in the RS group, although this was not a statistically 
significant difference.  Despite the differences in current activity levels 
between the retired groups, it would appear that being merely recreationally 
active is not sufficient to generate adaptations in platelet serotonin transporter 
density. 
 
Regulatory and adaptive mechanisms of controlling serotonin transportation 
remain largely undefined.  It is also yet to be determined whether platelet 
serotonin transporter density is a state or a trait marker.  A state marker was 
proposed by Rieder (1978) to be an aspect which can adapt under the 
influence of one or more factors.  A trait marker is therefore an aspect which 
is fixed and cannot be influenced by other factors.  Early studies into platelet 
binding and depression found that maximal [3H]Imipramine binding was 
significantly lower in those suffering (without treatment) from depression, 
compared to non-depressed controls (Briley et al., 1980).  This led to 
questions as to whether this lowered binding capacity was a state marker as a 
result of the depression, or a permanent phenomenon which may predispose 
certain individuals to suffering from depression, i.e. a trait marker.  However, 
Lawrence et al. (1993) subsequently found that there was no difference in the 
number of platelet serotonin binding sites in depressed patients compared to 
healthy controls.  The same group also found that the administration of 
antidepressant drugs, whilst altering clinical responses to treatments, did not 
alter the platelet binding parameters (Lawrence et al., 1994).   
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Both of these studies suggest that platelet serotonin transporter density is a 
trait marker and that psychological state does not influence this parameter.  
However, contrary to this, Biegon and colleagues (1990) found that as 
patients recovered from depression (using the antidepressant drug 
Maprotiline) their serotonin receptor binding capacity (assessed using 
[3H]Ketanserin) fell, compared to their pre-treatment values, suggesting that 
serotonin binding may be a state marker.  Unfortunately, it is difficult to 
compare data between studies and determine whether platelet serotonin 
transporter density is a state or a trait marker due to the large variability in 
results from controls and drug-free depressed patients.  
 
The drug used to determine binding is critical in ensuring that it displaces the 
radio-labelled drug from the specific binding sites but not from the non-specific 
sites.  Imipramine has been shown to bind to two classes of sites on the 
human platelet membrane (Ieni et al., 1984), one related to serotonin uptake 
and one unrelated to serotonin uptake.  DMI displaces the [3H]Imipramine 
from both sites, meaning that it generates inaccurate binding data.  Indeed, 
Lawrence and colleagues (1993) showed that both [3H]Paroxetine binding 
defined with Citalopram and [3H]Imipramine binding defined with sodium 
dependence were 20 – 30 % lower than DMI defined [3H]Imipramine binding 
in blood platelets.  This suggests that DMI defined [3H]Imipramine binding 
may not be a suitably specific test of serotonin transporter density, and 
therefore calls into question findings using this technique to assess serotonin 
transporter density.  Indeed, the single binding site models for Bmax data has 
been shown in both animal (Marcusson and Eriksson, 1988) and human 
(Marcusson et al., 1989) brain tissue to be the most appropriate method of 
data analysis for [3H]Paroxetine binding and this model was therefore used in 
the present study. 
 
Strachan (1996) suggested that his findings of elevated levels of serotonin 
transporters in platelets of endurance trained athletes compared to sedentary 
controls may represent further support for serotonin transporter density being 
a trait marker rather than a state marker.  He states that the difference in 
serotonin transporter density between his population of endurance athletes 
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and sedentary controls may produce different chemical responses in the brain 
to exercise, possibly explaining why some individuals choose to exercise 
regularly, while others choose not to do so.  
 
The data presented here would support the concept of serotonin transporter 
density being a state marker rather than a trait marker.  The greater Bmax 
values of those who are currently international level endurance athletes 
compared to those who have always been sedentary suggests that serotonin 
transporter density is a parameter which increases in response to training.  
However, the lack of any differences in Bmax values between participants 
who used to be international level endurance athletes and participants who 
have always been sedentary suggests that the adaptations gained through 
elite level endurance training are lost once training has stopped.  
 
The Kd values reported in this study (median of 62 pM (range: 43 – 76 pM) 
are slightly higher than those seen in the publications by Lawrence et al. 
(1993) who reported values of 34 ± 19 pM, Lawrence et al. (1994) who 
reported values of 45 ± 13 pM and Strachan and Maughan (1998) who 
reported values of 56 ± 28, all of which use the same technique as employed 
here.  Increased Kd is associated with sub-optimal assay conditions such as 
the incubation temperature and duration (Bylund and Toews, 1993).  
However, the equilibrium dissociation constant values in the present study are 
by no means high enough to suggest that there were problems with the assay 
technique.  
 
The Bmax values reported in this study are also slightly lower than those 
reported in the other literature employing the same techniques (936 ± 104 
fmol / mg protein).  Lawrence and colleagues found an average Bmax of 972 
± 246 fmol / mg protein and 1124 ± 286 fmol / mg protein (Lawrence et al., 
1993; Lawrence et al., 1994) studying depressed patients and controls, while 
Strachan and Maughan (1998) found an average Bmax value of 1092 ± 232 
fmol / mg protein in endurance athletes and sedentary controls.  Further 
examination of the data presented by Strachan and Maughan (1998) shows 
that the endurance trained individuals had an average Bmax of 1237 ± 182 
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fmol / mg protein and the sedentary controls had an average Bmax of 910 ± 
119 fmol / mg protein.  The current elite endurance trained participants in this 
study had a lower average Bmax value (1090 ± 76 fmol / mg protein), and the 
sedentary controls in this study also had a lower Bmax average (885 ± 45 
fmol / mg protein) than those in the Strachan and Maughan (1998) study.  
 
Platelets consist of approximately 60 % membrane protein and 40 % 
cytoplasmic protein (Barber and Jamieson, 1970).  The results of the binding 
assay are expressed on the basis of membranous protein.  Therefore, if 
during the preparatory stages of the assay there are some platelets left intact, 
which it has been suggested can occur (Friedl et al., 1983), the amount of 
protein present in the samples will be artificially elevated.  This would result in 
a lower level of binding when expressed relative to the protein present in the 
assay and it is impossible to say whether this is one of the reasons for the 
lower binding values seen in this study.  It is interesting to note, however, that 
the variance of the data in this study is much smaller than in either of the 
papers by Lawrence and colleagues (1993; 1994) or that by Strachan and 
Maughan (1998).  It is likely that this could be attributed to the relatively 
homogeneous population recruited to the present study.  
 
The sedentary group (I) was included to act as a control group since before 
recruitment began it was expected that there would be a broad range of age 
and body mass between the athlete and retired athlete participants.  The ages 
in the athlete groups spanned from 20 years to 69 years and the ages in the 
sedentary group spanned from 22 years to 61 years.  [3H]Imipramine binding 
in human platelet membranes has been shown to decrease with age (Langer 
et al., 1980).  Indeed, there was a significant correlation between age and 
Bmax values (P = 0.028, r = -0.458) in the participants, and therefore a large 
span of ages in the control group was essential.   
 
The mass of the participants in the athlete groups spanned from 57 kg to 95 
kg while in the sedentary group the mass spanned from 63 kg to 89 kg.  The 
broad spectrum of values and the lack of differences between I and any of the 
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other groups for any parameters shows that this group provide a suitable 
control and comparison for the athlete groups. 
 
In the present study there was no difference between groups in the number of 
platelets or the mean volume of the platelets in the samples.  Blood platelets 
have been shown to vary depending upon their size and their age; younger 
platelets are generally larger, denser and more metabolically active (Corash 
et al., 1977), although the relationship between age and size has since been 
called into question (Thompson et al., 1983).  Exercise has been shown to 
increase the platelet count by stimulating release of platelets from the store in 
the spleen, although the platelets released are believed to have similar 
properties to those in the circulation (Chamberlain et al., 1990).  Either way, in 
the current study there were no differences in the mean platelet volumes 
between groups and therefore this is unlikely to be a confounding factor in the 
Bmax data reported here.  
 
All the participants in this study were Caucasian, with the exception of three 
participants in the CS group.  If these participants are removed from the 
analysis there is a negligible change in the mean Bmax of the group (953 ± 68 
fmol / mg protein (n=9) and 958 ± 53 fmol / mg protein (n=6)).  Therefore, 
based on this small sample it would seem that ethnicity does not influence the 
maximum number of serotonin binding sites found on the blood platelet 
membrane.  As far as the author is aware there is no other research available 
on this aspect of serotonin transport and therefore further investigation would 
be required to confirm this. 
 
Due to a severely limited number of opportunities to collect samples from the 
elite athletes recruited to this study, it was impossible to take their blood 
samples with any standardisation.  Samples were taken between 1000 and 
2000 hours in the months of January, February or March. Exercise and diet 
were also not standardised prior to sampling.  It has been suggested that in 
control participants and depressed patients, the binding of [3H]Paroxetine is 
significantly increased in the Spring months (March 21st – June 20th) than in 
the Summer, Autumn or Winter months (D’Hondt et al., 1994).  All of the 
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samples in the present study were taken during the Winter months and 
therefore it can be assumed that seasonal effects are not the cause of the 
differences seen in binding data. 
 
Several of the athlete participants recruited to this study were sampled after 
training or racing.  Prior strenuous exercise has been shown to result in 
platelet activation and hyperreactivity in sedentary individuals, but this finding 
is not reflected in physically active participants (Kestin et al., 1993).  Whether 
such heightened activation and reactivity would influence the binding of 
[3H]Paroxetine to the platelet membrane remains to be seen.  However, none 
of the sedentary participants, by their very nature, had taken part in any 
physical exercise prior to the sampling process and therefore this is unlikely to 
be a confounding factor in the present study. 
 
Although the plasma amino acid concentrations showed no differences 
between groups for any of the amino acids analysed other than 
phenylalanine, this is possibly not a true reflection of the resting situation in 
these participants.  Strachan and Maughan (1998) found that, at rest after an 
overnight fast, the plasma concentrations of tyrosine and tryptophan were 
lower in their endurance trained participants than in their sedentary 
participants.  They hypothesised that these differences may be due to 
exercise induced increases in peripheral utilisation and metabolism of these 
amino acids (Chaouloff, et al., 1985).  The lack of a dietary standardisation 
prior to sampling in the current study means that it is impossible to determine 
if true resting differences do indeed exist between the groups of participants 
tested here.  
 
A possible avenue for future research would be to attempt to elucidate the 
role of Vmax, the maximum rate of binding, within the blood platelet.  As 
suggested before, a reduction in the concentration of serotonin in the synapse 
could be achieved by either an increased number of serotonin transporters, 
an increase in their activity levels, or a combination of these two factors.  This 
study has investigated the role of the number of transporters present and 
therefore a logical progression would be to examine the activity levels of those 
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transporters.  An alternative route for future investigations would be to 
conduct a training study with the aim of elucidating the time course for 
increasing serotonin transporter density. 
 
5.6 Conclusion 
In conclusion, this study shows that those who are currently participating in an 
elite level endurance running training regimen have a greater number of 
serotonin transporter sites on the membranes of their blood platelets 
compared to those who have retired from elite endurance running 
competition.  Current endurance athletes also have a greater number of 
serotonin transporters than those training for elite level sprint running events, 
those who used to train for elite level sprint running events and those who 
have never trained for any such activity.  Athletes participating in elite level 
sprint running also have a greater number of serotonin binding sites on the 
membranes of their blood platelets than those who have retired from such 
training and competition. 
 
Blood platelets have been shown to be a suitable peripheral model for the 
serotonergic neurones in the brain.  Therefore, the data presented here 
suggest that training, particularly for endurance events, may increase the 
number of serotonin transporters on the serotonergic neuron of the brain, 
aiding serotonin reuptake, and possibly altering the perception of fatigue. 
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CHAPTER SIX 
 
Responses to the application of 1 % menthol 
solution to the skin at rest in a warm 
environment. 
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6.1 Abstract 
 
Menthol is a compound that activates cutaneous cold receptors without 
actually cooling the skin.  The physiological and psychophysical effects of 
applying menthol to the skin while resting in a warm environment have not 
been investigated.  Therefore, the aim of this investigation was to determine 
the response to the application of menthol while at rest in a warm 
environment.  
 
Twenty four healthy male participants sat for thirty minutes in 32.5 ± 0.2 °C 
and 66 ± 3% relative humidity before patches soaked in a 1 % menthol 
solution (Menthol) of a control solution (Control) were applied to the back, 
forearms and forehead. They then remained seated for a further eighty 
minutes.  During the trials, core, skin and arm temperatures, heart rate, 
perceived local (forearm) and overall thermal sensation, together with overall 
thermal comfort ratings, were taken every five minutes and skin blood flow 
was measured every ten minutes.  
 
Thirteen participants perceived the Menthol patches to have a cooling effect, 
eight participants perceived a warming effect and three participants perceived 
no effect.  Applying either the Menthol or the Control solution had no effect on 
arm temperature (P = 0.133), and there was no difference in the arm 
temperature between those who felt a warming effect and those who felt a 
cooling effect (P = 0.267).  No differences were found between the two 
treatments or sensation groups for any of the physiological parameters 
measured.  For local and overall thermal sensation and overall thermal 
comfort, there were no differences between the two treatments, although 
there were differences for these parameters between the sensation groups (P 
≤ 0.004). These data suggest that while skin temperature receptors were 
activated by the application of menthol to the skin, no physiological changes 
occurred. 
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6.2 Introduction 
Menthol is a plant extract that is widely used for many medicinal and cosmetic 
purposes due to the cooling sensation it elicits when applied to the skin or 
mucous membrane.  Cool sensations can be caused by either the stimulation 
of cold receptors or the inhibition of warm receptors while conversely, warm 
sensations can be caused by either the stimulation of warm receptors or the 
inhibition of cold receptors (Eccles, 2000). Therefore, the application of 
menthol to the skin may result in a cooling or a warming sensation without a 
concomitant alteration in actual skin temperature. 
 
Since the application of menthol to the skin does not elicit its effects through 
either evaporation from the skin nor any form of localised vasodilation or 
vasoconstriction, it was deemed, as far back as the nineteenth century by 
Goldsheider (1886) that the warming and cooling sensations were caused by 
stimulation of sensory nerve endings.  It is now known that menthol exerts its 
effects on cold receptors by interfering with the movement of calcium across 
the cell membrane in thermoreceptors (Eccles, 1994).  However, the 
mechanisms of the actions of menthol are more complex than a simple 
stimulation of cold receptors, since menthol also modulates feelings of 
warmth, and in high concentrations can cause irritation and local anaesthesia 
(Eccles, 1994). 
 
Research on the dose-response characteristics of menthol is sparse and due 
to the different vehicles employed to apply it, comparisons between studies 
are difficult to draw.  Equally sparse is information on the effects of menthol 
during exposure to different ambient and skin temperatures and, once again, 
the data are not easily comparable. 
 
Existing research on topically applied menthol has predominantly been carried 
out in temperate environments of 18 - 23 °C (Yosipovitch et al., 1996; 
Kozyreva and Tkachenko, 2008).  It is probable however, that actual skin 
temperature plays a greater role in the perception of skin temperature after an 
application of menthol than the ambient temperature.  Kozyreva and 
Tkachenko (2008) used participants with a forearm skin temperature of 32.3 ± 
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0.11 °C (30.5 – 33.7 °C) to study skin sensitivity to the application of 1 % 
menthol.  They found that there are individual differences in the sensitivity of 
skin receptors to menthol, with some people showing an increase in the 
number of functioning cold receptors, while others have a decrease and some 
people show no change.  Indeed, this goes some way to explaining the 
findings of Yosipovitch and colleagues (1996) who showed that only around 
two thirds of people are sensitive to the cooling effects of menthol in 
temperate environments.  However, they fail to state the skin temperature at 
which they found this. 
 
Green (1992) maintained skin temperature of participants at 31 °C and found 
that the application of 5 % or 10 % menthol to the skin had an excitatory 
effect.  Green (1992) also showed that at lower skin temperatures (21 °C) 
menthol solutions had a proportionally smaller effect on the perceived 
intensity of cooling than at 29 °C compared to a 0 % menthol control solution. 
However, he also showed that for all of the solutions, the lower the skin 
temperature the greater the intensity of the cooling stimulus.  These findings 
were mirrored with higher skin temperatures, where the proportional intensity 
of the warming sensation of menthol was reduced as skin temperature 
increased from 33 °C to 41 °C,  and, as skin temperature increased so did the 
perceived intensity of the sensation. 
 
Watson et al. (1978) showed that the sensitivity of the skin to the application 
of menthol displayed a non-uniform response.  In different body surface areas 
there are varying densities of thermoreceptors. Watson and colleagues (1978) 
showed that the eyes and the buccal region were most sensitive to the 
application of menthol, while the palms and soles were least sensitive. 
However, Nakamura et al. (2008) suggest that the preferential cooling of the 
head during heat exposure and maintaining the warmth of the core during 
cold exposure, could not be solely explained by the distribution of peripheral 
thermoreceptors, thereby implicating processing mechanisms within the 
central nervous system. 
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The possibility that the central nervous system is involved in thermal comfort 
over and above simply receiving inputs from the peripheral thermoreceptors 
may have implications for heat exposure and exercise performance in warm 
environments.  However, due to the lack of data on the effects of menthol on 
the skin in the heat, the aim of this study was to elucidate the physiological 
and psychophysical responses to the application of a 1 % menthol solution to 
the skin whilst resting in the heat.  The results of this chapter will inform the 
study design of Chapter Seven. 
 
6.3 Methods 
6.3.1 Participants 
Twenty four healthy male recreationally active and non-heat acclimatised 
volunteers participated in this study.  The physical characteristics of the 
participants were (mean ± standard deviation): age 25 ± 5 y, height 1.80 ± 
0.09 m and body mass 79.7 ± 9.9 kg.  
 
6.3.2 Experimental protocol 
Participants undertook one preliminary trial and two experimental trials.  The 
experimental trials were performed at least seven days apart and at the same 
time of day, in a single-blinded, randomised, counter-balanced, cross over 
design.   
 
The preliminary trial was completed at least twenty four hours before the first 
main trial.  It involved participants sitting in a comfortable environment and 
having a patch soaked in the 1 % menthol solution (see Chapter Two for 
details) applied to the skin of their right forearm.  This remained in place for 
twenty minutes.  The preliminary test was a precautionary one, undertaken 
simply to ensure that there was no adverse reaction to the patches or the 
menthol solution used in the main trials.  No other measures were taken 
during this time.  
 
Briefly, the experimental trials involved a period of resting heat exposure, 
during which patches containing a 1 % menthol solution or a 0 % control 
solution were applied to the skin of the forehead, the upper back and the 
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forearms (see Chapter Two for details).  The physiological and 
psychophysical responses to the heat exposure were monitored before and 
after the application of the patches.  On one occasion all of the patches 
applied contained the 0 % control solution (Control).  On the other occasion all 
of the patches contained the 1 % menthol solution (Menthol) except the one 
which was applied to the left forearm.  The patch that did not contain the 
menthol solution (applied to the left forearm) instead contained the control 
solution, to allow the direct comparison of the two solutions on the same day.  
Participants were blinded to the different solutions used in the forearm 
patches during the Menthol trial, as well as to the trial order.  
 
A schematic of the protocol employed is presented in Figure 6.1.  Details of 
the pre-trial conditions and analytical techniques used are given in Chapter 
Two.  Participants reported to the laboratory in the morning at either 0600 or 
0900 hours.  After arriving, participants emptied their bladder and a sample 
was retained (see Chapter Two for details).  Post-void, nude body mass was 
noted and the participants then positioned a rectal thermometer to allow the 
measurement of core body temperature.  A heart rate telemetry band was 
positioned and skin temperature was measured at four sites (chest, triceps, 
thigh and calf) for the calculation of weighted mean skin temperature using an 
infrared laser thermometer (see Chapter Two for details).  Left and right 
forearm temperatures were also measured slightly distally of where the 
patches were to be placed.  Participants wore only shorts and shoes for the 
trials.  Finally, before entering the chamber, participants were asked to 
complete the subjective feelings questionnaire made up of four visual 
analogue scales (see Appendix D).  The first two scales referred to the 
thermal sensation of the right and left forearms (local thermal sensation).  The 
third scale related to the overall thermal sensation of the body and the final 
scale referred to the overall thermal comfort of the body. 
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Figure 6.1. A schematic representing the protocol employed during the main trials in Chapter Six. 
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Upon entering the climatic chamber, maintained at 32.5 ± 0.2 °C, 66 ± 3 % 
relative humidity and 0.7 ± 0.1 m / s wind speed, participants were seated.  
Participants sat for thirty minutes and measures of core temperature, skin 
temperature, heart rate and subjective feelings were taken every ten minutes.  
After thirty minutes skin blood flow on each forearm was also measured (see 
Chapter Two for details).  After this, the patches containing the solutions 
appropriate to the trial being completed were applied to the skin. Participants 
remained seated in the chamber for a further eighty minutes. Every five 
minutes after the patches had been positioned measures of core temperature, 
skin temperature, heart rate and subjective feelings were taken. Skin blood 
flow was taken every ten minutes from minute five (see Chapter Two for 
details).  At the end of the test period participants left the heat chamber, 
removed the patches, heart rate monitor and the rectal probe and were again 
weighed nude.  They were then given food and beverages and were allowed 
to leave the laboratory. 
 
6.3.3 Statistical analysis 
All data sets were investigated for normality of distribution using the Shapiro-
Wilk test, and for skewness and kurtosis.  Where the data were analysed 
within participants, i.e. between the two conditions, paired t-tests or repeated 
measures ANOVA were used. Where the data were analysed between 
individuals, i.e. between those who perceived a warming effect and those who 
perceived a cooling effect, independent samples t-tests were used, or a 
repeated measures ANOVA mixed design where appropriate.  Correlations 
were analysed using a Pearson’s product-moment correlation coefficient.  In 
this part of the analysis those who perceived no effect of the treatment were 
omitted from the investigation.  All analysis was performed on SPSS version 
17.0 and statistical significance was set at P < 0.05. 
 
6.4 Results 
6.4.1 Menthol vs. Control 
The data from all participants was included in the following analysis (n = 24). 
Urine osmolality was not different between the two treatments (P = 0.784), 
showing that participants were in the same hydration state on both trials (667 
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± 244 mosmol / L for the Menthol trial and 680 ± 248 mosmol / L for the 
Control trial).  
 
The main finding of this aspect of the study was there appeared to be no 
physiological effects of applying menthol to the skin.  Forearm skin 
temperature was not affected by the Menthol compared to the Control (P = 
0.133), although it did increase significantly (P < 0.001) upon entering the 
chamber from 31.1 ± 0.7 °C to 34.6 ± 0.5 °C by Pre20; it then fell very slowly 
over the trial to 34.2 ± 0.5 °C at the end of the trial.  For the mean skin 
temperature there was no difference between the two treatments (P = 0.097), 
but it did change over time (P = 0.004) from 30.4 ± 0.6 °C to 33.9 ± 0.5 °C 
during the initial thirty minutes in the heat chamber; it then slowly fell to 33.4 ± 
0.4 °C by the end of the trials.  Core temperature also did not differ with 
treatment (P = 0.172) but did show an effect of time (P = 0.001), rising upon 
entering the chamber (from 37.00 ± 0.31 °C to 37.04 ± 0.30 °C), falling before 
the application of the patches (37.02 ± 0.29 °C) and then rising again very 
slowly to the end of the trials (37.11 ± 0.26 °C; Figure 6.2). 
 
 
Figure 6.2.  Core temperature over the duration of the Menthol and Control trials.   
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Body mass loss was not different between the two treatments (0.23 ± 0.11 kg 
and 0.26 ± 0.11 kg for the Menthol and Control trials respectively; P = 0.175). 
Heart rate did not differ between treatments (P = 0.219) nor over time (P = 
0.415; Figure 6.3).  The percentage changes in skin blood flow between the 
Menthol trial and the Control trial were also not different between treatments 
(P = 0.448), nor over time (P = 0.059). 
 
 
 
Figure 6.3.  Heart rate over the duration of the Menthol and Control trials.  
 
When comparing the Menthol and the Control trials there was no difference in 
the temperature sensation of the arms (P = 0.789), nor was there an influence 
of time (P = 0.107).  Overall thermal sensation was not different between 
treatments (P = 0.068), but was affected by time, increasing during the first 
ten minutes of heat exposure in the chamber (P < 0.001; Figure 6.4).  Overall 
thermal comfort followed the same pattern; it was not different between 
treatments (P = 0.231) but there was a shift towards being too hot within the 
first ten minutes of heat exposure (P < 0.001). 
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Figure 6.4.  Overall thermal sensation over the duration of the Menthol and Control trials.  
 
6.4.2 Warming vs. cooling 
The greatest difference for any individual at any time point between the arm 
thermal sensation scores from the start of the trial to immediately before the 
patches were applied was 2 %.  Therefore, to interpret thermal sensation data 
in a conservative manner it was deemed that a difference of 5 % or more was 
a clear indication of a variation in perception and not merely a careless error 
in reporting.  
 
From the data gathered on the Menthol trial, participants were retrospectively 
grouped according to their perception on the thermal effects of the menthol.  If 
their right arm (1 % menthol solution) thermal sensation score was 5 % or 
more below their left arm (control solution) thermal sensation score, at the 
same time point within ten minutes of the patch application, they were 
classified as perceiving a cooling effect.  Equally, if their right arm thermal 
sensation score was 5 % or more above that of their left arm at the same time 
point within ten minutes of the patch application, they were classified as 
perceiving a warming effect.  Of the twenty four participants recruited to the 
study; thirteen perceived that the patches elicited a cooling effect; eight felt 
that the patches warmed the skin; and three did not perceive any difference 
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compared to the control patch.  All subsequent analysis has omitted the 
participants who perceived no effect of the menthol (n = 3). The details of the 
participants in the warming and cooling groups are presented in Table 6.1.   
 
Table 6.1. Participant information grouped by local thermal sensation ten minutes after the 
application of menthol patches, and the difference between the groups.   
 
 Body mass 
(kg) 
Height 
(m) 
Age 
(y) 
Cooling 77.6 ± 7.0 1.77 ± 0.07 24 ± 3 
Warming 83.3 ± 11.4 1.84 ± 0.11 26 ± 6 
P value 0.156 0.115 0.623 
 
Figure 6.5 shows the difference in the local thermal sensation between the 
right arm (menthol patch) and the left arm (control patch) over the duration of 
the trial, divided into those who felt a cooling sensation (n = 13) and those 
who felt a warming sensation (n=8).  There was a significant difference 
between the groups over the trial (P < 0.001).  Fifteen minutes after the 
menthol was applied the cooling sensation group perceived their right arm (1 
% menthol solution) to be 12 ± 7 % cooler than their left (control solution), 
while the warming sensation group perceived their right arm to be 16 ± 10 % 
warmer than their left, although this was not significantly affected by time (P = 
0.076).  
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Figure 6.5.  The difference in thermal sensation scores on the Menthol trial between the right 
arm (1 % menthol solution) and the left arm (control solution), leading to the grouping of 
participants into a group who perceive a warming sensation (n = 8) and a group who 
perceived a cooling sensation (n = 13).   
 
The local thermal sensation scores also reflected the overall thermal 
sensation scores (P = 0.004; Figure 6.6), and this was likewise significantly 
influenced by time (P < 0.001).  This difference between the groups was 
greatest ten minutes after the application of the menthol, where the cooling 
group had a mean score of 49 ± 10 % and the warming group had a score of 
67 ± 13 %.  Thermal comfort data mirrored that of thermal sensation, with a 
significant difference between those who felt a local warming effect and those 
who felt a local cooling effect (P = 0.004).  Again, this also demonstrated a 
significant effect of time (P < 0.001) with the greatest difference between the 
two groups occurring after ten minutes (52 ± 9 % and 67 ± 11 %, cooling and 
warming respectively; Figure 6.7). 
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Figure 6.6.  Overall thermal sensation of participants grouped according to local thermal 
sensation ratings.   
 
 
 
 
Figure 6.7.  Overall thermal comfort of participants grouped according to local thermal 
sensation ratings.   
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There was no difference in body mass index between those who perceived 
the patches as warming (25.2 ± 2.9 kg / m2) and those who perceived them as 
cooling (24.4 ± 3.7 kg / m2; P = 0.607).  Similarly, the body mass loss did not 
differ between the warming group (0.28 ± 0.12 kg) and the cooling group (0.22 
± 0.11 kg; P = 0.299).  Percentage change in blood flow did not alter over time 
(P = 0.462) nor was it affected by the local thermal sensation of the 
participants (P = 0.072). Heart rate showed a significant effect of time (P = 
0.045; Figure 6.8) but did not differ with sensation (P = 0.223). 
 
 
 
Figure 6.8.  Heart rate of participants over the Menthol trials, split into groups depending upon 
their perceived local thermal sensation.   
 
There was no difference in arm temperature between the two groups (P = 
0.267).  There was a significant effect of time as arm temperature increased 
for the initial twenty minutes of heat exposure from 31.1 ± 0.9 °C to 34.5 ± 0.7 
°C in the cooling group, and 31.2 ± 0.6 °C to 34.7 ± 0.4 °C in the warming 
group (Figure 6.9).  Core temperature and mean skin temperature also 
changed significantly over time (P < 0.001 for both); both increased upon 
entering the heat chamber.  Skin temperature then fell slowly over the trials; 
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core temperature increased very slightly over the trials.  There was no 
difference between the groups for either core temperature (P = 0.486) or skin 
temperature (P = 0.983). 
 
 
 
Figure 6.9.  Arm temperature of participants over the Menthol trials, grouped depending upon 
their perceived local thermal sensation.   
 
6.4.3 Sensation vs. treatment 
The two treatments (Menthol and Control) have been compared to each other. 
The participants, having been split into two groups, depending upon their local 
perception of thermal sensation in response to the application of menthol, 
have also been compared to each other.  The final comparisons to be drawn 
are those within the same participant between the two treatments.  As before, 
those who perceived no difference in local thermal sensation between the 
Menthol and the Control patches have been omitted from this analysis. 
 
For those who perceived a warming effect (n = 8) and for those who perceived 
a cooling effect (n = 13), there was no difference between the two treatments 
for body mass loss (0.22 ± 0.11 kg Menthol and 0.23 ± 0.10 kg Control in the 
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cooling group, P = 0.598; 0.28 ± 0.12 kg Menthol and 0.31 ± 0.11 kg Control 
in the warming group, P = 0.423).  Heart rate was not different between trials 
(P = 0.219, P = 0.753) nor over time (P = 0.062, P = 0.13) for cooling and 
warming groups respectively.  There were also no changes in skin blood flow 
between trials (P = 0.959, P = 0.148) nor over time (P = 0.26, P = 0.136) for 
the cooling or the warming groups respectively. 
 
The core temperature of those in the cooling group showed no difference 
between treatments (P = 0.237) and no change over time (P = 0.100).  Those 
in the warming group showed no difference between treatments (P = 0.440) 
but there was an increase in core temperature over time (P = 0.010).  Mean 
skin temperature did not differ between trials for the cooling (P = 0.395) or the 
warming group (P = 0.619), but both groups showed an increase over time (P 
< 0.001).  The same pattern was seen for arm temperatures, where there was 
an increase over time for both groups (P < 0.001), but no difference between 
the treatments (P = 0.236 for the cooling group and P = 0.299 for the warming 
group). 
 
For the local thermal sensation, the cooling group showed a significant 
difference between the treatments (39 ± 10 % Menthol treatment and 53 ± 8 
% Control treatment at fifteen minutes; P < 0.001), with a significant influence 
of time (P = 0.002).  The same was seen for the warming group, the local 
thermal sensation between the two treatments was different (74 ± 14 % 
Menthol treatment and 59 ± 7 % Control treatment at fifteen minutes; P = 
0.015) and there was also an effect of time (P = 0.001; Figure 6.10). Overall 
thermal sensation in the warming group did change with time (P = 0.001), but 
did not differ between the two treatments (P = 0.887).  However, in the cooling 
group both time (P = 0.02) and treatment (P = 0.02) affected overall thermal 
sensation (Figure 6.11).  The same pattern for overall thermal sensation is 
mirrored in overall thermal comfort measures (Figure 6.12).  In the warming 
group there is no effect of the treatment (P = 0.256), but there was an effect of 
time (P = 0.003), whereas in the cooling group the data were significantly 
affected by the treatment (P = 0.007) and by the time (P = 0.035). 
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Figure 6.10.  Arm thermal sensation scores over the duration of the trials with participants 
split into warming (n = 8) and cooling (n = 13) sensation groups and the data from their 
Menthol trial compared to their Control trial. 
 
 
 
Figure 6.11.  Overall thermal sensation scores over the duration of the trials with participants 
split into warming (n = 8) and cooling (n = 13) sensation groups and the data from their 
Menthol trial compared to their Control trial. 
152 
 
 
 
Figure 6.12.  Overall thermal comfort scores over the duration of the trials with participants 
split into warming (n = 8) and cooling (n = 13) sensation groups and the data from their 
Menthol trial compared to their Control trial. 
 
6.5 Discussion 
Arm skin temperature was not different between the Menthol and Control 
trials, nor was it different between the right arm (1 % menthol solution) and 
the left arm (control solution) in the Menthol trial and finally, it was also not 
different between those who perceived a warming sensation compared to 
those who perceived a cooling sensation on the Menthol trial.  Likewise, mean 
skin temperature did not show any differences between the Menthol and the 
Control trials, nor between the warming and cooling groups and the same can 
also be said for the skin blood flow data.  Therefore, this shows that there was 
no effect of the menthol on actual skin temperature or skin blood flow, and 
that the alteration in perceived thermal sensation occurred centrally as a 
result of the stimulation of thermoreceptors.  This supports the data seen in 
other investigations using human participants (Yosipovitch et al., 1996; 
Kozyreva and Tkachenko, 2008), but it conflicts with findings in animal 
studies.  
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Tajino and colleagues (2008) found that when a 10 % menthol solution was 
applied to the skin on the whole trunk of mice, after an initial fifteen minute 
lowering of core temperature probably due to the evaporation of the vehicle 
from the skin, menthol caused an increase in core temperature of 1.3 °C in 
the subsequent fifteen minutes compared to when the vehicle only was 
applied in the same way.  This elevated core temperature then persisted for 
over ninety minutes (Tajino et al., 2008).  The authors suggest that the 
menthol, through activating the skin thermoreceptors, evoked a heat gain 
response, possibly through peripheral vasoconstriction and shivering-like 
autonomic heat gain responses, which have been seen before as a result of 
menthol application to mouse skin (Tajino et al., 2007), resulting in the 
increase in core temperature seen in the mice. 
 
It seems that for those who felt a cooling sensation of the menthol, it was a 
stronger sensation than for those who experienced a warming sensation. 
Significant differences were seen in the cooling group between the Menthol 
and Control trials in overall thermal sensation and overall thermal comfort, 
which were not present in the warming group (Figure 6.11 and Figure 6.12). 
Menthol is most commonly known for its cooling sensation properties and 
therefore it is possible that participants were predisposed to assume a cooling 
sensation upon application to the skin.  By mixing the menthol solution in 
methylated spirits there was no difference in colour between the test liquids. 
Methylated spirits also helped to mask the smell of the menthol and therefore 
acted as a suitable vehicle for the menthol, while also allowing for the trials to 
be blinded, thereby minimising any confounding factor due to the possible 
expectation of a cooling sensation. 
 
In a study by Green (1992) skin temperature was manipulated and the 
response to applying either a 0 % vehicle only or a 5 % or 10 % menthol 
solution was investigated.  At skin temperatures of 33 °C, similar to those in 
the present study, 75 % of trials on the 5 % menthol application saw the 
sensation of warmth reported, while the 10 % menthol solution elicited a 
response of close to 90 % reporting a sensation of warmth.  However, it 
should be noted that the control substance also elicited a rate of 75 % of trials 
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eliciting a warm sensation, therefore suggesting that the menthol had little or 
no effect at 33 °C compared to the vehicle alone.  The perceived intensity of 
this warming sensation was slightly greater on both of the menthol trials than 
on the 0 % control trial during the initial five and ten minutes of exposure. 
Over a large range of skin temperatures the pattern emerged that at lower 
skin temperatures, menthol elicited a large cooling effect (at 29 °C ~75 % vs. 
~40 % of trials reported cooling for menthol and control trials respectively). 
When skin temperature was increased a warming sensation was elicited from 
the menthol application (at 39 °C ~55 % vs. ~20 % of trials reported warming 
for menthol and control trials respectively).  
 
However, in the present study there was only a weak correlation between arm 
temperature and overall thermal sensation in the cooling (r = 0.31) and 
warming (r = 0.45) groups.  There was no correlation between skin 
temperature and overall thermal sensation, skin temperature and arm 
sensation, or arm temperature and arm sensation, in either the warming or the 
cooling sensation groups.  Of course, the present study did not have the 
range of skin temperatures seen in the Green (1992) study. 
 
Previous research has shown that around one third of people are not sensitive 
to the application of menthol to the skin (Yosipovitch et al., 1996).  In the 
present study, three participants of the twenty four recruited (12.5 %) did not 
perceive any effect of the menthol solution.  It is possible that by coincidence, 
more of the participants recruited to the Yosipovitch study were immune to the 
effects of the menthol than the general population, or that by the same 
coincidence, fewer of the participants recruited to the present study were 
immune to the effects of menthol.  As the Yosipovitch study only recruited 
eighteen participants, and this study only recruited twenty four participants, to 
gain a true perspective on the prevalence of skin sensitivity to menthol in the 
general population, much greater numbers would need to be recruited.  
 
It is also possible that the ambient temperature or the skin temperature may 
alter individual sensitivity to menthol.  There could be a specific, possibly 
individualised, temperature at which the thermal sensation of menthol 
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changes from a cooling sensation to a warming sensation, passing through no 
perceivable temperature sensation.   This hypothesis might also explain the 
difference in the levels of sensitivity between the Yosipovitch trial and the 
present study. It might be expected that the findings of the two studies would 
be reversed since the menthol applied here was only a 1 % solution, while the 
solution Yosipovitch and colleagues (1996) applied contained 10 % menthol 
and consequently the stronger concentration of menthol might reasonably be 
expected to increase the number of people able to feel its effect.  
 
There also appears to be a difference between individuals in the rate of 
response to heat exposure in mean skin temperature and arm skin 
temperature.  The standard deviation bars at time point Pre10 on Figure 6.9 
demonstrate that after ten minutes of heat exposure some participants’ arm 
temperature had not yet responded to the heat exposure, while other 
participants’ arm temperature had already reached the elevated arm 
temperature seen in all participants after twenty minutes of heat exposure.  
No such lag was seen in participants’ perception of thermal sensation (Figure 
6.4).  This suggests that the rate of initiation of physiological responses to 
increased environmental temperature varies between individuals, but that this 
is not reflected by equally variable rates in the perception of environmental 
conditions. 
 
A 1 % menthol solution was used here, since in a pilot study looking at 
different concentrations of menthol that could be used, feelings of burning, 
itching and discomfort increased with increasing concentration, but perception 
of cooling or warming did not intensify.  Indeed, Green (1992) found that 
doubling the concentration of menthol (5 % to 10 %) used in his study at skin 
temperatures ranging from 21 °C to 35 °C, resulted in a greater incidence of 
burning sensation but did not change the intensity of the cooling sensation.  
He suggests that this could be due either to a near saturation point of the 
effect of menthol or that the psychophysical methods employed in the study 
were not sensitive enough to detect such a change.  
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In the present study the menthol patches were covered with a non-porous 
adhesive dressing to prevent the effects of evaporative heat loss.  However, 
the action of menthol is to activate the skin thermoreceptors and this 
activation remains even once the menthol is removed, meaning that after 
application to the skin, the menthol makes other substances such as water or 
air which pass over the body feel cool (Eccles, 2000).  Therefore, it is possible 
that if the patches had been removed after a time and the measures 
continued, the findings of the present study may have been altered.  
 
Certain parts of the skin are more sensitive to temperature changes than 
others.  By isolating a participants’ head and exposing it to different 
temperatures, McCaffrey et al. (1975) showed that sweat rates could be 
altered.  When sitting from the neck down in 40 °C, the participants’ head was 
exposed to either heating (70 °C) or cooling (29 °C) for thirty minutes. 
Naturally, with heating head skin temperature increased quickly, followed by a 
slower rise in core temperature, and sweat rate increased rapidly and 
continued to increase, even after skin temperature had stabilised.  When the 
participants’ head was cooled, sweating rates fell and core temperature 
remained unchanged.  Indeed people preferentially cool the face when in a 
warm environment (Nakamura et al., 2008) and therefore, by applying 
menthol solution to the forehead, a stronger thermal sensation may be 
expected than if applying the menthol to only other skin surface areas.  
 
The hypothalamus co-ordinates the thermoregulation of the body.  Skin 
temperature receptors terminate in the pre-optic area of the hypothalamus 
and core temperature receptors terminate in the pre-optic area and the brain 
stem.  Skin thermoreceptors can be stimulated by application of menthol to 
the skin, eliciting a cooling sensation making the body feel cooler.  It has been 
suggested that some aspects of peripheral cooling sensation occur centrally.  
Nakamura et al. (2008) suggested that the qualitative differences in the 
thermal comfort of various body areas seen in their study could not be solely 
explained by the distribution of peripheral thermoreceptors, thereby 
implicating processing mechanisms within the central nervous system.  Frank 
et al. (1999) demonstrated that core temperature and skin temperature 
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contribute equally to levels of thermal comfort in men, assessed by a ten point 
visual analogue scale.  Therefore, by artificially manipulating the perception of 
skin temperature to lower than its true temperature, it may be possible to 
manipulate thermal comfort.   
 
6.6 Conclusion 
Applying 1 % menthol solution to the skin during exposure to a warm 
environment evokes differing sensations between individuals, varying from a 
very cold sensation, through no sensation to a very warm sensation. 
However, no matter what the perceived response to the application of menthol 
to the skin, there is no alteration in the skin temperature or skin blood flow. 
 
Applying menthol to small patches of skin altered overall thermal sensation 
and thermal comfort.  Improving thermal comfort during heat exposure may 
improve heat tolerance.  Furthermore, if this pattern were to hold true, 
exercise performance or exercise capacity in the heat could be improved.  
This is the rationale which we aimed to test in the subsequent experiment, 
detailed in Chapter Seven. 
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CHAPTER SEVEN 
 
The influence of the application of a 1 % 
menthol solution to the skin during a cycling 
time trial in the heat. 
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7.1 Abstract  
 
In a warm environment, the application of menthol to the skin caused a 
warming sensation in some individuals and a cooling sensation in other 
individuals.  It is plausible that altered thermal sensation may have important 
implications for exercise performance but this has never been investigated.  
Therefore, the aim of this investigation was to determine in alterations in 
thermal sensation, without alterations in actual core or skin temperatures 
could alter endurance exercise performance in the heat.  
 
Six participants who perceived a warming sensation due to menthol and six 
who perceived a cooling sensation due to menthol completed a sixty minute 
pre-load bout of cycling at 55 %  ̇O2 peak in 30.4 ± 0.3 °C and 44 ± 3 % 
relative humidity. Patches soaked in 1 % menthol (Menthol) or a control 
(Control) were then applied to the skin immediately prior to a twenty minute 
time-trial.  During the time-trial, core and skin temperatures, heart rate, rating 
of perceived exertion, work done and pedal cadence were recorded every five 
minutes.  Local and overall thermal sensation ratings were taken every ten 
minutes, expired air was collected for the last minute and a blood sample was 
drawn immediately upon completion of the exercise.  
 
There were no differences (P > 0.05) between the Menthol and Control trials 
for any of the parameters except heart rate, which was slightly higher in the 
Menthol trials than the Control trials (P = 0.031).  There was no difference in 
overall exercise performance (work done) between the cooling group and the 
warming group (P = 0.200).  Within the warming group, thermal sensation 
scores were greater on the Menthol than the Control trials (P = 0.009), but this 
did not affect performance (P = 0.405).  Within the cooling group thermal 
sensation scores tended to be lower with Menthol (P = 0.053), and there was 
a tendency for an improvement in performance (P = 0.071).  This suggests 
that when participants feel cooler than they actually are, exercise performance 
in a warm environment may be improved. 
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7.2 Introduction 
During exercise in the heat there is unequivocal evidence that both endurance 
exercise capacity and exercise performance are reduced compared to when 
the same endurance exercise is performed in a cool environment (Galloway 
and Maughan, 1997; Nybo and Nielsen, 2001B; Tatterson et al., 2000).  It is 
likely that the elevation of core body temperature due to exercise, and the 
reduced ability to lose the excess heat to the surrounding environment during 
heat exposure, is a significant factor in the reduced ability to perform exercise 
in a warm environment (Pitsiladis and Maughan, 1999; Nielsen et al., 1997; 
Gonzalez-Alonso et al., 1999B).  However, another influential factor in such 
situations may be skin temperature.  Indeed, lowering of skin temperatures 
during exercise in the heat has been shown to greatly reduce the elevated 
perception of effort associated with elevated core temperatures (Armada-da-
Silva et al., 2004).  Furthermore, it has been shown to modulate the effects of 
high core temperatures on hormonal responses to exercise in the heat (Bridge 
et al., 2003B) and possibly even improve endurance exercise capacity 
(Marvin et al., 1999).  
 
Frank et al. (1999) showed that core temperature and skin temperature 
contribute equally to levels of thermal comfort in men assessed by a ten point 
visual analogue scale.  Therefore, by artificially manipulating the perception of 
skin temperature to lower than the true physiological temperature, it may be 
possible to manipulate thermal comfort and consequently improve heat 
tolerance.  If this hypothesis holds true during exercise in a warm 
environment, endurance exercise performance or capacity may be improved.  
Equally, by artificially manipulating the perception of skin temperature to 
higher than its true value, endurance exercise performance or capacity may 
be reduced.  
 
Several products containing the plant extract menthol are emerging onto the 
market claiming to make people feel cooler.  Menthol is widely used in many 
medicinal and cosmetic products due to the cooling sensation it causes when 
applied to the skin or mucous membrane and then making other stimuli, such 
as air or water, also feel cool (Watson et al., 1978).   
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The application of menthol on the skin does not elicit its effects through either 
evaporation from the skin nor any form of localised vasodilation or 
vasoconstriction.  According to Eccles (1994) it was deemed as far back as 
the nineteenth century, by Goldsheider (1886) that the warming and cooling 
sensations were caused by stimulation of sensory nerve endings.  Cool 
sensations can be caused by either the stimulation of cold receptors or the 
inhibition of warm receptors; conversely, warm sensations can be caused by 
either the stimulation of warm receptors or the inhibition of cold receptors.  
Existing research on topically applied menthol is limited and has been carried 
out at rest (Yosipovitch et al., 1996; Kozyreva and Tkachenko, 2008; Green, 
1992). 
 
While the studies by Yosipovitch et al. (1996) and Kozyreva and Tkachenko 
(2008) were carried out at ambient temperatures of 18 - 23 °C, it is likely that 
the skin temperature is of greater importance to the thermal sensation elicited 
by the application of menthol than the environmental temperature.  Green 
(1992) conducted a thorough analysis of the responses of participants to the 
application of menthol to the skin at different skin temperatures.  He found 
that at a mid-range of skin temperatures (27 - 31 °C) menthol resulted in a 
greater incidence of reporting a cold sensation.  At lower skin temperatures 
(21 - 27 °C) he found that menthol did not affect the incidence of reporting a 
cold sensation, and at higher temperature (37 - 41 °C) menthol reduced the 
incidence of reporting a hot sensation.  However, these sensation ratings 
were all taken locally, at the site at which skin temperature was manipulated 
(forearm only), whilst the participant remained seated.  Ambient temperature 
and overall thermal sensation ratings were either not measured or not 
reported.    
 
In a recent study by Mundel and Jones (2010) it was shown that cycling 
exercise capacity in the heat (34 °C) was improved by 9 ± 12 % when swilling 
a menthol solution around the oral cavity, compared to swilling a placebo 
solution (63 ± 14 minutes compared to 58 ± 16 minutes with the menthol and 
placebo solutions respectively).  Central ratings of perceived exertion (defined 
by the authors as the RPE specifically relating to the cardiopulmonary system) 
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was significantly lower for the initial forty minutes and pulmonary ventilation 
was greater after twenty and forty minutes on the menthol trials compared to 
the placebo trials. 
 
Mundel and Jones (2010) postulated that the mechanism for the improvement 
in exercise capacity was an alteration in the sensation of oropharyngeal 
temperature through alterations in psychophysical processes.  The reduction 
in central RPE was likely due to the improved ventilation, as there were no 
differences in any of the circulatory or metabolic parameters measured.  The 
oropharyngeal cold receptors of the mouth were likely to have been 
stimulated by the menthol and this may have altered the perception of the 
effort required to breath.  Anecdotal evidence from comments made by 
participants also suggested that the menthol caused a sensation that was 
described as ‘refreshing’ and ‘stimulating’ (Mundel and Jones, 2010).  
 
The effect of 1 % menthol application to the skin during resting heat exposure 
was assessed in Chapter Six.  It was found that some participants reported a 
warming sensation while other reported a cooling sensation elicited by the 
menthol application.  Therefore, the aim of this investigation was to determine 
if the manipulation of thermal sensation through the application of menthol to 
the skin would alter exercise performance in the heat. 
 
7.3 Methods 
7.3.1 Participants 
Twelve healthy male volunteers participated in this study.  The physical 
characteristics of the participants (mean ± SD) were: height 1.81 ± 0.07 m, 
body mass 79.1 ± 10.3 kg,  ̇O2peak 59.0 ± 9.9 ml / kg / min and age (median 
(range)) 23 (20 - 31) y.  
 
7.3.2 Experimental protocol 
Participants undertook one preliminary trial involving a patch test and a 
maximal oxygen uptake test (details can be found in Chapter Two), followed 
by two familiarisations and two experimental trials.  The familiarisations and 
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experimental trials were performed at least seven days apart and the 
experimental trials were performed in a blinded, randomised, counter-
balanced, crossover design.  Briefly, the experimental trials involved 
participants completing a sixty minute cycle ergometer exercise bout at 55 % 
of their  ̇O2peak in a warm environment.  Immediately after that, patches 
containing either a 1 % menthol solution or a control solution were applied to 
the skin on the forehead, upper and lower back, and the forearms (see 
Chapter Two for details).  As soon as all the patches were in place the 
participants started a time-trial where they were instructed to complete as 
much work as possible in twenty minutes. A schematic of the experimental 
protocol is presented in Figure 7.1.  
 
During both of the familiarisation trials and one experimental trial all of the 
patches applied contained the 0 % control solution (Control).  On the other 
occasion all of the patches contained the 1 % menthol solution (Menthol), 
except one patch which was applied to the left forearm.  The patch that did 
not contain the menthol solution instead contained the control solution, to 
allow the direct comparison of the two solutions on the same day.  
Participants were blinded to the different solutions used in the forearm 
patches during the Menthol trial. 
 
The preliminary testing was done at least three days prior to the first 
familiarisation.  The patch test involved participants sitting in a warm 
environment (30 °C and 45 % relative humidity) for twenty minutes to allow 
the adjustment of skin temperature.  A patch soaked in the 1 % menthol 
solution was then applied to the skin of their right forearm and a patch soaked 
in a control solution was applied to the skin of their left forearm.  These 
remained in place for a further twenty minutes before participants were 
presented with two 10 cm visual analogue scales with verbal anchors at either 
end (‘‘Cold’’ and ‘‘Hot’’) and asked to rate their right and left forearm 
temperatures (see Appendix D).   
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Figure 7.1. A schematic representing the protocol employed during the main trials in Chapter Seven. 
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The aim of this patch test was twofold; firstly to ensure that there was no 
adverse reaction to the patches or the menthol solution used in the main trials 
and secondly, to allow the investigators to determine if the participant 
perceived a warming sensation or a cooling sensation due to the menthol.  Six 
participants who perceived a warming effect of the menthol and six who 
perceived a cooling effect were recruited to the study.  No other measures 
were taken during the patch test.  After the patch tests the  ̇O2peak test was 
completed (for details see Chapter Two). 
 
For the familiarisation and experimental trials, participants reported to the lab 
at either 0600 or 0900 hours.  Upon arrival, participants were asked to empty 
their bladder and a small sample of the urine passed was retained.  Post-void, 
nude body mass was taken and participants inserted a rectal thermometer to 
allow the measurement of core body temperature (Tc).  A heart rate telemetry 
band was then positioned and skin temperature was measured using an 
infrared laser thermometer.  Skin temperature was measured at four sites 
(chest, triceps, thigh and calf) for the calculation of weighted mean skin 
temperature and estimation of body heat content as described in Chapter 
Two.  Participants wore only shorts and trainers for the duration of the trials.  
 
Upon entering the climatic chamber, maintained at 30.4 ± 0.3 °C and 44 ± 3 % 
relative humidity, participants were seated for twenty minutes during which 
measures of core temperature, skin temperature, heart rate and subjective 
feelings were taken every ten minutes.  The subjective feelings questionnaire 
measured local (forearm) thermal sensation of the right and the left forearms, 
as in the preliminary testing, and also overall thermal sensation using visual 
analogue scales (see Appendix D).  
 
During this resting period an indwelling cannula was inserted into a superficial 
forearm vein (see Chapter Two for details) and a 5 ml baseline blood sample 
was drawn at twenty minutes.  Participants were then given 150 ml of plain 
water, served at room temperature, to consume.  After this, participants 
started cycling at an equivalent of 55 %  ̇O2peak.  During this one hour 
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preload phase, measures of core and skin temperature, heart rate, rating of 
perceived exertion and thermal sensations were taken every ten minutes 
while samples of exhaled air and blood were taken every fifteen minutes.  
Also, after every fifteen minutes participants drank 150 ml of plain water 
served at room temperature.  The total work done at the end of the sixty 
minutes was noted.  
 
Immediately at the end of the sixty minute pre-load exercise period the skin 
was dried as thoroughly as possible and the patches were applied (see 
Chapter Two for details).  As soon as the patches were secured, the time-trial 
commenced.  Participants began the exercise at a workload that equated to 
75 % of their  ̇O2peak and were allowed to alter the workload throughout the 
time-trial as they liked.  The bike was set in hyperbolic mode, meaning that 
participants could cycle at any pedal cadence and the workload would remain 
the same.  The participants altered the workload by pressing buttons on the 
console of the ergometer but they received no feedback on their workload or 
any other performance or physiological measures.  The participants could see 
a timer during the trial but were given no other information.  
 
During the time-trial, measures of core and skin temperature, heart rate and 
rating of perceived exertion were taken every five minutes.  Thermal 
sensations were taken after ten and twenty minutes, a gas sample was taken 
during the final minute and a venous blood sample was drawn as soon as 
exercise was finished.  The power output (W), cumulative work done (kJ), and 
pedal cadence (rpm) data displayed by the bike were also recorded every five 
minutes during the time-trial. 
 
At the end of the test period, participants left the heat chamber to recover.  
Once they felt ready, the patches, cannula, heart rate monitor and the rectal 
probe were removed.  Finally, participants were again weighed nude before 
dressing and being given food and beverages.  They were then allowed to 
leave the laboratory. 
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7.3.3 Blood handling and analysis 
All blood samples (5 ml) were collected into dry syringes.  Samples were 
analysed for glucose and haemoglobin concentrations, haematocrit values 
and serum osmolality.  Details of the techniques used can be found in 
Chapter Two. 
 
7.3.4 Statistical analysis 
All data sets were investigated for normality of distribution using the Shapiro-
Wilk test, and skewness and kurtosis.  Where the data were analysed within 
participants, i.e. between the two conditions, paired t-tests or repeated 
measures ANOVA were used.  Where the data were analysed between the 
two groups of responses on the Menthol trial, i.e. between those who felt a 
warming sensation and those who felt a cooling sensation, independent 
samples t-tests were used or a repeated measures ANOVA mixed design 
where appropriate.  In this part of the analysis the participant who perceived 
no effect of the treatment was omitted from the investigation.  All analysis was 
performed on SPSS version 17.0 and statistical significance was set at P < 
0.05. 
 
7.4 Results 
7.4.1 Pre-load data 
There were no differences between the trials for any of the measured 
parameters during the sixty minute preload phase of the trials (P > 0.05).  This 
result was to be expected since no intervention had been applied at that 
stage.  It also implies that the participants started both time-trials in the same 
physiological state.  Most parameters increased over the duration of the sixty 
minute pre-load exercise, including: core temperature (P < 0.001), weighted 
mean skin temperature (P < 0.001), estimated body heat content (P < 0.001), 
heart rate (P < 0.001), right and left arm thermal sensation scores (P < 0.001 
for both), overall thermal sensation scores (P < 0.001), ratings of perceived 
exertion (P < 0.001), glucose concentration (P = 0.008), serum osmolality (P < 
0.001) and fat oxidation rates (P < 0.001), while carbohydrate oxidation rates 
fell during the exercise (P < 0.001). 
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There was no order effect of the trials (P = 0.695).  There was no difference in 
body mass loss over the duration of the tests between the Menthol and the 
Control trials (1.65 ± 0.32 kg Menthol and 1.72 ± 0.39 kg Control; P = 0.184). 
There was no difference in urine osmolality between the Menthol and the 
Control trials (549 ± 241 mosmol / L Menthol and 552 ± 284 mosmol / L 
Control; P = 0.948), indicating that participants were in a similar hydration 
state for both trials. 
 
7.4.2 Time trial protocol 
The co-efficient of variation between the first and second familiarisations was 
4.7 ± 11.0 % (r = 0.956).  The co-efficient of variation between the second 
familiarisation and the control trial was 3.9 ± 9.6 % (r = 0.976). 
 
7.4.3 Menthol vs. Control  
There was no difference in the total work done during the time-trial between 
the Menthol and the Control treatments (249.3 ± 40.7 kJ Menthol and 248.9 ± 
42.0 kJ Control; P = 0.925).  Also, the distribution of work over the twenty 
minutes, analysed in five minute blocks, was not different between the trials 
(P = 0.925) nor over the duration of the trials (P = 0.299). 
 
There was no difference between the treatments for pedal cadence, which 
was noted every five minutes.  There was however, an effect of time, spiking 
from 93 ± 10 rpm and 95 ± 11 rpm at fifteen minutes to 111 ± 25 rpm and 116 
± 24 rpm at twenty minutes for the Control and Menthol trials respectively (P = 
0.014; Figure 7.2).  Self-selected power output, also noted every five minutes, 
showed no difference between trials (P = 0.559) nor a significant effect of time 
(P = 0.067), although there was a tendency for this to increase in the final five 
minutes (203 ± 40 W and 205 ± 39 W at fifteen minutes increased to 253 ± 91 
W and 241 ± 76 W at twenty minutes for the Control and Menthol trials 
respectively; Figure 7.3). 
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Figure 7.2.  Pedal cadence during the Control and the Menthol treatments, noted at five 
minute intervals.  A significant increase in pedal cadence occurred at the end of the time-trial 
in both conditions (P=0.014).   
 
 
 
Figure 7.3. Power output during the Control and the Menthol treatments, noted at five minute 
intervals.  There was a tendency for an increase in the power output at the end of the time-
trial in both conditions (P=0.067). 
75
85
95
105
115
125
135
145
5 10 15 20
P
e
d
a
l 
c
a
d
e
n
c
e
 (
rp
m
) 
 
Time (minutes) 
Menthol
Control
150
170
190
210
230
250
270
290
310
330
350
5 10 15 20
W
o
rk
 l
o
a
d
 (
W
) 
Time (min) 
Menthol
Control
170 
 
As with the pre-load phase of the trials, core temperature continued to 
increase during the time-trial (P < 0.001) but was not different between the 
trials (P = 0.619; Figure 7.4).  Skin temperature showed a similar pattern, 
increasing over time (P = 0.001), but again showing no influence of menthol 
application (P = 0.588), and estimated body heat content also reflected this 
pattern with a significant rise over time (P < 0.001), but no difference between 
the trials (P = 0.667). 
 
 
 
Figure 7.4.  Core temperature over the time-trial.  There was no difference between the trials 
(P = 0.619) but a significant increase over time (P < 0.001).   
 
Ratings of perceived exertion increased during the time-trial (15.6 ± 1.3 and 
14.9 ± 1.6 at five minutes to 18.8 ± 1.0 and 18.9 (17-20) at twenty minutes for 
the Control and Menthol trials respectively; P < 0.001), but did not differ 
between trials (P = 0.339).  Right arm (1 % menthol solution) thermal 
sensation scores increased over time (P = 0.012), but were not affected by 
the trial (P = 0.470).  Left arm (control solution) and overall thermal sensation 
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scores were not affected by time (P = 0.222 and P = 0.107 respectively), or 
trial (P = 0.108 and P = 0.372 respectively). 
 
Blood glucose concentrations were not different between trials at the end of 
the time-trial (Control 4.95 ± 0.89 mmol / L and Menthol 5.28 ± 0.53 mmol / L; 
P = 0.136).  Serum osmolality was also not different between trials (P = 
0.244), nor were plasma volume changes from baseline (P = 0.399), 
carbohydrate oxidation rates (P = 0.632) or fat oxidation rates (P = 0.537).  
 
Heart rate, however, was consistently slightly higher on the Menthol trial than 
the Control trial (P = 0.031), and increased over time (P < 0.001) from 161 ± 
12 and 164 ± 12 beats per minute at five minutes rising to 180 ± 11 and 182 ± 
10 beats per minute at twenty minutes for the Control and the Menthol trials 
respectively (Figure 7.5). 
 
 
 
Figure 7.5.  Heart rate over the time-trial.  There was an increase in heart rate over time (P < 
0.001) and the Menthol trial produced consistently slightly higher heart rates than the Control 
trial (P = 0.031).   
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7.4.4 Warming vs. cooling  
From the effects of the menthol solution on local thermal sensation, assessed 
during the preliminary trial, six participants who perceived the menthol to have 
a warming sensation and six who perceived it to have a cooling sensation 
were recruited to the study.  However, analysis of the thermal sensation data 
generated in the main trials does not reflect the local sensations perceived in 
the preliminary trial.  Therefore, participants have been reclassified based on 
their overall thermal sensation ratings ten minutes into the time-trial on the 
Menthol trial, compared to the Control trial.  Six participants perceived an 
overall warming effect (n = 6) and five perceived an overall cooling effect (n = 
5) of the menthol solution.  The details of these participants, grouped by 
thermal sensation, are presented in Table 7.1.  One participant felt no effect of 
the menthol solution on their overall thermal sensation and when analysing 
differences between or within the sensation groups his data has been omitted.  
 
Table 7.1. Participant information grouped by overall thermal sensation after ten minutes of 
the cycling time trial, and the difference between the groups. 
   
 Body mass 
(kg) 
Height 
(m) 
Age 
(y) 
 ̇O2peak 
(ml / kg / min) 
Cooling 84.1 ± 14.2 1.82 ± 0.10 23 ± 3 56.9 ± 9.8 
Warming 76.1 ± 5.1 1.79 ± 0.06 23 ± 4 58.2 ± 9.5 
P value 0.287 0.582 0.937 0.833 
 
Figure 7.6 shows the difference in perceived overall thermal sensation 
between the Menthol trial and the Control trial, within the warming and the 
cooling groups.  There was a strong difference (P = 0.004) between the 
warming and the cooling group (Figure 7.6).  The overall thermal sensation 
scores of those in the warming group compared to those in the cooling group 
on the Menthol trial also tended to be different (P = 0.064; Figure 7.7), as did 
the right arm (1 % menthol solution) local thermal sensation scores (P = 
0.086).  By analysing the difference between the local thermal sensation 
scores on the Menthol and Control trials, there was a strong tendency for a 
difference between the groups (P = 0.060), supporting the re-grouping. 
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Figure 7.6.  Difference between Menthol and Control trials for overall thermal sensation in the 
cooling (n = 5) and warming (n = 6) groups.  There was a significant difference in the overall 
thermal sensation between the groups (P = 0.004) but no effect of time.   
 
 
Figure 7.7.  Overall thermal sensation scores on the Menthol trial for the warming (n = 6) and 
the cooling (n = 5) groups.  The difference between the groups just failed to reach statistical 
significance (P = 0.064) and there was no effect of time (P = 0.643).   
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Other than the thermal sensation data however, there were no differences 
between the warming and the cooling groups.  There was no difference in 
body mass loss (P = 0.941) suggesting that the perception of increased 
warmth did not evoke a thermoregulatory cooling mechanism, such as an 
increase in sweating.  Most importantly there was no difference in the total 
work done between the groups (P = 0.200), nor in the distribution of the work 
during the time-trial between groups (P = 0.215) or over time (P = 0.509).  
Pedal cadence increased over time in both groups but, once again, there was 
no difference between the groups. 
 
Core temperature increased over the duration of the time-trial in both groups 
(P < 0.001) but did not differ according to overall thermal sensation (P = 
0.559).  Again, skin temperature and body heat content followed the same 
pattern as core temperature, increasing over the time-trial (P = 0.017; P < 
0.001) but without differing between the groups (P = 0.443; P = 0.189) for skin 
temperature and body heat content respectively.  Heart rate and RPE also 
both increased during the time-trial (P < 0.001 for both parameters) but 
neither differed between groups (P = 0.931 for heart rate; P = 0.712 for RPE).  
Blood glucose concentration (P = 0.765), serum osmolality (P = 0.162) and 
plasma volume (P = 0.760) were all similar between groups and there were no 
differences in fat (P = 0.422) and carbohydrate (P = 0.787) oxidation rates. 
 
7.4.5 Sensation vs. treatment  
The two trials (Menthol and Control) have been compared to each other.  The 
participants, having been split into two groups depending upon their overall 
perception of thermal sensation in response to the application of menthol, 
have also been compared to each other.  The final comparisons to be drawn 
are those within the same participant between the two trials.  Once again, the 
participant who perceived no difference in overall thermal sensation between 
the Menthol and the Control trials has been omitted from this analysis. 
 
For those who perceived a warming sensation (n = 6), their overall thermal 
sensation was higher on the Menthol trial compared to the Control trial (P = 
0.009) and this increased over the time-trial (P = 0.022; Figure 7.8).  However, 
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the increased thermal sensation did not negatively influence performance as 
there was no difference in the total work done in the time-trial (P = 0.400; 
Figure 7.9), nor in the cumulative work done, assessed every five minutes 
during the time-trial (P = 0.405; Figure 7.10). 
 
 
Figure 7.8.  The overall thermal sensation scores in the warming group (n = 6) for the Menthol 
and the Control trials.   
 
 
 
Figure 7.9.  The difference in work done between the Menthol and Control trials in the 
warming group (n = 6) and the cooling group (n = 5).  There was no difference between the 
groups (P=0.400).   
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Figure 7.10.  Cumulative work done during the time-trial for the warming (n = 6) and cooling 
(n = 5) groups of both the Menthol and the Control trials.  The error bars above the data 
display the variability of the data. 
 
For those participants who perceived the menthol to have an overall cooling 
effect there was a strong tendency for them to feel cooler overall, when they 
had the Menthol patches applied, compared to the Control patches (P = 
0.054; Figure 7.11).  When these participants then performed a time-trial there 
was a tendency (P = 0.071; Figure 7.10) for the cumulative work done to be 
greater on the Menthol trial than on the Control trial, although the total work 
done was not different between treatments (P = 0.130; Figure 7.9). 
 
There were no other differences in any of the measured parameters between 
the Menthol and the Control trials in either the warming group or the cooling 
group, suggesting that the tendency for any difference in performance that 
may have occurred was not due to thermoregulatory or metabolic differences 
induced by the treatments. 
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Figure 7.11.  The overall thermal sensation scores in the cooling group (n = 5) for the Menthol 
and the Control trials.  The Menthol trial tended to elicit lower thermal sensation scores than 
the Control trial (P = 0.054).   
 
7.5 Discussion 
The preliminary tests employed at the start of this investigation were not a 
suitable means of assessing participants’ perception of the 1 % menthol 
solution during exercise in the heat.  Although the preliminary tests were 
undertaken in the heat after a twenty minute period to allow for acclimation of 
skin temperature, clearly this did not reflect the conditions seen after sixty 
minutes of steady state exercise in the same warm environmental conditions.  
The effect of applying menthol to the skin when it is in different physiological 
states has not been investigated.  Alterations in the perceived sensation 
effects of the menthol between the preliminary tests and the main trials in 
several participants suggests that the perception of the effect of menthol on 
the skin may be influenced by the condition of the skin, although this was not 
the focus of this investigation and is therefore purely speculative.  Also, since 
the main aim of this investigation was to analyse the performance effects of 
altered perception of thermal sensation, conclusions can still be drawn based 
on the present data.  
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The main finding of this study was that altering thermal sensation through 
application of menthol to the skin during exercise in the heat did not affect 
performance.  This is in contrast to the findings of Mundel and Jones (2010) 
who found that swilling a 0.01 % menthol solution around the oral cavity 
increased endurance exercise capacity in the heat (34 °C) by 9 ± 12 % (63 ± 
14 and 58 ± 16 minutes for the menthol and the placebo trials respectively), 
and resulted in improved exercise capacity in eight of the nine participants.   
 
The menthol mouth swill resulted in greater pulmonary ventilation after twenty 
(72 ± 12 vs. 63 ± 7 L / min) and forty (75 ± 12 vs. 67 ± 8 L / min) minutes of 
exercise, compared to a placebo mouth swill trial respectively (Mundel and 
Jones, 2010).  They also reported that while local (i.e. muscular) RPE did not 
differ between trials, they said global (i.e. overall) RPE tended to be lower (P 
= 0.09) and central (i.e. cardiovascular) RPE was lower (P = 0.01) on the 
menthol trials than on the control trials.  The authors attribute the increase in 
exercise capacity to these differences, since there were no other differences 
between the trials, in any of the measured parameters.  During the present 
investigation, no differences were found in any of the measured parameters.  
This may have occurred due to the shorter duration of the exercise test, or the 
different modality and site of menthol application, or, perhaps more likely, a 
combination of these factors.  
 
Rating of perceived exertion in this experiment did not differ between the 
sensation groups, or between the trials within the sensation groups.  This may 
suggest that the alteration in thermal sensation due to the menthol solution 
was not sufficient to alter the perception of the effort required to perform the 
exercise task.  Indeed, facial cooling, using a mist of cold water, has been 
shown to blunt the elevation in rating of perceived exertion seen without facial 
cooling during cycling exercise in the heat (Mundel et al., 2007).  However, 
menthol does not actively cool the skin and this could be a reason for the lack 
of response in the cooling group to the application of menthol to the skin, 
including the facial skin.  Also, with a time-trial protocol participants are asked 
to give their maximum effort over the twenty minutes. Therefore no matter 
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what their workload, it is not surprising that the ratings of perceived exertion 
scores did not differ between groups, or between trials within groups.  
 
Although there was a tendency (P = 0.071) for the menthol solution to 
increase cumulative work done in the cooling group compared to the warming 
group, this failed to reach statistical significance.  However, as this was the 
first investigation into the effect of applying menthol to the skin during exercise 
in the heat, it might be possible, through certain methodological changes, to 
show an effect of altering thermal sensation by applying menthol to the skin 
on exercise performance. 
 
If an exercise to exhaustion protocol had been employed, or possibly a longer 
time-trial with regular re-application of the menthol patches, a difference in 
exercise capacity or performance may have become apparent.  Indeed, since 
the cooling sensation of menthol remains even once the menthol is removed 
from the skin or mucous membrane (Eccles, 1994; Burrow et al., 1983), it is 
possible that by uncovering or removing the patches after an initial exposure, 
significant changes in performance may have been seen.  This, however, is 
purely speculative. 
 
It should also be noted that the estimated average mean body surface area of 
the participants, calculated using the equation formulated by Mosteller (1987), 
was 1.99 ± 0.16 m2, while the total surface area covered by the patches was 
only 0.05 m2 meaning that only approximately 2.5 % of body surface area was 
exposed to the menthol.  Therefore, it is possible that if a greater surface area 
had been covered by the menthol patches, a greater response to the 
alteration of thermal sensation may have been elicited, which in turn may 
have caused significant alterations in exercise performance.  Indeed, many of 
the menthol infused clothing products available vaguely claim to ‘‘reduce the 
physiological factors that affect performance whilst exercising in the heat’’ 
(www.skins.net).  Such clothing will cover a much greater surface area than 
was covered here, thereby increasing the chance of seeing effects of applying 
menthol to the skin.  However, a balance needs to be met as increasing the 
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surface area covered by the patches (or some types of clothing) decreases 
the opportunity for evaporative heat loss (Parsons, 2003A). 
 
Furthermore, if a strong cooling sensation was to be elicited through the 
application of menthol to the skin it is possible that this could actually have a 
negative effect on prolonged exercise capacity or performance in the heat.  
The application of a 10 % solution of menthol to the skin of the whole trunk of 
mice led to an increase in core temperature of 1.3 °C that persisted for ninety 
minutes, compared to when the control solution was applied in the same way 
(Tajino et al., 2008).  The authors suggest that menthol, through activating the 
skin thermoreceptors, evoked heat gain responses including peripheral 
vasoconstriction and shivering-like responses.  These responses have been 
seen before as a result of menthol application to the skin of mice (Tajino et al., 
2007).  If a similar physiological response was to be evoked in humans 
performing prolonged exercise in the heat, it is likely that performance would 
be impaired.  Therefore, it is important to note that, while sufficient menthol 
needs to be applied to elicit a cooling sensation and therefore possibly an 
improvement in exercise performance in the heat, an excessive activation of 
the peripheral thermoreceptors may result in heat gain responses, to the 
detriment of exercise performance in the heat. 
 
Heart rate was consistently slightly, but significantly (P = 0.031), higher on the 
Menthol trials than on the Control trials.  One possible explanation for this 
could be that the menthol caused an increase in blood flow to the skin.  This 
would have required an increased cardiac output which may have been 
satisfied by a slight elevation in heart rate.  However, previous published 
literature (Yosipovitch et al., 1996), and the data shown in Chapter Six, show 
that the application of menthol to the skin has no effect on skin blood flow 
(see Chapter Seven for more details).  Furthermore, there was no difference 
in the skin temperature between the Menthol and Control trials.  Therefore, 
such a theory is unlikely to be the true explanation for the elevated heart rate 
seen on the Menthol trial.  
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In fact, the elevated heart rate on the Menthol trials is more surprising, as the 
cooling of facial skin through cold water (4 - 6 °C) immersion stimulates 
trigeminal receptors, altering vagal tone and producing a bradycardia (Finley 
et al., 1979).  Therefore, by activating the facial cooling thermoreceptors 
through the application of a menthol patch to the forehead, it may have been 
expected that heart rate would have been slightly lower on the menthol trials.  
However, with an average difference of only three beats per minute after five 
minutes of the time-trial and two beats per minute after twenty minutes of the 
time-trial, it is unlikely that this slight elevation would have had any 
physiological influence on participants or their performance.  
 
There was a significant effect of time on pedal cadence during the time-trial, 
regardless of treatment.  At fifteen minutes pedal cadence was 94 ± 11 
revolutions per minute, while at twenty minutes pedal cadence was 114 ± 24 
revolutions per minute.  Of the twenty four time-trials completed throughout 
this study, pedal cadence increased during the last five minutes in twenty of 
the trials, despite participants being told very clearly at the start of each time-
trial that the amount of work completed was independent of pedal cadence, as 
the ergometer was left in hyperbolic mode for the entire investigation.  
Whether this increase in pedal cadence would still have been seen if the 
ergometer was in linear mode, where power output is directly related to pedal 
cadence, is unclear.  Sewell and McGregor (2008), upon whose protocol the 
present study is based, do not report pedal cadence at any point during their 
trials.  
 
The hypothalamus co-ordinates the thermoregulation of the body.  Skin 
temperature receptors terminate in the pre-optic area of the hypothalamus, 
and core temperature receptors terminate in the pre-optic area and the brain 
stem.  The thermoregulatory responses to these inputs are the outputs of the 
serotonergic and dopaminergic pathways of the hypothalamus, which are also 
responsible for the elevation in prolactin concentrations, in response to high 
core temperatures.   
 
182 
 
Mills and Robertshaw (1981) found that, in resting males there is an 
association between mean body temperature and plasma prolactin 
concentration where when body temperature increases so does plasma 
prolactin concentration.  Bridge and colleagues (2003B) showed that prolactin 
release during exhaustive cycling at 73 %  ̇O2max was significantly lower 
from ten minutes onwards when the exercise was performed in 20 °C 
compared to 35 °C.  They postulated therefore, that skin temperature, which 
was ~4 °C lower in the cooler climatic conditions, may modulate prolactin 
release, and not core temperature which increased similarly regardless of the 
climatic conditions.  Armada-da-Silva et al. (2004) showed that facial cooling 
by 2 °C during exercise in the heat attenuated the rise in plasma prolactin 
concentration seen with no facial cooling, although this was not statistically 
significance.  In a similar study, facial cooling did attenuate the increase in 
prolactin release seen in response to exercise in a warm environment 
reducing the elevation from a six-fold increase in the control condition to a 
two-fold increase in the facial cooling condition (Ansley et al., 2008). 
 
Prolactin release during exercise, and its blunted release with facial cooling, 
suggests that the hypothalamus or associated areas of the brain are involved 
in exercise fatigue (Ansley et al., 2008).  Although menthol does not actually 
cool skin, it does stimulate the thermoreceptors of the skin which terminate in 
the hypothalamus.  It is therefore possible that the application of menthol to 
the skin may slow the rate of prolactin release during exercise in the heat.  
Plasma prolactin concentrations were not measured in the present study.  
However, it might be plausible to speculate that those who perceived a 
warming effect of the menthol would have had greater plasma prolactin 
concentrations in the Menthol trial than the Control trial.  Conversely, those 
who perceived a cooling effect of the menthol may have had lower prolactin 
concentrations in the Menthol trial than the Control trial.  This is an avenue for 
further research.  
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7.6 Conclusion 
The application of a 1 % menthol solution to the skin during exercise in the 
heat did not alter exercise performance compared to a control solution when 
assessed by a pre-loaded twenty minute time-trial.  This was found to be true 
whether analysed between treatments, between sensation groups, or within 
sensation groups between treatments.  It was also found that there was a 
slight tendency for those who perceived the menthol to have a cooling effect 
to do more work during the time-trial. 
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CHAPTER EIGHT 
 
General discussion and conclusions.  
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8.1 Discussion 
There is a vast volume of literature on the peripheral physiological effects of 
prolonged exercise and the peripheral factors that cause fatigue.  The central 
mechanisms of fatigue, and the role of the serotonergic system in the 
reduction in exercise performance, particularly in the heat, are yet to be fully 
clarified.  The studies in this thesis aimed to investigate potential central 
limiting factors to exercise performance and possible manipulations of 
exercise related to this problem. 
 
Based on their findings, Watson et al. (2004) purported that the exercise 
capacity of some individuals may be improved with branched-chain amino 
acid supplementation, while other individuals will not benefit from the same 
supplementation regimen.  Therefore, the first experimental study in this 
thesis aimed to investigate this theory by using a protocol in which 
participants underwent the supplementation regimen twice, and the control 
regimen twice, and the difference in the response to branched-chain amino 
acid supplementation during an exercise capacity test in the heat was 
assessed.   
 
None of the participants recruited can categorically be stated as having 
benefitted from an ergogenic effect of branched-chain amino acid 
supplementation.  One participant did exercise for longer on the BCAA trials 
(168.5 minutes) than on the Control trials (157.9 minutes), and the duration of 
this individuals’ exercise test was longer than that of all other participants 
(group mean of 105 minutes).  Mittleman and colleagues (1998) also showed 
that during prolonged exercise in the heat, exercise capacity is improved with 
branched-chain amino acid supplementation (153.1 ± 13.3 minutes) 
compared to a placebo supplement (137.0 ± 12.2 minutes).  However, none of 
the other participants showed an improvement in performance as a result of 
the supplementation protocol, which is in line with research from several 
authors (Blomstrand et al., 1995; Blomstrand et al., 1997; Galiano et al., 1991; 
Struder et al., 1998; Van Hall et al., 1995; Watson et al., 2004). 
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Indeed, an increase in brain tryptophan uptake during prolonged exercise is 
suggested to contribute to an elevation in central serotonergic activity 
(Blomstrand et al., 1989).  This has been suggested to reduce arousal levels 
and increase in the perception of tiredness and lethargy during exercise 
(Blomstrand et al., 1997).  By reducing the free tryptophan to branched-chain 
amino acid ratio in the blood, there should be a reduction in the uptake of the 
serotonin precursor into the brain.  This may lead to a reduced production of 
serotonin, and consequently, theoretically, a delay in the onset of feelings of 
fatigue.  Based on this theory, the ratings of perceived exertion might have 
been expected to be lower on the branched-chain amino acid trials where the 
ratio of free tryptophan to branched-chain amino acids was reduced.  
However, the ratings of perceived exertion in Chapter Three were not different 
between trials, a finding that corresponds well with other research (Watson et 
al., 2004; Mittleman et al., 1998; Struder et al., 1996). 
 
Improving exercise capacity by reducing the transport of tryptophan across 
the blood brain barrier using branched-chain amino acids has proven largely 
unsuccessful.  Despite being used in several psychology studies, the effect of 
acute tryptophan depletion on exercise capacity has never been investigated.  
Based on the same principles as branched-chain amino acid 
supplementation, acute tryptophan depletion aims to reduce the entry of 
tryptophan into the brain, thereby reducing serotonin production, and 
theoretically delaying fatigue.  However, when acute tryptophan depletion was 
undertaken by the participants in Chapter Four, there was no improvement in 
exercise capacity in the heat.  In fact, the exercise times to exhaustion tended 
to be shorter with acute tryptophan depletion, compared to when the control 
amino acid load was administered (P=0.088).  Possible explanations for this 
unexpected finding can be proposed, based on the supporting physiological 
data collected.  Serotonin is known to play a critical role in the control of heart 
rate (Jordan, 2005; Ramage and Fozard, 1987).  Van der Veen and 
colleagues (2008) found that heart rate did not fall on acute tryptophan 
depletion trials when negative feedback was given as it did on the control 
trials.  It is possible therefore that  acute tryptophan depletion may lead to a 
relative increase in heart rate.  Put another way, the increases seen in heart 
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rate during exercise, such as in the control trial of Chapter Four, may naturally 
be slightly blunted due to the presence of serotonin in greater concentrations 
than during trials designed to reduce serotonin concentration, such the 
tryptophan depletion trial in Chapter Four.  This hypothesis is backed up by 
the trend throughout the tryptophan depletion trials for a higher heart rate than 
on the control trials (P=0.053). 
 
It is possible that if acute tryptophan depletion did cause a reduction in 
serotonin activation, it could have led to the tendency (P=0.069) for rectal 
temperatures to be higher in the tryptophan depletion trials of Chapter Four 
compared to the control trials.  There are several sub-groups of serotonin 
receptors, and the 5-HT2C receptor is thought to be related to 
thermoregulation (Schwartz et al., 1995).  When a 5-HT2C receptor antagonist 
(Pizotifen) was administered to healthy human participants it resulted in an 
elevated resting core temperature (Strachan et al., 2005).  The aim of both 
acute tryptophan depletion and administration of serotonin receptor 
antagonists is theoretically the same, i.e. a reduction in serotonin release, and 
both methods have now been shown to result in elevations in resting core 
temperatures. 
 
In combination, the tendencies for a higher heart rate and core temperature 
on the tryptophan depletion trials in Chapter Four may have led to the trend 
for exercise capacity to be impaired compared to the control trials.  It is likely 
that any benefit which may have been seen due to the influences of the acute 
tryptophan depletion on serotonin synthesis or release were overridden by the 
trends for a higher heart rate and core temperature that acute tryptophan 
depletion evoked. 
 
Serotonin has an influential role in factors which may ultimately affect exercise 
performance or capacity, but does not appear to influence it directly.  It is 
possible that manipulation of influential factors, such as core temperature and 
heart rate, along with the ratio of serotonin to other neurotransmitters, may 
still hold interesting opportunities for further exploration, as suggested in 
section 8.3.  Based on the possible involvement of serotonin in fatigue, the 
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focus of the research conducted in this thesis moved from the nutritional 
manipulation of serotonin production to the transport of serotonin at the 
synapse. 
 
After serotonin is synthesised and transported to the nerve terminal in 
vesicles, it is released into the synapse where it then participates in a plethora 
of responses.  The concentration of serotonin in the synapse is altered by 
serotonin transporters.  A reduction in the concentration of serotonin in the 
synapse could be achieved by either an increased number of serotonin 
transporters, an increase in the activity levels of such transporters, or possibly 
a combination of these two factors.  
 
However, due to obvious restrictions, the direct examination of the 
transporters on the neurones is near impossible in humans.  Fortunately, 
serotonin transporters are found not only in the serotonergic neurones but 
also on the membranes of blood platelets.  The blood platelets offer an 
imperfect yet simplistic, accessible and consistent model for the serotonergic 
neuron.  Previous research has shown that there are elevated levels of 
serotonin transporters on the membranes of platelets of endurance trained 
athletes compared to sedentary controls (Strachan and Maughan, 1998). 
What remained unclear was whether these differences were a state marker 
(an aspect which can adapt under the influence of one or more factors; 
Rieder, 1978) or a trait marker (an aspect which is fixed and cannot be 
influenced by other factors). 
 
Chapter Five shows that those who follow an elite level training program, 
particularly for endurance events, have a greater number of serotonin 
transporters on the membranes of their blood platelets (CE: 1090 ± 76 fmol / 
mg protein; CS: 953 ± 68 fmol / mg protein) compared to those who had 
previously trained to a similar standard in a similar discipline (RE: 892 ± 88 
fmol / mg protein; RS: 866 ± 58 fmol / mg protein), or those who have never 
done any training (I: 885 ± 58 fmol / mg protein).   
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The data suggests that platelet serotonin transporter density is a state marker 
as the maximum number of binding sites increases as a result of training but 
the adaptation is lost once training has stopped.  Therefore, if the platelet 
model is transferable to the situation in the serotonergic neuron, it is possible 
that the perception of fatigue is altered in those currently undertaking a 
training regimen, compared to those who are not currently undertaking a 
training regimen. 
 
Strachan (1996) offered this as a explanation for why some individuals 
choose to exercise regularly, while other choose not to.  The data from 
Chapter Five refutes this hypothesis, and perception of fatigue can only be 
one reason in a plethora of reasons as to why an individual will not undertake 
regular exercise.  However, it must also be noted that research into 
depression has found that psychological state does not influence platelet 
serotonin transporter density, implying that it is a trait marker and not a state 
marker of the illness (Lawrence et al., 1993; Lawrence et al., 1994).  
 
Chapter Six looked at the effects of applying a 1 % menthol solution to the 
skin during heat exposure.  Thirteen participants perceived a cooling 
sensation of menthol application, while eight perceived a warming sensation 
and three perceived no change in thermal sensation when compared to a 
control solution.  There were no differences in skin temperature, core 
temperature or skin blood flow between any of the trials.  This agrees with 
previous research in which menthol has been shown to elicit both warming 
and cooling sensations when applied to human skin, without a concomitant 
change in skin temperature or skin blood flow (Yosipovitch et al., 1996; 
Kozyreva and Tkachenko, 2008). 
 
However, the findings in human studies conflict with findings in animal studies 
where a 10 % menthol solution, applied to the skin on the whole trunk of mice, 
caused an increase in core temperature of 1.3 °C in fifteen minutes that then 
persisted for over ninety minutes (Tajino et al., 2008).  The authors suggest 
that the menthol, through activating the skin thermoreceptors, evoked heat 
gain responses such as shivering-like muscle contractions, tail 
190 
 
vasoconstriction and heat seeking behaviours (Tajino et al., 2007), resulting in 
the increase in core temperature seen in the mice. 
  
These results, although opposing in some aspects, both imply that alterations 
in perceived thermal sensations occur centrally as a result of the stimulation 
of skin thermoreceptors. These thermoreceptors terminate in the pre-optic 
area of the hypothalamus, the region of the brain responsible for co-ordinating 
thermoregulation. Indeed, based on their qualitative data, Nakamura et al. 
(2008) suggested that the central nervous system must be involved in the 
processing of peripheral thermal sensation information.   
 
Frank et al., (1999) demonstrated that core temperature and skin temperature 
contribute equally to levels of thermal comfort in men, assessed by a ten point 
visual analogue scale.  By artificially manipulating the perception of skin 
temperature to lower than its true temperature during heat exposure, Chapter 
Six showed that ratings of thermal comfort and thermal sensation also tended 
towards being colder. Conversely, by artificially manipulating the perception of 
skin temperature to be higher than its true temperature, ratings of thermal 
comfort and thermal sensation tended towards being warmer.  Chapter Seven 
aimed to further investigate these findings and discover if the responses 
persisted during exercise in the heat, and if exercise performance would be 
influenced. 
 
In Chapter Six the cooling sensation of the menthol seemed to be stronger 
than the warming sensation.  Significant differences in overall thermal 
sensation and overall thermal comfort seen in the cooling group between the 
menthol and control trials were not present in the warming group.  However, 
in Chapter Seven the opposite effect was seen; within the warming group the 
thermal sensation scores were greater with the menthol than the control 
treatment (P=0.009), while in the cooling group thermal sensation scores only 
tended to be lower with the menthol treatment (P=0.053). 
 
Performance was not altered due to the menthol in those who perceived a 
warming sensation (P=0.405); those who felt a cooling sensation tended to 
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perform better on the menthol trial compared to the control trial (P=0.071). 
This suggests that when participants feel cooler than they actually are, 
exercise performance in a warm environment may be improved.  Mundel and 
Jones (2010) found that swilling a menthol solution around the oral cavity 
increased endurance exercise capacity in the heat by 9 ± 12 %.  They 
reported that overall ratings of perceived exertion tended to be lower (P=0.09) 
and cardiopulmonary ratings of perceived exertion were lower (P=0.01) on the 
menthol trials than on the control trials.  
 
Ratings of perceived exertion in this experiment did not differ between the 
sensation groups, or between the treatments within the sensation groups. 
This may suggest that the alteration in thermal sensation due to the menthol 
solution was not sufficient to alter the perception of the effort required to 
perform the required exercise.  However, with a time-trial protocol participants 
are asked to give their maximum effort over the twenty minutes and therefore 
no matter what their workload was, it is not surprising that the rating of 
perceived exertion scores did not differ between groups, or between 
treatments within groups.  
 
It should also be noted that only approximately 2.5 % of body surface area 
was exposed to the menthol solution in Chapter Seven.  Therefore, it is 
possible that if a greater surface area had been covered by the menthol 
patches, a greater response to the alteration of thermal sensation may have 
been elicited, which in turn may have caused significant alterations in exercise 
performance.  However, future research in this area should also consider the 
results of Tajino et al., (2008) who found that applying menthol to a large 
surface area and thus stimulating many peripheral cold thermoreceptors, 
albeit of mice, elicited heat gain responses which would be likely to have a 
detrimental effect on exercise performance. 
 
The thermoregulatory responses to the inputs from skin thermoreceptors are 
outputs from the serotonergic and dopaminergic pathways of the 
hypothalamus.  Once again it appears that serotonin many have a role to play 
in exercise capacity and performance through its effects on related 
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physiological systems.  Indeed, the serotonergic and dopaminergic pathways 
are responsible for the elevation in prolactin concentrations at high core 
temperatures. Bridge and colleagues (2003B) postulated that skin 
temperature, and not core temperature, may modulate prolactin release.  
Although menthol does not actually alter skin temperature, it does stimulate 
the thermoreceptors of the skin and mucous membranes which terminate in 
the hypothalamus.  It is therefore possible that those who perceived a 
warming sensation due to menthol would have had higher plasma prolactin 
concentrations in the menthol trial than the control trial; while conversely, 
those who perceived a cooling sensation may have had lower prolactin 
concentrations in the menthol trial than the control trial.  
 
Despite being used for many years, it was not until 1989 that a study was 
conducted with the sole purpose of assessing the reliability of the time to 
exhaustion exercise capacity test.  Krebs and Powers (1989) showed that the 
day to day variability of high intensity cycle to exhaustion tests had a within 
participant variability ranging from 5 % to 56 %.  However, these findings were 
widely dismissed due to the lack of a familiarisation trial, minimal 
standardisation of pre-test conditions and because the exercise intensity was 
not accurately measured meaning that different workloads could have been 
performed on each trial.  The findings were also dismissed as much lower 
levels of variability were also reported (7.0 ± 5.1 %; Maughan et al., 1989).  
The issue of the reliability of time to exhaustion tests was again brought to the 
fore when Jeukendrup and colleagues (1996) showed that, while time-trial 
protocols had a coefficient of variation of around 3.5 %, time to exhaustion 
tests had a coefficient of variation of around 26.6 %.  
 
Indeed, the data presented in this thesis does back-up their findings to some 
extent, with time to exhaustion trials showing a greater variation (11.0 ± 11.2 
% in Chapter Three and 11.5 ± 12.4 % in Chapter Four) than a pre-loaded 
time-trial protocol (3.9 ± 9.6 % in Chapter Seven).  However, the variation in 
the cycle to exhaustion data in the Jeukendrup study (1996) seems 
questionably large.  For example, one participant exercised for 43.8 minutes 
on one occasion, and then 111.8 minutes on another occasion.  It is possible 
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that there were underlying reasons for such dramatic alterations in ability, but 
it is not possible to explore this avenue due to the lack of supporting 
physiological data presented in their study.  
 
Although Coyle et al. (1991) have shown that performance in a one hour 
laboratory-based exercise test is closely related to the performance of a forty 
kilometre time-trial, Palmer and colleagues (1996) found that forty kilometre 
time-trial tests using competitive cyclists were approximately 8 % faster when 
done in a laboratory environment than in an outdoor competitive setting.  
Reasons for this will include environmental conditions, air resistance, road 
surface, terrain and route.  These factors will always exist outside of a 
laboratory, causing athletes to slow down slightly.  These findings also 
suggest that the competitiveness of real race environments is not sufficient to 
override such external influences.   
 
A purported problem of time-trial tests is that they are influenced by pacing 
strategies (Baron et al., 2009) and due to the infinite number of strategies 
available (St Clair Gibson et al., 2006), sometimes these pacing strategies do 
not produce optimal performance (Hinckson and Hopkins, 2005) and merely 
add noise to any data.  However, Atkinson and Nevill (2005) argue that pacing 
strategies are an inherent component of real exercise and sporting 
performance and therefore cannot be dismissed as a disadvantage of the 
time-trial method.  Unfortunately, in exercise physiology the re-creation of a 
sporting situation is not usually the aim of the research, it is often conducted 
to explore or elucidate physiological mechanisms and try to generate 
explanations of responses seen due to interventions.   
 
It has been suggested that one of the reasons that time to exhaustion tests 
appear to have greater variability is simply because a small change in a 
participants’ ability to produce power will result in a large change in time to 
exhaustion (Hopkins et al., 2001).  Through sophisticated mathematical 
models Hinckson and Hopkins (2005) have successfully shown that time to 
exhaustion can actually be a highly reliable measurement (coefficients of 
variation of only 1 – 2 %), allowing the detection of small changes in capacity 
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caused by an intervention. However, the complexity of the methodology 
required to generate data that is suitable for such mathematical modelling is 
greatly increased.   
 
Some studies appear to find no learning effect of the time-trial tests (Currell et 
al., 2006; Jeukendrup et al., 1996) while others find that coefficient of variation 
decreases as the number of trials increases (Marino et al., 2002; Laursen et 
al., 2003), as was seen in all of the exercise chapters in this thesis.  In the 
data presented here, all coefficient of variation values were reduced by the 
inclusion of a familiarisation trial (Chapter Three 21.7 ± 20.4 % to 11.0 ± 11.2 
% , Chapter Four 14.4 ± 14.8 % to 11.5 ± 12.4 %, Chapter Seven 4.7 ± 11.0 
% to 3.9 ± 9.6 %) indicating that there is a learning effect with both protocols.   
 
8.2 Conclusions 
1) The nutritional manipulation of the ratio of free tryptophan to branched-
chain amino acids or the total tryptophan concentration in the plasma had 
no effect on prolonged exercise capacity in the heat. 
 
2) Endurance training appears to increase the number of serotonin transporter 
sites on the blood platelet, which can be used as a suitable peripheral 
model for the central serotonergic neuron. 
 
3) Menthol can elicit warming or cooling sensations when applied to the skin 
during heat exposure.  If a warming sensation is perceived, exercise 
performance in the heat does not seem to be impaired.  However, if a 
cooling sensation is perceived, there is a tendency for exercise 
performance in the heat to improve. 
 
4) Exercise performance measures in the heat seem more reliable than 
exercise capacity measures, although the aims of an investigation should 
be considered when choosing an exercise test protocol. 
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8.3 Future areas of research 
There are still a great number of unanswered questions regarding the origin of 
fatigue during exercise.  This thesis has tried to investigate just a small 
selection of the potential avenues for research in this field.  Firstly, the 
purported alterations to exercise capacity that amino acid supplementation 
could theoretically cause were investigated.  The thesis went on to look at the 
role that training could play in bringing about adaptations to improve 
resistance to central fatigue.  Finally, the role that altering temperature 
perception, through the use of menthol, could have both physiologically and in 
an exercise performance setting was investigated.  Based on the conclusions 
outlined above in section 8.2, this section will raise research questions which 
would be interesting to attempt to answer and may provide further insight in to 
the role of the brain during exercise fatigue.  
 
From the findings presented in the first two experimental chapters (Chapters 
Three and Four), the Newsholme theory of central fatigue appears to be too 
simplistic.  The concept of altering serotonin production solely through the 
manipulation of tryptophan delivery across the blood brain barrier lacks 
supporting evidence in human participants.  It seems fruitless to continue 
research down this avenue with the aim of improving exercise capacity or 
performance.  However, research employing pharmacological agents offers a 
much more direct avenue of exploration into serotonin-mediated fatigue.  
Furthermore, pharmacological agents exist which can influence more than just 
the serotonergic system, and the role of the dopaminergic system, and the 
ratio in the activity of the dopaminergic and serotonergic systems, in fatigue 
during prolonged exercise warrants further systematic investigation.   
 
Chapter Five suggests that endurance training may lead to adaptations within 
the central nervous system; potentially altering an individual’s the perception 
of fatigue.  Several interesting avenues of research could grow from these 
findings.  Is there a dose-response relationship in terms of training history or 
training load / intensity / duration / frequency and the increases seen in 
serotonin transporter density on the blood platelet?  Is this apparent 
adaptation to training possibly linked to ethnicity, thereby providing an 
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explanation for the dominance of those of North and East African descent in 
distance running?  What is the role of Vmax, the maximum rate of binding, 
within the blood platelet and does this differ between sporting disciplines or 
alter with training?  What is the time course for this apparent adaptation?  The 
answers to all of these questions will undoubtedly be difficult to come by and 
involve time-consuming, expensive and extensive studies, but this does not 
mean that such questions should be ignored. 
 
Chapter Six and Chapter Seven investigated the effects of manipulating the 
perception of skin temperature without a concomitant alteration in actual skin 
temperature.  The altered afferent sensory input, received by the pre-optic 
area of the anterior hypothalamus from the peripheral thermoreceptors, after 
an application of menthol may influence the thermoregulatory responses 
initiated based on the information received. Future research based on 
Chapter Seven could consider covering a larger surface area in the menthol 
solution.  If assessment of thermoregulatory responses is of interest then a 
longer exercise period after the application of the menthol to the skin could 
also be employed.  A compound which targets warm receptors, such a 
capsaicin, could also be employed to look at the physiological responses to 
the manipulation of thermal sensation.  The precise relationship between 
prolactin, heat exposure, and actual and perceived skin temperature is also 
an avenue for further investigation. Furthermore, the relationship between 
thermal comfort and exercise performance, independent of core and/or skin 
temperature, would also be an interesting avenue of exploration, if appropriate 
methodologies could be developed. 
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A: Gas equations 
 
 
SWVP = (1.1001 * gas temperature) – 4.19mmHg 
 
VESTPD (L/min) = VEATPS * ((BP - SWVP) / 760) * (273 / (273 + room temp)) 
 
FIN2 (%) = 100 – 20.93 – 0.03 
 
FEN2 (%) = 100 – FEO2 – FECO2 
 
VI (L/min) = (FEN2 / FIN2) * VE 
 
VO2I (L/min) = VI * FIO2 / 100 
 
VO2E (L/min) = VE * FEO2 / 100 
 
VCO2I (L/min) = VI * FICO2 / 100 
 
VCO2E (L/min) = VE * FECO2 / 100 
 
VO2 (L/min) = VO2I – VO2E 
 
VCO2 (L/min) = VCO2E – VCO2I 
 
RER = VCO2 / VO2 
 
Rate of CHO oxidation (g/min)= (4.585 * VCO2) – (3.226 * VO2) 
 
Rate of fat oxidation (g/min) = (1.695 * VO2) – (1.701 * VCO2) 
 
Energy expenditure (kJ/min) = (rate of fat oxidation * 39) + (rate of CHO 
oxidation * 16) 
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B: Rating of perceived exertion 
 
 
6 
7  Very very light 
8 
9   Very light 
10 
11 Fairly Light 
12 
13  Fairly hard 
14 
15   Hard  
16 
17   Very hard 
18 
19   Extremely hard 
20 Maximum 
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C: Thermal comfort scale  
 
 
-10 Cold impossible to bear 
-9 
-8 Very cold, shivering hard 
-7 
-6 Cold, light shivering 
-5 
-4 Most areas of the body feel cold 
-3 
-2 Some areas of the body feel cold 
-1 
0 Neutral 
1 
2 Some areas of the body feel warm 
3 
4 Most areas of the body feel hot 
5 
6 Very hot, uncomfortable 
7 
8 Extremely hot, close to limit 
9 
10 Heat impossible to bear
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D: Visual analogue scales 
 
Subjective feelings Questionnaire 
 
 
1) Thinking about your CURRENT thermal sensation, please indicate on the 
scales below how you feel now. 
 
Right forearm? 
a)   
         Cold         Hot 
 
 
Left forearm? 
b)  
   Cold         Hot 
 
 
 
 
 
2) With reference to your whole body, please consider your OVERALL thermal 
sensation. 
 
  
              
Cold    Neutral    Hot 
 
 
 
 
 
3) With reference to your whole body please consider your OVERALL thermal 
comfort. 
 
  
       
Too much cool   Comfortable     Too much warm 
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E: Blood volume calculations 
 
In the equations below the subscript B denotes the first sample (Before) and 
the subscript A denotes the second sample (After).   
 
 
BVA = BVB * (HbB/HbA) 
CVA = BVA * HctA 
PVA = BVA - CVA 
PVB = 100 * (1 – HctA) 
 
 
 
The values are reported as a percentage change relative to the first sample 
collected and are calculated using the equations below: 
 
 
ΔBV = 100 * (BVA-BVB) / BVB 
  ΔCV = 100 * (CVA-CVB) / CVB 
ΔPV = 100 * (PVA-PVB) / PVB 
 
